false
Q3
--12-31
0001054102
0001054102
2024-01-01
2024-09-30
0001054102
2024-11-01
0001054102
2024-09-30
0001054102
2023-12-31
0001054102
us-gaap:SeriesBPreferredStockMember
2024-09-30
0001054102
us-gaap:SeriesBPreferredStockMember
2023-12-31
0001054102
2024-07-01
2024-09-30
0001054102
2023-07-01
2023-09-30
0001054102
2023-01-01
2023-09-30
0001054102
us-gaap:CommonStockMember
2022-12-31
0001054102
us-gaap:TreasuryStockCommonMember
2022-12-31
0001054102
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001054102
us-gaap:RetainedEarningsMember
2022-12-31
0001054102
2022-12-31
0001054102
us-gaap:CommonStockMember
2023-03-31
0001054102
us-gaap:TreasuryStockCommonMember
2023-03-31
0001054102
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001054102
us-gaap:RetainedEarningsMember
2023-03-31
0001054102
2023-03-31
0001054102
us-gaap:CommonStockMember
2023-06-30
0001054102
us-gaap:TreasuryStockCommonMember
2023-06-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001054102
us-gaap:RetainedEarningsMember
2023-06-30
0001054102
2023-06-30
0001054102
us-gaap:CommonStockMember
2023-12-31
0001054102
us-gaap:TreasuryStockCommonMember
2023-12-31
0001054102
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001054102
us-gaap:RetainedEarningsMember
2023-12-31
0001054102
us-gaap:CommonStockMember
2024-03-31
0001054102
us-gaap:TreasuryStockCommonMember
2024-03-31
0001054102
us-gaap:AdditionalPaidInCapitalMember
2024-03-31
0001054102
us-gaap:RetainedEarningsMember
2024-03-31
0001054102
2024-03-31
0001054102
us-gaap:CommonStockMember
2024-06-30
0001054102
us-gaap:TreasuryStockCommonMember
2024-06-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001054102
us-gaap:RetainedEarningsMember
2024-06-30
0001054102
2024-06-30
0001054102
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001054102
us-gaap:TreasuryStockCommonMember
2023-01-01
2023-03-31
0001054102
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001054102
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001054102
2023-01-01
2023-03-31
0001054102
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001054102
us-gaap:TreasuryStockCommonMember
2023-04-01
2023-06-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001054102
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001054102
2023-04-01
2023-06-30
0001054102
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001054102
us-gaap:TreasuryStockCommonMember
2023-07-01
2023-09-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001054102
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001054102
us-gaap:CommonStockMember
2024-01-01
2024-03-31
0001054102
us-gaap:TreasuryStockCommonMember
2024-01-01
2024-03-31
0001054102
us-gaap:AdditionalPaidInCapitalMember
2024-01-01
2024-03-31
0001054102
us-gaap:RetainedEarningsMember
2024-01-01
2024-03-31
0001054102
2024-01-01
2024-03-31
0001054102
us-gaap:CommonStockMember
2024-04-01
2024-06-30
0001054102
us-gaap:TreasuryStockCommonMember
2024-04-01
2024-06-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2024-04-01
2024-06-30
0001054102
us-gaap:RetainedEarningsMember
2024-04-01
2024-06-30
0001054102
2024-04-01
2024-06-30
0001054102
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001054102
us-gaap:TreasuryStockCommonMember
2024-07-01
2024-09-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0001054102
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0001054102
us-gaap:CommonStockMember
2023-09-30
0001054102
us-gaap:TreasuryStockCommonMember
2023-09-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001054102
us-gaap:RetainedEarningsMember
2023-09-30
0001054102
2023-09-30
0001054102
us-gaap:CommonStockMember
2024-09-30
0001054102
us-gaap:TreasuryStockCommonMember
2024-09-30
0001054102
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0001054102
us-gaap:RetainedEarningsMember
2024-09-30
0001054102
IDXG:ComericaBankMember
2021-10-31
0001054102
IDXG:TermLoanMember
IDXG:BroadOakMember
2021-10-31
0001054102
IDXG:TermLoanMember
IDXG:BroadOakMember
us-gaap:ConvertibleDebtMember
2022-05-31
0001054102
us-gaap:SubsequentEventMember
2024-11-01
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesBPreferredStockMember
2024-10-10
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesBPreferredStockMember
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesCPreferredStockMember
2024-10-10
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesCPreferredStockMember
2024-10-10
0001054102
srt:MinimumMember
2024-09-30
0001054102
srt:MaximumMember
2024-09-30
0001054102
us-gaap:SeriesBPreferredStockMember
2024-07-01
2024-09-30
0001054102
us-gaap:SeriesBPreferredStockMember
2024-01-01
2024-09-30
0001054102
us-gaap:EmployeeStockOptionMember
2024-07-01
2024-09-30
0001054102
us-gaap:EmployeeStockOptionMember
2023-07-01
2023-09-30
0001054102
us-gaap:EmployeeStockOptionMember
2024-01-01
2024-09-30
0001054102
us-gaap:EmployeeStockOptionMember
2023-01-01
2023-09-30
0001054102
us-gaap:RestrictedStockUnitsRSUMember
2024-07-01
2024-09-30
0001054102
us-gaap:RestrictedStockUnitsRSUMember
2023-07-01
2023-09-30
0001054102
us-gaap:RestrictedStockUnitsRSUMember
2024-01-01
2024-09-30
0001054102
us-gaap:RestrictedStockUnitsRSUMember
2023-01-01
2023-09-30
0001054102
IDXG:AsuragenMember
2024-09-30
0001054102
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
IDXG:AsuragenMember
2024-09-30
0001054102
IDXG:AsuragenMember
us-gaap:FairValueInputsLevel1Member
2024-09-30
0001054102
IDXG:AsuragenMember
us-gaap:FairValueInputsLevel2Member
2024-09-30
0001054102
us-gaap:FairValueInputsLevel3Member
IDXG:AsuragenMember
2024-09-30
0001054102
IDXG:BroadOakLoanMember
2024-09-30
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
2024-09-30
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueInputsLevel1Member
2024-09-30
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueInputsLevel2Member
2024-09-30
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueInputsLevel3Member
2024-09-30
0001054102
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
2024-09-30
0001054102
us-gaap:FairValueInputsLevel1Member
2024-09-30
0001054102
us-gaap:FairValueInputsLevel2Member
2024-09-30
0001054102
us-gaap:FairValueInputsLevel3Member
2024-09-30
0001054102
IDXG:AsuragenMember
2023-12-31
0001054102
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
IDXG:AsuragenMember
2023-12-31
0001054102
IDXG:AsuragenMember
us-gaap:FairValueInputsLevel1Member
2023-12-31
0001054102
IDXG:AsuragenMember
us-gaap:FairValueInputsLevel2Member
2023-12-31
0001054102
us-gaap:FairValueInputsLevel3Member
IDXG:AsuragenMember
2023-12-31
0001054102
IDXG:BroadOakLoanMember
2023-12-31
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
2023-12-31
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueInputsLevel1Member
2023-12-31
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueInputsLevel2Member
2023-12-31
0001054102
IDXG:BroadOakLoanMember
us-gaap:FairValueInputsLevel3Member
2023-12-31
0001054102
us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember
2023-12-31
0001054102
us-gaap:FairValueInputsLevel1Member
2023-12-31
0001054102
us-gaap:FairValueInputsLevel2Member
2023-12-31
0001054102
us-gaap:FairValueInputsLevel3Member
2023-12-31
0001054102
IDXG:AsuragenMember
2024-01-01
2024-09-30
0001054102
IDXG:BroadOakLoanMember
2024-01-01
2024-09-30
0001054102
IDXG:StockIncentivePlanMember
2024-01-01
2024-09-30
0001054102
us-gaap:CostOfSalesMember
2024-07-01
2024-09-30
0001054102
us-gaap:CostOfSalesMember
2023-07-01
2023-09-30
0001054102
us-gaap:CostOfSalesMember
2024-01-01
2024-09-30
0001054102
us-gaap:CostOfSalesMember
2023-01-01
2023-09-30
0001054102
us-gaap:SellingAndMarketingExpenseMember
2024-07-01
2024-09-30
0001054102
us-gaap:SellingAndMarketingExpenseMember
2023-07-01
2023-09-30
0001054102
us-gaap:SellingAndMarketingExpenseMember
2024-01-01
2024-09-30
0001054102
us-gaap:SellingAndMarketingExpenseMember
2023-01-01
2023-09-30
0001054102
us-gaap:GeneralAndAdministrativeExpenseMember
2024-07-01
2024-09-30
0001054102
us-gaap:GeneralAndAdministrativeExpenseMember
2023-07-01
2023-09-30
0001054102
us-gaap:GeneralAndAdministrativeExpenseMember
2024-01-01
2024-09-30
0001054102
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-09-30
0001054102
IDXG:TermLoanMember
IDXG:BroadOakMember
2021-10-29
0001054102
IDXG:TermLoanMember
IDXG:AmpersandTwoThousandEighteenMember
2021-10-28
2021-10-29
0001054102
IDXG:TermLoanMember
IDXG:AmpersandTwoThousandEighteenMember
2021-10-29
0001054102
IDXG:ComericaBankMember
us-gaap:RevolvingCreditFacilityMember
2021-10-29
0001054102
us-gaap:RevolvingCreditFacilityMember
IDXG:ComericaBankMember
2021-10-28
2021-10-29
0001054102
IDXG:TermLoanMember
IDXG:BroadOakMember
2022-05-31
0001054102
IDXG:BroadOakLoanAgreementMember
2023-10-29
2023-10-30
0001054102
IDXG:BroadOakLoanAgreementMember
2023-10-23
2023-10-24
0001054102
IDXG:BroadOakLoanAgreementMember
2023-10-31
0001054102
IDXG:BroadOakLoanAgreementMember
2023-11-01
0001054102
IDXG:BroadOakLoanAgreementMember
2023-11-01
2023-11-01
0001054102
IDXG:LoanAndSecurityAgreementMember
2024-03-29
2024-03-29
0001054102
IDXG:LoanAndSecurityAgreementMember
2024-04-01
2024-04-01
0001054102
IDXG:SecurityPurchaseAndExchangeAgreementMember
us-gaap:SeriesBPreferredStockMember
2020-01-09
2020-01-10
0001054102
IDXG:SecurityPurchaseAndExchangeAgreementMember
us-gaap:SeriesBPreferredStockMember
2020-01-10
0001054102
IDXG:SecurityPurchaseAndExchangeAgreementMember
us-gaap:SeriesBPreferredStockMember
IDXG:OneThreeOneFiveCapitalMember
2020-01-09
2020-01-10
0001054102
IDXG:SecurityPurchaseAndExchangeAgreementMember
us-gaap:SeriesBPreferredStockMember
IDXG:AmpersandLimitedPartnersMember
2020-01-09
2020-01-10
0001054102
us-gaap:SeriesAPreferredStockMember
2020-01-09
2020-01-10
0001054102
us-gaap:SeriesAPreferredStockMember
2020-01-10
0001054102
us-gaap:SeriesBPreferredStockMember
2020-01-09
2020-01-10
0001054102
us-gaap:SeriesBPreferredStockMember
2020-01-10
0001054102
us-gaap:CommonStockMember
2024-01-01
2024-09-30
0001054102
IDXG:ComericaLoanAgreementMember
us-gaap:RevolvingCreditFacilityMember
2021-10-13
0001054102
IDXG:ComericaLoanAgreementMember
us-gaap:RevolvingCreditFacilityMember
2023-10-06
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesBPreferredStockMember
IDXG:ExchangeAgreementMember
2024-10-10
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesBPreferredStockMember
IDXG:AmpersandLimitedPartnersMember
IDXG:ExchangeAgreementMember
2024-10-10
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesBPreferredStockMember
IDXG:OneThreeOneFiveCapitalMember
IDXG:ExchangeAgreementMember
2024-10-10
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesCPreferredStockMember
IDXG:ExchangeAgreementMember
2024-10-10
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesCPreferredStockMember
IDXG:ExchangeAgreementMember
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesCPreferredStockMember
IDXG:AmpersandLimitedPartnersMember
IDXG:ExchangeAgreementMember
2024-10-10
2024-10-10
0001054102
us-gaap:SubsequentEventMember
us-gaap:SeriesCPreferredStockMember
IDXG:OneThreeOneFiveCapitalMember
IDXG:ExchangeAgreementMember
2024-10-10
2024-10-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
IDXG:Segment
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
(Mark
One)
☒ |
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended September 30, 2024
OR
☐ |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the transition period from _______________ to _______________
Commission
File Number: 000-24249
Interpace
Biosciences, Inc. |
(Exact
name of registrant as specified in its charter) |
Delaware |
|
22-2919486 |
(State
or other jurisdiction of |
|
(I.R.S.
Employer |
Incorporation
or organization) |
|
Identification
No.) |
Waterview
Plaza, Suite 310, 2001 Route 46, Parsippany, NJ 07054 |
(Address
of principal executive offices and zip code) |
|
(855)
776-6419 |
(Registrant’s
telephone number, including area code) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes ☒ No☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”,
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer ☐ |
|
Accelerated
filer ☐ |
Non-accelerated
filer ☒ |
|
Smaller
reporting company ☒ |
|
|
Emerging
Growth Company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Indicate
the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
Class |
|
Shares
Outstanding November 1, 2024 |
Common
Stock, par value $0.01 per share |
|
4,404,795 |
INTERPACE
BIOSICENCES, INC.
FORM
10-Q FOR PERIOD ENDED SEPTEMBER 30, 2024
TABLE
OF CONTENTS
PART
I. FINANCIAL INFORMATION
INTERPACE
BIOSCIENCES, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(in
thousands, except share and per share data)
| |
September 30, | | |
December 31, | |
| |
2024 | | |
2023 | |
| |
(unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 2,113 | | |
$ | 3,498 | |
Accounts receivable, net of allowance for credit loss of $26 and $0, respectively | |
| 7,293 | | |
| 4,983 | |
Other current assets | |
| 1,704 | | |
| 1,841 | |
Total current assets | |
| 11,110 | | |
| 10,322 | |
Property and equipment, net | |
| 1,352 | | |
| 790 | |
Operating lease right of use assets | |
| 1,532 | | |
| 1,864 | |
Other long-term assets | |
| 45 | | |
| 45 | |
Total assets | |
$ | 14,039 | | |
$ | 13,021 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ DEFICIT | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,701 | | |
$ | 1,544 | |
Accrued salary and bonus | |
| 1,687 | | |
| 1,969 | |
Other accrued expenses | |
| 9,033 | | |
| 8,201 | |
Note payable at fair value, current | |
| 5,688 | | |
| 5,100 | |
Current liabilities of discontinued operations | |
| 660 | | |
| 660 | |
Total current liabilities | |
| 18,769 | | |
| 17,474 | |
Operating lease liabilities, net of current portion | |
| 1,189 | | |
| 1,472 | |
Note payable at fair value | |
| - | | |
| 4,243 | |
Other long-term liabilities | |
| 5,227 | | |
| 4,968 | |
Total liabilities | |
| 25,185 | | |
| 28,157 | |
| |
| | | |
| | |
Commitments and contingencies (Note 8) | |
| - | | |
| - | |
| |
| | | |
| | |
Redeemable preferred stock, $.01 par value; 5,000,000 shares authorized,47,000 shares Series B issued and outstanding | |
| 46,536 | | |
| 46,536 | |
| |
| | | |
| | |
Stockholders’ deficit: | |
| | | |
| | |
Common stock, $.01 par value; 100,000,000 shares authorized; 4,532,991 and 4,447,489 shares issued,
respectively; 4,404,795 and 4,351,445 shares outstanding, respectively | |
| 406 | | |
| 405 | |
Additional paid-in capital | |
| 188,363 | | |
| 188,146 | |
Accumulated deficit | |
| (244,405 | ) | |
| (248,215 | ) |
Treasury stock, at cost (128,196 and 96,044 shares, respectively) | |
| (2,046 | ) | |
| (2,008 | ) |
Total stockholders’ deficit | |
| (57,682 | ) | |
| (61,672 | ) |
Total liabilities and stockholders’ deficit | |
| (32,497 | ) | |
| (33,515 | ) |
| |
| | | |
| | |
Total liabilities, preferred stock and stockholders’ deficit | |
$ | 14,039 | | |
$ | 13,021 | |
The
accompanying notes are an integral part of these condensed consolidated financial statements
INTERPACE
BIOSCIENCES, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited,
in thousands, except for per share data)
| |
| | |
| | |
| | |
| |
| |
For The Three Months | | |
For The Nine Months | |
| |
Ended September 30, | | |
Ended September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Revenue, net | |
$ | 12,295 | | |
$ | 9,078 | | |
$ | 34,610 | | |
$ | 29,931 | |
Cost of revenue | |
| 4,789 | | |
| 4,124 | | |
| 13,602 | | |
| 12,163 | |
Gross profit | |
| 7,506 | | |
| 4,954 | | |
| 21,008 | | |
| 17,768 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Sales and marketing | |
| 2,864 | | |
| 2,498 | | |
| 8,571 | | |
| 7,444 | |
Research and development | |
| 199 | | |
| 149 | | |
| 483 | | |
| 484 | |
General and administrative | |
| 2,538 | | |
| 2,124 | | |
| 6,918 | | |
| 7,515 | |
Acquisition related amortization expense | |
| - | | |
| 199 | | |
| - | | |
| 834 | |
Total operating expenses | |
| 5,601 | | |
| 4,970 | | |
| 15,972 | | |
| 16,277 | |
| |
| | | |
| | | |
| | | |
| | |
Operating income (loss) from continuing operations | |
| 1,905 | | |
| (16 | ) | |
| 5,036 | | |
| 1,491 | |
Interest accretion expense | |
| (4 | ) | |
| (26 | ) | |
| (34 | ) | |
| (92 | ) |
Note payable interest | |
| (141 | ) | |
| (230 | ) | |
| (514 | ) | |
| (682 | ) |
Other expense, net | |
| (394 | ) | |
| (252 | ) | |
| (406 | ) | |
| (408 | ) |
Provision for income taxes | |
| 4 | | |
| 4 | | |
| 12 | | |
| 12 | |
Income (loss) from continuing operations | |
| 1,362 | | |
| (528 | ) | |
| 4,070 | | |
| 297 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations, net of tax | |
| (82 | ) | |
| (86 | ) | |
| (260 | ) | |
| (385 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) | |
$ | 1,280 | | |
$ | (614 | ) | |
$ | 3,810 | | |
$ | (88 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic income (loss) per share of common stock: | |
| | | |
| | | |
| | | |
| | |
From continuing operations | |
$ | 0.31 | | |
$ | (0.12 | ) | |
$ | 0.93 | | |
$ | 0.07 | |
From discontinued operations | |
| (0.02 | ) | |
| (0.02 | ) | |
| (0.06 | ) | |
| (0.09 | ) |
Net income (loss) per basic share of common stock | |
$ | 0.29 | | |
$ | (0.14 | ) | |
$ | 0.87 | | |
$ | (0.02 | ) |
| |
| | | |
| | | |
| | | |
| | |
Diluted income (loss) per share of common stock: | |
| | | |
| | | |
| | | |
| | |
From continuing operations | |
$ | 0.31 | | |
$ | (0.12 | ) | |
$ | 0.92 | | |
$ | 0.07 | |
From discontinued operations | |
| (0.02 | ) | |
| (0.02 | ) | |
| (0.05 | ) | |
| (0.09 | ) |
Net income (loss) per diluted share of common stock | |
$ | 0.29 | | |
$ | (0.14 | ) | |
$ | 0.87 | | |
$ | (0.02 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of common shares and common share equivalents outstanding: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 4,393 | | |
| 4,319 | | |
| 4,380 | | |
| 4,313 | |
Diluted | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
The
accompanying notes are an integral part of these condensed consolidated financial statements
INTERPACE
BIOSCIENCES, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(unaudited,
in thousands)
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
| | |
| | |
| | |
| | |
Additional | | |
| | |
| |
| |
Common Stock | | |
Treasury Stock | | |
Paid in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Balance -December 31, 2022 | |
| 4,367,830 | | |
$ | 405 | | |
| 71,120 | | |
$ | (1,976 | ) | |
$ | 187,516 | | |
$ | (249,017 | ) | |
$ | (63,072 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock | |
| 22,996 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Treasury stock purchased | |
| | | |
| - | | |
| 8,292 | | |
| (9 | ) | |
| - | | |
| - | | |
| (9 | ) |
Stock-based compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 192 | | |
| - | | |
| 192 | |
Net income | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 351 | | |
| 351 | |
Balance -March 31, 2023 | |
| 4,390,826 | | |
$ | 405 | | |
| 79,412 | | |
$ | (1,985 | ) | |
$ | 187,708 | | |
$ | (248,666 | ) | |
$ | (62,538 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock-based compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 157 | | |
| - | | |
| 157 | |
Net income | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 175 | | |
| 175 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance -June 30, 2023 | |
| 4,390,826 | | |
$ | 405 | | |
| 79,412 | | |
$ | (1,985 | ) | |
$ | 187,865 | | |
$ | (248,491 | ) | |
$ | (62,206 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock | |
| 16,666 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Treasury stock purchased | |
| - | | |
| - | | |
| 6,308 | | |
| (12 | ) | |
| - | | |
| - | | |
| (12 | ) |
Stock-based compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 152 | | |
| - | | |
| 152 | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (614 | ) | |
| (614 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance -September 30, 2023 | |
| 4,407,492 | | |
$ | 405 | | |
| 85,720 | | |
$ | (1,997 | ) | |
$ | 188,017 | | |
$ | (249,105 | ) | |
$ | (62,680 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance -December 31, 2023 | |
| 4,447,489 | | |
$ | 405 | | |
| 96,044 | | |
$ | (2,008 | ) | |
$ | 188,146 | | |
$ | (248,215 | ) | |
$ | (61,672 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock | |
| 39,668 | | |
| 1 | | |
| - | | |
| - | | |
| (1 | ) | |
| - | | |
| - | |
Treasury stock purchased | |
| - | | |
| - | | |
| 14,715 | | |
| (16 | ) | |
| - | | |
| - | | |
| (16 | ) |
Stock-based compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 79 | | |
| - | | |
| 79 | |
Net income | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 468 | | |
| 468 | |
Balance -March 31, 2024 | |
| 4,487,157 | | |
$ | 406 | | |
| 110,759 | | |
$ | (2,024 | ) | |
$ | 188,224 | | |
$ | (247,747 | ) | |
$ | (61,141 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Stock-based compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 53 | | |
| - | | |
| 53 | |
Net income | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 2,062 | | |
| 2,062 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance -June 30, 2024 | |
| 4,487,157 | | |
$ | 406 | | |
| 110,759 | | |
$ | (2,024 | ) | |
$ | 188,277 | | |
$ | (245,685 | ) | |
$ | (59,026 | ) |
Balance | |
| 4,487,157 | | |
$ | 406 | | |
| 110,759 | | |
$ | (2,024 | ) | |
$ | 188,277 | | |
$ | (245,685 | ) | |
$ | (59,026 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Issuance of common stock | |
| 45,834 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Treasury stock purchased | |
| - | | |
| - | | |
| 17,437 | | |
| (22 | ) | |
| - | | |
| - | | |
| (22 | ) |
Stock-based compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 86 | | |
| - | | |
| 86 | |
Net income | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,280 | | |
| 1,280 | |
Net income (loss) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 1,280 | | |
| 1,280 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance -September 30, 2024 | |
| 4,532,991 | | |
$ | 406 | | |
| 128,196 | | |
$ | (2,046 | ) | |
$ | 188,363 | | |
$ | (244,405 | ) | |
$ | (57,682 | ) |
Balance | |
| 4,532,991 | | |
$ | 406 | | |
| 128,196 | | |
$ | (2,046 | ) | |
$ | 188,363 | | |
$ | (244,405 | ) | |
$ | (57,682 | ) |
The
accompanying notes are an integral part of these condensed consolidated financial statements.
INTERPACE
BIOSCIENCES, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited,
in thousands)
| |
| | |
| |
| |
For The Nine Months Ended September 30, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
Cash Flows From Operating Activities | |
| | | |
| | |
Net income (loss) | |
$ | 3,810 | | |
$ | (88 | ) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 205 | | |
| 954 | |
Interest accretion expense | |
| 34 | | |
| 92 | |
Amortization of deferred financing fees | |
| - | | |
| 42 | |
Stock-based compensation | |
| 218 | | |
| 501 | |
Bad debt expense reversal | |
| (100 | ) | |
| - | |
Credit loss expense | |
| 26 | | |
| - | |
Change in fair value of note payable | |
| 445 | | |
| 400 | |
Amortization on operating lease right of use asset | |
| 332 | | |
| 461 | |
Other changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (2,336 | ) | |
| 202 | |
Other current assets | |
| 237 | | |
| 176 | |
Accounts payable | |
| 137 | | |
| 228 | |
Accrued salaries and bonus | |
| (320 | ) | |
| (157 | ) |
Other accrued expenses | |
| 870 | | |
| (118 | ) |
Operating lease liabilities | |
| (355 | ) | |
| (292 | ) |
Other long-term liabilities | |
| 259 | | |
| 248 | |
Net cash provided by operating activities | |
| 3,462 | | |
| 2,649 | |
| |
| | | |
| | |
Cash Flows From Investing Activity | |
| | | |
| | |
Working capital adjustment on sale of Interpace Pharma Solutions | |
| - | | |
| (117 | ) |
Proceeds from sale of Interpce Pharma Solutions, net | |
| - | | |
| 500 | |
Purchase of property and equipment | |
| (747 | ) | |
| (328 | ) |
Net cash (used in) provided by investing activities | |
| (747 | ) | |
| 55 | |
| |
| | | |
| | |
Cash Flows From Financing Activities | |
| | | |
| | |
Payments made on note payable | |
| (4,100 | ) | |
| - | |
Payments on line of credit | |
| - | | |
| (2,500 | ) |
Net cash used in financing activities | |
| (4,100 | ) | |
| (2,500 | ) |
| |
| | | |
| | |
Net (decrease) increase in cash and cash equivalents | |
| (1,385 | ) | |
| 204 | |
Cash and cash equivalents from continuing operations– beginning | |
| 3,498 | | |
| 4,828 | |
Cash and cash equivalents from discontinued operations– beginning | |
| - | | |
| - | |
Cash and cash equivalents – beginning | |
$ | 3,498 | | |
$ | 4,828 | |
Cash and cash equivalents from continuing operations– ending | |
$ | 2,113 | | |
$ | 5,032 | |
Cash and cash equivalents from discontinued operations– ending | |
| - | | |
| - | |
Cash and cash equivalents – ending | |
$ | 2,113 | | |
$ | 5,032 | |
The
accompanying notes are an integral part of these condensed consolidated financial statements.
INTERPACE
BIOSCIENCES, INC.
NOTES
TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(Tabular
information in thousands, except per share amounts)
1.
OVERVIEW
Nature
of Business
Interpace
Biosciences, Inc. (“Interpace” or the “Company”) is a company that provides molecular diagnostics, bioinformatics
and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient
diagnosis and management. The Company develops and commercializes genomic tests and related first line assays principally focused on
early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.
2.
BASIS OF PRESENTATION
The
accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”)
should be read in conjunction with the consolidated financial statements of the Company and its wholly-owned subsidiaries (Interpace
Diagnostics Lab Inc., Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC), and related notes as included in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities & Exchange Commission (“SEC”)
on April 1, 2024 and as amended on April 26, 2024.
The
Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United
States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by GAAP for complete financial statements. The Interim Financial Statements
include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial
statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, InServe Support Solutions;
and TVG, Inc., its Commercial Services business unit, which was sold on December 22, 2015 and its Interpace Pharma Solutions business
(“Pharma Solutions”) which was sold on August 31, 2022. All significant intercompany balances and transactions have been
eliminated in consolidation. Operating results for the three-month period ended September 30, 2024 are not necessarily indicative of
the results that may be expected for the fiscal year ending December 31, 2024.
3.
LIQUIDITY
In
October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica Bank (“Comerica”) (the “Comerica
Loan Agreement”). In February 2024, the Company terminated the Comerica Loan Agreement. The Company did not owe anything outstanding
on the line of credit at the time of termination and does not owe anything further to Comerica. See Note 16, Revolving Line of Credit.
Also in October 2021, the Company entered into an $8.0 million term loan with BroadOak Fund V, L.P. (“BroadOak”) (the “Term
Loan”), the proceeds of which were used to repay in full at their maturity the existing secured promissory note with Ampersand
Capital Partners (“Ampersand”) and 1315 Capital II, L.P (“1315 Capital”). In May 2022, the Company entered into
a Subordinated Convertible Promissory Note agreement with BroadOak for an additional $2.0 million (the “Convertible Note”),
which was converted into a subordinated term loan and was added to the outstanding Term Loan balance. The Term Loan has been subsequently
amended. See Note 13, Notes Payable, for more details.
Along
with many laboratories, the Company may be affected by the Proposed Local Coverage Determination (“LCD”) DL39365, which is
currently under consideration by Novitas, the Company’s medical administrator contractor. If finalized, this Proposed LCD, which
governs “Genetic Testing for Oncology,” could impact the existing Medicare coverage for one of our molecular tests, PancraGEN®.
On June 5, 2023, the Company announced that Novitas issued the final LCD of Genetic Testing for Oncology (L39365) which if finalized,
would have established non-coverage for the Company’s widely used PancraGEN® test effective July 17, 2023. On July
6, 2023, Novitas announced that it would not be implementing the final Genetic Testing for Oncology LCD (L39365) as scheduled on July
17, 2023. Novitas then issued a new virtually identical proposed LCD affecting the same companies and tests and reaching the same conclusions
as noted in the previously rescinded LCD on July 27, 2023. In response, the Company participated in a public meeting presentation and
submitted detailed written comments supporting the use of PancraGEN®. The timing and content of any final implemented
LCD is uncertain at this time; the process could potentially take a year or longer from issuance of the updated proposed LCD to reach
a conclusion. On July 29, 2024 the Company announced that CMS granted Novitas an undefined extension to the final decision for the LCD.
As a result, the Company is able to continue offering PancraGEN® and the related Point2® fluid chemistry
tests for amylase, CEA, and glucose. In the event Novitas ultimately restricts coverage for the PancraGEN® test, the Company’s
liquidity could be negatively impacted.
For
the nine months ended September 30, 2024, the Company had operating income from continuing operations of $5.0 million. As of September
30, 2024, the Company had cash and cash equivalents of $2.1 million, total current assets of $11.1 million and current liabilities of
$18.8 million. As of November 1, 2024, the Company had approximately $1.8 million of cash and cash equivalents.
The
Company intends to meet its ongoing capital needs by using its available cash, as well as through targeted margin improvement; collection
of accounts receivable; containment of costs; and the potential use of other financing options and other strategic alternatives.
The
Company continues to explore various strategic alternatives, dilutive and non-dilutive sources of funding, including equity and debt
financings, strategic alliances, business development and other sources in order to provide additional liquidity. With the delisting
of its common stock from Nasdaq in February 2021, the Company’s ability to raise additional capital on terms acceptable to it has
been adversely impacted. There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable
to it.
On
October 10, 2024, Ampersand and 1315 Capital exchanged (the “Exchange”) 47,000 shares of the Company’s Series B convertible
preferred stock of the Company, par value $0.01 per share (the “Series B Preferred Stock”) for 47,000 shares of the Company’s
Series C Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”). See Note 18, Subsequent Events.
The Company believes that the 47,000 shares of Series C Preferred Stock will constitute stockholders’ equity under generally accepted
accounting principles. The Exchange is the first significant step for the Company to seek an uplisting of its common stock to Nasdaq.
Other steps may need to be taken in order to satisfy Nasdaq listing requirements, including meeting Nasdaq’s stockholder equity
and minimum bid price requirements. The Company believes that a Nasdaq listing would assist it in raising additional capital, increasing
investor interest and trading volume in its common stock, and pursuing acquisitions. No assurance can be given that a Nasdaq listing
will be achieved.
With
the improvement in operating cash flows associated with the disposition of the Pharma Solutions business, and the Company’s improved
operating performance, as of the date of this filing, the Company anticipates that current cash and cash equivalents and forecasted cash
receipts will be sufficient to meet its anticipated cash requirements through the next twelve months from the date of the filing of this
report.
4.
DISCONTINUED OPERATIONS
Liabilities
classified as discontinued operations as of both September 30, 2024 and December 31, 2023 consists of accrued expenses which are liabilities
related to the former Commercial Services business unit.
The
table below presents the significant components of its former Pharma Solutions business unit’s results included within loss from
discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and nine months ended September
30, 2024 and 2023.
SCHEDULE
OF COMPONENTS OF ASSETS AND LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED
| |
| | |
| | |
| | |
| |
| |
For The Three Months Ended | | |
For The Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Revenue, net | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
| - | | |
| - | | |
| - | | |
| (137 | ) |
Income tax expense | |
| 82 | | |
| 86 | | |
| 260 | | |
| 248 | |
Loss from discontinued operations, net of tax | |
$ | (82 | ) | |
$ | (86 | ) | |
$ | (260 | ) | |
$ | (385 | ) |
Cash
used from discontinued operations, operating activities, was $20,000, and provided by investing activities was $0.4 million for the nine
months ended September 30, 2023. There was no cash used from discontinued operations for the nine months ended September 30, 2024. There
was no depreciation and amortization expense for the three or nine months ended September 30, 2024 and September 30, 2023, respectively,
in discontinued operations.
5.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Accounting
Estimates
The
preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical
experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the
circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration,
allowances for credit losses, revenue recognition, unrecognized tax benefits, and asset impairments involving intangible assets. The
Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially
differ from those estimates.
Revenue
Recognition
We
derive our revenues from the performance of proprietary assays or tests. The Company’s performance obligation is fulfilled upon
the completion, review and release of test results to the customer. We subsequently bill third-party payers or direct-bill payers for
the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net
realizable value, which is determined based on historical collection rates by each payer category for each proprietary test offered by
the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary
tests, we estimate the amount of variable consideration that should be included in the transaction price using the expected value method
based on historical experience.
We
regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates
and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly
from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become
known.
Financing
and Payment
For
non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically
thirty days and in our now discontinued pharma services, were up to sixty days. Commercial third-party-payers are required to respond
to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment
for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where
multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly
for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full.
Costs
to Obtain or Fulfill a Customer Contract
Sales
commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the
condensed consolidated statements of operations.
Accounts
Receivable
The
Company’s accounts receivable represent unconditional rights to consideration and are generated using its clinical services. The
Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with
fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference
between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed
to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months.
The allowance for credit losses balance was $26,000 and $0 at September 30, 2024 and December 31, 2023, respectively.
Leases
The
Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”)
assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation
to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset
and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides
all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information
available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease
when readily determinable.
Our
lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably
certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line
basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases.
Other
Current Assets
Other
current assets consisted of the following as of September 30, 2024 and December 31, 2023:
SCHEDULE
OF OTHER CURRENT ASSETS
| |
September 30, 2024 | | |
December 31, 2023 | |
Lab supplies | |
$ | 1,220 | | |
$ | 1,227 | |
Prepaid expenses | |
| 441 | | |
| 590 | |
Other | |
| 43 | | |
| 24 | |
Total other current assets | |
$ | 1,704 | | |
$ | 1,841 | |
Long-Lived
Assets, including Finite-Lived Intangible Assets
Finite-lived
intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized
on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related
amortization expense in the condensed consolidated statements of operations.
The
Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances
indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is
less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair
value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and,
where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining
whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.
Basic
and Diluted Net Income (Loss) per Share
A
reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted income
(loss) per share for the three- and nine-month periods ended September 30, 2024 and 2023 is as follows:
SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Basic weighted average number of common shares | |
| 4,393 | | |
| 4,319 | | |
| 4,380 | | |
| 4,313 | |
Potential dilutive effect of stock-based awards | |
| 30 | | |
| - | | |
| 24 | | |
| 42 | |
Diluted weighted average number | |
| | | |
| | | |
| | | |
| | |
of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
Diluted weighted average number of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
The
Company’s Series B Redeemable Preferred Stock, on an as converted basis into common stock of 7,833,334 shares for the three- and
nine-months ended September 30, 2024, and the following outstanding stock-based awards, were excluded from the computation of the effect
of dilutive securities on income (loss) per share for the following periods as they would have been anti-dilutive (rounded to thousands):
SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Options | |
| 288 | | |
| 469 | | |
| 288 | | |
| 394 | |
Restricted stock units (RSUs) | |
| 145 | | |
| 277 | | |
| 145 | | |
| 277 | |
Anti-dilutive
securities | |
| 433 | | |
| 746 | | |
| 433 | | |
| 671 | |
6.
FAIR VALUE MEASUREMENTS
Cash
and cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short-term nature. The Company’s
financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration, warrant
liability and note payable. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including
market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants
would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation
technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used
in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy
ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:
|
Level
1: |
Valuations
for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical
assets or liabilities. |
|
|
|
|
Level
2: |
Valuations
for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services
for identical or similar assets or liabilities. |
|
|
|
|
Level
3: |
Valuations
incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities. |
In
instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy,
the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is
significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to
the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation
methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification
of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:
SCHEDULE
OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS
| |
As of September 30, 2024 | | |
Fair Value Measurements | |
| |
| | |
Fair | | |
As of September 30, 2024 | |
| |
Amount | | |
Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| |
| | |
| | |
| | |
| | |
| |
Liabilities: | |
| | | |
| | | |
| | | |
| | | |
| | |
Contingent consideration: | |
| | | |
| | | |
| | | |
| | | |
| | |
Asuragen (1) | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Note payable: | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loan | |
| 5,900 | | |
| 5,688 | | |
| - | | |
| - | | |
| 5,688 | |
| |
$ | 5,900 | | |
$ | 5,688 | | |
$ | - | | |
$ | - | | |
$ | 5,688 | |
| |
As of December 31, 2023 | | |
Fair Value Measurements | |
| |
Carrying | | |
Fair | | |
As of December 31, 2023 | |
| |
Amount | | |
Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
Liabilities: | |
| | |
| | |
| | |
| | |
| |
Contingent consideration: | |
| | | |
| | | |
| | | |
| | | |
| | |
Asuragen (1) | |
$ | 453 | | |
$ | 453 | | |
$ | - | | |
$ | - | | |
$ | 453 | |
Note payable: | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loan | |
| 10,000 | | |
| 9,343 | | |
| - | | |
| - | | |
| 9,343 | |
| |
$ | 10,453 | | |
$ | 9,796 | | |
$ | - | | |
$ | - | | |
$ | 9,796 | |
In
connection with the acquisition of certain assets from Asuragen, Inc., the Company recorded contingent consideration related to contingent
payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted
income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market
and thus represents a Level 3 measurement.
In
connection with the Term Loan, the Company records the loan at fair value. The fair value of the loan is determined by a probability-weighted
approach regarding the loan’s change in control feature. See Note 13, Notes Payable, for more details. The fair value measurement
is based on the estimated probability of a change in control and thus represents a Level 3 measurement.
A
roll forward of the carrying value of the Contingent Consideration Liability and BroadOak Loan to September 30, 2024 is as follows:
SCHEDULE
OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION
| |
| | |
| | |
| | |
| | |
Adjustment | | |
| |
| |
| | |
| | |
| | |
| | |
to Fair | | |
| |
| |
December 31, 2023 | | |
Payments | | |
Transferred to Accrued Expenses | | |
Accretion/Interest Accrued | | |
Value/
Mark to Market | | |
September 30, 2024 | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Asuragen | |
$ | 453 | | |
$ | - | | |
$ | (487 | ) | |
$ | 34 | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loans | |
| 9,343 | | |
| (4,100 | ) | |
| - | | |
| - | | |
| 445 | | |
| 5,688 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
$ | 9,796 | | |
$ | (4,100 | ) | |
$ | (487 | ) | |
$ | 34 | | |
$ | 445 | | |
$ | 5,688 | |
Certain
of the Company’s non-financial assets, such as intangible assets are measured at fair value on a nonrecurring basis when there
is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.
7.
LEASES
The
table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:
SCHEDULE
OF LEASE RELATED ASSETS AND LIABILITIES
| |
Classification on the Balance Sheet | |
September 30, 2024 | | |
December 31, 2023 | |
| |
| |
| | |
| |
Assets | |
| |
| | | |
| | |
Operating lease assets | |
Operating lease right of use assets | |
| 1,532 | | |
| 1,864 | |
Total lease assets | |
| |
$ | 1,532 | | |
$ | 1,864 | |
| |
| |
| | | |
| | |
Liabilities | |
| |
| | | |
| | |
Current | |
| |
| | | |
| | |
Operating lease liabilities | |
Other accrued expenses | |
| 305 | | |
| 377 | |
Total current lease liabilities | |
| |
$ | 305 | | |
$ | 377 | |
Noncurrent | |
| |
| | | |
| | |
Operating lease liabilities | |
Operating lease liabilities, net of current portion | |
| 1,189 | | |
| 1,472 | |
Total long-term lease liabilities | |
| |
| 1,189 | | |
| 1,472 | |
Total lease liabilities | |
| |
$ | 1,494 | | |
$ | 1,849 | |
The
weighted average remaining lease term for the Company’s operating leases was 3.7 years as of September 30, 2024 and the weighted
average discount rate for those leases was 12.0%. Total operating lease expense from continuing operations under these agreements for
both the three months ended September 30, 2024 and 2023 was approximately $0.2 million and for the nine months ended September 30, 2024
and 2023 was approximately $0.5 million and $0.6 million, respectively. Total cash paid under these agreements for both the nine months
ended September 30, 2024 and 2023 was approximately $0.5 million and $0.6 million respectively. The Company’s operating lease expenses
are recorded within “Cost of revenue” and “General and administrative expenses.”
The
table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as
of September 30, 2024:
SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES
| |
Operating Leases | |
2024 - remaining three months | |
$ | 155 | |
2025 | |
| 450 | |
2026 | |
| 450 | |
2027 | |
| 550 | |
2028 | |
| 275 | |
Total minimum lease payments | |
| 1,880 | |
Less: amount of lease payments representing effects of discounting | |
| 386 | |
Present value of future minimum lease payments | |
| 1,494 | |
Less: current obligations under leases | |
| 305 | |
Long-term lease obligations | |
$ | 1,189 | |
| |
| | |
8.
COMMITMENTS AND CONTINGENCIES
Litigation
From
time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.
When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a
loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition
to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim.
Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may
harm the Company’s business. There is no pending litigation involving the Company at this time.
Due
to the nature of the businesses in which the Company is engaged, it is subject to certain risks. Such risks include, among others, risk
of liability for personal injury or death to persons using products or services that the Company promotes or commercializes. There can
be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business
activities. There is also the risk of employment related litigation and other litigation in the ordinary course of business.
The
Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside
the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages
or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although
applicable, is not performed in accordance with its terms, or if the Company’s liability exceeds the amount of applicable insurance
or indemnity.
9. OTHER ACCRUED EXPENSES
Other accrued expenses consisted of the
following as of September 30, 2024 and December 31, 2023:
SCHEDULE OF OTHER ACCRUED EXPENSES
| |
September 30, 2024 | | |
December 31, 2023 | |
Accrued royalties | |
$ | 7,235 | | |
$ | 6,268 | |
Contingent consideration | |
| - | | |
| 453 | |
Operating lease liability | |
| 305 | | |
| 377 | |
Accrued sales and marketing | |
| 55 | | |
| 43 | |
Accrued lab costs | |
| 233 | | |
| 68 | |
Accrued professional fees | |
| 369 | | |
| 241 | |
Taxes payable | |
| 259 | | |
| 261 | |
All others | |
| 577 | | |
| 490 | |
Total other accrued expenses | |
$ | 9,033 | | |
$ | 8,201 | |
10. STOCK-BASED COMPENSATION
Historically, stock options have been granted
with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they
are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will
be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees
generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.
There were no stock option awards issued
during the nine months ended September 30, 2024 and September 30, 2023.
The Company recognized approximately $0.1
million and $0.2 million of stock-based compensation expense within continuing operations during the three-month periods ended September
30, 2024 and 2023, respectively, and approximately $0.2 million and $0.5 million for the nine-month periods ended September 30, 2024 and
2023, respectively. The following table has a breakout of stock-based compensation expense from continuing operations by line item.
SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD
| |
| | | |
| | | |
| | | |
| | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| |
Cost of revenue | |
$ | - | | |
$ | 13 | | |
$ | 4 | | |
$ | 39 | |
Sales and marketing | |
| 28 | | |
| 31 | | |
| 81 | | |
| 92 | |
General and administrative | |
| 58 | | |
| 108 | | |
| 133 | | |
| 370 | |
Total stock compensation expense | |
$ | 86 | | |
$ | 152 | | |
$ | 218 | | |
$ | 501 | |
11. INCOME TAXES
Generally, accounting standards require
companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative
guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due
to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate
estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.
As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following
table summarizes income tax expense on income from continuing operations and the effective tax rate for the three- and nine-month periods
ended September 30, 2024 and 2023:
SCHEDULE OF EFFECTIVE INCOME TAX RATE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Provision for income tax | |
$ | 4 | | |
$ | 4 | | |
$ | 12 | | |
$ | 12 | |
Effective income tax rate | |
| 0.3 | % | |
| (0.8 | %) | |
| 0.3 | % | |
| 3.9 | % |
Income tax expense for both periods was
primarily due to state franchise taxes.
Other long-term liabilities consisted of
uncertain tax positions as of September 30, 2024 and December 31, 2023.
12. SEGMENT INFORMATION
We operate under one segment which is the
business of developing and selling clinical services.
13. NOTES PAYABLE
BroadOak Loan
On October 29, 2021, the Company and its
subsidiaries entered into the Term Loan with BroadOak, providing for a term loan in the aggregate principal amount of $8,000,000. Funding
of the Term Loan took place on November 1, 2021. The Term Loan was scheduled to mature upon the earlier of (i) October 31, 2024 or (ii)
the occurrence of a change in control, and bears interest at the rate of 9% per annum. The Term Loan is secured by a security interest
in substantially all of the Company’s and its subsidiaries’ assets and was subordinate to the Company’s $7,500,000 revolving
credit facility with Comerica Bank. See Note 16, Revolving Line of Credit. The Term Loan had an origination fee of 3% of the Term
Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs
on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the
change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii)
30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the
Term Loan, or if the Term Loan is repaid on its maturity date.
The Term Loan contains affirmative and negative
restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants, which include
restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business.
The Term Loan also contains customary events of default.
The Company concluded that the Term Loan
met the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair
value option under ASC 825-10-15-4, and did not meet the definition of any of the financial instruments listed within ASC 825-10-15-5
that are not eligible for the fair value option. The Note is not convertible and does not have any component recorded to stockholders’
deficit. Accordingly, the Company elected the fair value option for the Note.
In May 2022, the Company issued a convertible
note to BroadOak, pursuant to which BroadOak funded a term loan in the aggregate principal amount of $2.0 million, which was converted
into a subordinated term loan and was added to the outstanding balance of the Term Loan.
On October 24, 2023, the Company entered
into a Second Amendment to Loan and Security Agreement (the “Second Amendment”) with BroadOak. The primary changes to the
original Term Loan were as follows:
|
● |
The Company made a one-time payment in an aggregate amount equal to $2,500,000, on October 30, 2023 and applied the payment in full satisfaction of the $3,000,000 Terminal Payment (as defined in the Term Loan). See above regarding the Terminal Payment. |
|
● |
Effective November 1, 2023, the interest rate under the Term Loan was reduced from 9% to 8% through the maturity date of October 31, 2024 or earlier, upon the occurrence of a change in control (“Loan Maturity Date”). |
|
|
|
|
● |
The Company had the option to request an extension of the Loan Maturity Date in writing no less than sixty days prior to the Loan Maturity Date. If BroadOak agreed to the extension, the Loan Maturity Date would automatically be extended. |
On March 29, 2024, the Company entered into
a Third Amendment to Loan and Security Agreement with BroadOak (the “Third Amendment”). The primary changes to the Second
Amendment were as follows:
|
● |
The maturity date was extended to June 30, 2025. |
|
● |
Beginning April 1, 2024, the Company will make $500,000 monthly payments with the remaining loan balance due on the new maturity date. |
The Third Amendment was treated as a debt
modification which is accounted for prospectively. Since the Term Loan is carried at fair value under the fair value option, the Second
Amendment did not result in any extinguishment gain or loss upon amendment, and the impact of the revised terms was incorporated into
the Company’s first quarter 2024 fair value calculation.
The balance of the loan outstanding at September
30, 2024 was $5.9 million.
14. SUPPLEMENTAL CASH FLOW INFORMATION
Supplemental Disclosures of Non-Cash Activities
(in thousands)
SUPPLEMENTAL CASH FLOW INFORMATION
| |
| | |
| |
| |
Nine Months Ended | |
| |
September 30, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
Taxes accrued for repurchase of restricted shares | |
$ | 38 | | |
$ | 21 | |
Purchase of property and equipment included in accounts payable | |
| 20 | | |
| 74 | |
15. MEZZANINE EQUITY
Redeemable Preferred Stock
On January 10, 2020, the Company entered
into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and
Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $20.0
million in Series B Preferred Stock of the Company, at an issuance price per share of $1,000 (“New Investment Shares”). Pursuant
to the Securities Purchase and Exchange Agreement, 1315 Capital agreed to purchase 19,000 shares of Series B Preferred Stock at an aggregate
purchase price of $19.0 million and Ampersand agreed to purchase 1,000 shares of Series B Preferred Stock at an aggregate purchase price
of $1.0 million.
In addition, the Company agreed to exchange
$27.0 million of the Company’s existing Series A convertible preferred stock, par value $0.01 per share, held by Ampersand (the
“Series A Preferred Stock”), represented by 270 shares of Series A Preferred Stock with a stated value of $100,000 per share,
which represents all of the Company’s issued and outstanding Series A Preferred Stock, for 27,000 newly issued shares of Series
B Preferred Stock (such shares of Series B Preferred Stock, the “Exchange Shares” and such transaction, the “Exchange”).
Following the Exchange, no shares of Series A Preferred Stock remained designated, authorized, issued or outstanding. The Series B Preferred
Stock has a conversion price of $6.00. On October 10, 2024, the Investors (as defined below) exchanged their shares of Series B Preferred
Stock for shares of Series C Preferred Stock with a conversion price of $2.02. See Note 18, Subsequent Events.
Voting
On any matter presented to the stockholders
of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of Series B Preferred Stock will be entitled to cast the number of votes equal
to the number of whole shares of the Company’s common stock into which the shares of Series B Preferred Stock held by such holder
are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the
Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “Series B Certificate
of Designation”), holders of Series B Preferred Stock will vote together with the holders of common stock as a single class and
on an as-converted to common stock basis.
Director Designation Rights
The Series B Certificate of Designation
also provides each Investor with the following director designation rights: for so long such Investor holds at least sixty percent (60%)
of the Series B Preferred Stock issued to it on the Issuance Date (as defined therein), such Investor will be entitled to elect two directors
to the Company’s Board of Directors (the “Board”), provided that one of the directors qualifies as an “independent
director” under Rule 5605(a)(2) of the listing rules of the Nasdaq Stock Market (or any successor rule or similar rule promulgated
by another exchange on which the Company’s securities are then listed or designated) (“Independent Director”). However,
if at any time such Investor holds less than sixty percent (60%), but at least forty percent (40%), of the Series B Preferred Stock issued
to them on the Issuance Date, such Investor would only be entitled to elect one director to the Board. Any director elected pursuant to
the terms of the Series B Certificate of Designation may be removed without cause by, and only by, the affirmative vote of the holders
of Series B Preferred Stock. A vacancy in any directorship filled by the holders of Series B Preferred Stock may be filled only by vote
or written consent in lieu of a meeting of such holders of Series B Preferred Stock or by any remaining director or directors elected
by such holders of Series B Preferred Stock.
On November 15, 2023, Edward Chan, a director
designated by 1315 Capital to the Board, provided notice to the Company of his resignation from the Board, effective immediately. Further,
on December 7, 2023, Robert Gorman, a director designated by Ampersand to the Board, provided notice to the Company of his resignation
as a director and as Chairman of the Board, effective immediately.
As of the date of this report, each of 1315
Capital and Ampersand has appointed one director to the Board, and each has not appointed a second director to the Board.
Conversion
The Series B Certificate of Designation
provides that from and after the Issuance Date and subject to the terms of the Series B Certificate of Designation, each share of Series
B Preferred Stock is convertible, at any time and from time to time, at the option of the holder into a number of shares of common stock
equal to dividing the amount equal to the greater of the Stated Value of such Series B Preferred Stock, plus any dividends declared but
unpaid thereon, or such amount per share as would have been payable had each such share been converted into common stock immediately prior
to a liquidation, by six dollars ($6.00) (subject to adjustment in the event of any stock dividend, stock split, combination, or other
similar recapitalization affecting such shares). The aggregate number of shares of common stock that may be issued through conversion
of all of the New Investment Shares and Exchange Shares is 7,833,334 shares (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization affecting such shares).
Mandatory Conversion
If the Company consummates the sale of shares
of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under
the Securities Act pursuant to which the price of the common stock in such offering is at least equal to twelve dollars ($12.00) (subject
to adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization affecting such shares) and
such offering does not include warrants (or any other convertible security) and results in at least $25,000,000 in proceeds, net of the
underwriting discount and commissions, to the Company, and the common stock continues to be listed for trading on the Nasdaq Capital Market
or another exchange, all outstanding shares of Series B Preferred Stock will automatically be converted into shares of common stock, at
the then effective Series B Conversion Ratio (as defined in the Series B Certificate of Designation).
Liquidation
Upon any voluntary or involuntary liquidation,
dissolution or winding up of the Company or Deemed Liquidation (as defined in the Series B Certificate of Designation) (a “Liquidation”),
the holders of shares of Series B Preferred Stock then outstanding will be entitled to be paid out of the assets of the Company available
for distribution to its stockholders (on a pari passu basis with the holders of any class or series of preferred stock ranking on liquidation
on a parity with the Series B Preferred Stock), and before any payment will be made to the holders of common stock or any other class
or series of preferred stock ranking on liquidation junior to the Series B Preferred Stock by reason of their ownership thereof, an amount
per share of Series B Preferred Stock equal to the greater of (i) the Stated Value of such share of Series B Preferred Stock, plus any
dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had each such share been converted into
common stock immediately prior to such Liquidation.
As of September 30, 2024 and December 31,
2023, there were 47,000 issued and outstanding shares of Series B Preferred Stock, respectively. See Note 18, Subsequent Events,
for updates regarding the status of the Series B Preferred Stock.
16. REVOLVING LINE OF CREDIT
On October 13, 2021, the Company and its
subsidiaries entered into the Comerica Loan Agreement with Comerica, providing for a revolving credit facility of up to $7,500,000 (the
“Credit Facility”). The Company could use the proceeds of the Credit Facility for working capital and other general corporate
purposes.
On October 6, 2023, effective September
30, 2023, the Company entered into a Fifth Amendment to its Loan and Security Agreement (the “Fifth Amendment to the Comerica Loan
Agreement”) with Comerica providing for a revolving credit facility of up to $5,000,000.
In February 2024, the Company terminated
the Comerica Loan Agreement. The Company did not owe anything outstanding on the line of credit at the time of termination and does not
owe anything further to Comerica.
17. RECENT ACCOUNTING STANDARDS
Accounting Pronouncements
Adopted
In August 2020, the FASB issued ASU 2020-06,
Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s
Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments
with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU
2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. This
was adopted on January 1, 2024 and there was no impact upon adoption.
Accounting Pronouncements
Pending
In November 2023, the FASB
modified authoritative guidance within the codification’s Segment Reporting topic (ASC 280), which enhanced the disclosure requirements
for significant segment expenses and other segment items. The authoritative guidance will become effective for fiscal years beginning
after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The Company will adopt the standard
as of the effective date.
In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure
of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09
is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the
impact the adoption of this standard on its financial statements.
18. SUBSEQUENT EVENTS
On
October 10, 2024, the Company and the Investors entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to
which the Investors exchanged (the “Exchange”) an aggregate of 47,000 shares of the Company’s Series B Preferred Stock,
comprised of 28,000 shares of Series B Preferred Stock held by Ampersand and 19,000 shares of Series B Preferred Stock held by 1315 Capital,
which represented all of the Company’s issued and outstanding Series B Preferred Stock, for 47,000 newly created shares of Series
C Preferred Stock, at an issuance price per share of $1,000. In the Exchange, Ampersand received 28,000 shares of Series C Preferred Stock
and 1315 received 19,000 shares of Series C Preferred Stock.
The
Series C Preferred Stock is convertible into the Company’s common stock at a conversion price of $2.02 per share of common stock
(subject to further adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization affecting
such shares) which was the closing price of the common stock on the date of the Exchange Agreement. The Series C Preferred Stock does
not have a liquidation preference over the common stock in the event of a sale or dissolution of the Company, does not have director designation
rights and includes limited customary protective provisions. The Series B Preferred Stock had a conversion price of $6.00 per share of
common stock and included additional protective provisions not applicable to the Series C Preferred Stock, including (i) limitations on
the Board to declare dividends, (ii) director designation rights for each of the Investors, (iii) liquidation rights of holders upon “deemed
liquidation” events, including a liquidation preference over the common stock, (iv) limitations on the ability to authorize, issue
or create debt securities, (v) limitations on the ability to enter into mergers or acquisitions and (vi) limitations on the ability to
conduct public offerings of the Company’s common stock. See Note 15, Mezzanine Equity. The Series C Preferred Stock is convertible
into 23,267,326 shares of common stock.
In
connection with the Exchange, on October 11, 2024 the Company filed a Certificate of Designation of Preferences, Rights and Limitations
of Series C Convertible Preferred Stock (the “Series C Certificate of Designation”), with the Secretary of State of the State
of Delaware. The Series C Certificate of Designation set forth the rights and obligations of the Series C Preferred Stock, including with
respect to voting rights, conversion rights, certain protective provisions and liquidation rights. Please refer to the Company’s
current report on Form 8-K, filed with the SEC on October 15, 2024, for more information.
The
closing of the transactions contemplated by the Exchange Agreement occurred on October 11, 2024, following the satisfaction of customary
conditions set forth in the Exchange Agreement and did not result in the receipt of any cash proceeds by the Company.
INTERPACE BIOSCIENCES, INC
Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations
FORWARD-LOOKING STATEMENTS
This quarterly report on Form
10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the
“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements
that are not historical facts, including statements about our plans, objectives, beliefs and expectations, are forward-looking statements.
Forward-looking statements include statements preceded by, followed by or that include the words “believes,” “expects,”
“anticipates,” “plans,” “estimates,” “intends,” “projects,” “should,”
“could,” “may,” “will” or similar words and expressions. These forward-looking statements are contained
throughout this Form 10-Q.
Forward-looking statements are
only predictions and are not guarantees of future performance. These statements are based on current expectations and assumptions involving
judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are
difficult or impossible to predict accurately and many of which are beyond our control. These predictions are also affected by known and
unknown risks, uncertainties and other factors that may cause our actual results to be materially different from those expressed or implied
by any forward-looking statement. Many of these factors are beyond our ability to control or predict. Our actual results could differ
materially from the results contemplated by these forward-looking statements due to a number of factors. Such factors include, but are
not limited to, the following:
|
● |
our history of operating losses prior to fiscal 2023; |
|
|
|
|
● |
our expectations of future revenues, expenditures, capital or other funding requirements; |
|
|
|
|
● |
our reliance on Medicare reimbursement for our clinical services and our being subject to decisions of the Center for Medicare and Medicaid Services (“CMS”) regarding reimbursement and pricing of our clinical services which could have a material adverse effect on our business and financial results; |
|
|
|
|
● |
our ability to continue to perform, bill and receive reimbursement for our PancraGEN® molecular test long-term under the existing local coverage determination (“LCD”), given that such LCD is currently under review by Novitas, the Company’s Medicare administrative contractor; |
|
|
|
|
● |
our secured lender has the right to foreclose on substantially all of our assets if we are unable to timely repay our outstanding obligations; |
|
|
|
|
● |
our dependence on sales and reimbursements from our clinical services for all of our revenue; |
|
|
|
|
● |
the ability to continue to generate sufficient revenue from our clinical service products and other products and/or solutions that we develop in the future is important for our ability to meet our financial and other targets; |
|
|
|
|
● |
our ability to finance our business on acceptable terms in the future, which may limit the ability to grow our business, develop and commercialize products and services, develop and commercialize new molecular clinical service solutions and technologies; |
|
|
|
|
● |
our obligations to make royalty and milestone payments to our licensors; |
|
● |
our dependence on third parties for the supply of some of the materials used in our clinical services tests; |
|
● |
the potential adverse impact of current and future laws, licensing requirements and governmental regulations upon our business operations, including but not limited to the evolving U.S. regulatory environment related to laboratory developed tests (“LDTs”), pricing of our tests and services and patient access limitations; |
|
|
|
|
● |
our reliance on our sales and marketing activities for future business growth and our ability to continue to expand our sales and marketing activities; |
|
|
|
|
● |
our being subject to the controlling interests of our two private equity investors who control, on an as-converted basis, an aggregate of 84.1% of our outstanding shares of common stock through their holdings of our Series C Preferred Stock, this concentration of ownership may have a substantial influence on our decisions; |
|
|
|
|
● |
the delisting of our common stock from Nasdaq has adversely affected and may continue to adversely affect our common stock and business and financial condition; |
|
|
|
|
● |
our ability to successfully uplist our shares of common stock onto Nasdaq; |
|
|
|
|
● |
geopolitical and other economic and political conditions or events (such as the wars in Ukraine and Israel/Gaza); |
|
|
|
|
● |
our ability to implement our business strategy; and |
|
|
|
|
● |
the potential impact of existing and future contingent liabilities on our financial condition. |
Please see Part I – Item
1A – “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC
on April 1, 2024, and as amended on April 26, 2024, as well as other documents we file with the SEC from time-to-time, for other important
factors that could cause our actual results to differ materially from our current expectations as expressed in the forward-looking statements
discussed in this Form 10-Q. Because of these and other risks, uncertainties and assumptions, you should not place undue reliance on these
forward-looking statements. In addition, these statements speak only as of the date of the report in which they are set forth and, except
as may be required by law, we undertake no obligation to revise or update publicly any forward-looking statements for any reason.
OVERVIEW
We are a fully integrated commercial
company that provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the
latest technology in personalized medicine for improved patient diagnosis and management. We develop and commercialize genomic tests and
related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using
the latest technology.
Impact of Our Reliance on CMS and Novitas
Along with many laboratories,
we may be affected by the Proposed LCD DL39365, which is currently under consideration by our local Medicare Administrative Contractor,
Novitas. If finalized, this Proposed LCD, which governs “Genetic Testing for Oncology,” could impact the existing Medicare
coverage for one of our molecular tests, PancraGEN®. On June 5, 2023 we announced that Novitas issued the final LCD of
Genetic Testing for Oncology (L39365) which, if finalized, would have established non-coverage for the Company’s widely used PancraGEN®
test effective July 17, 2023. On July 6, 2023, Novitas announced that it would not be implementing the final Genetic Testing for Oncology
LCD (L39365) as scheduled on July 17, 2023. Novitas then issued a new virtually identical proposed LCD affecting the same companies and
tests and reaching the same conclusions as noted in the previously rescinded LCD on July 27, 2023. In response, the Company participated
in a public meeting presentation and submitted detailed written comments supporting the use of PancraGEN®. The timing and
content of any final implemented LCD is uncertain at this time; the process could potentially take a year or longer from issuance of the
updated proposed LCD to reach a conclusion. On July 29, 2024 the Company announced that CMS granted Novitas an undefined extension to
the final decision for the LCD. As a result, we are able to continue offering PancraGEN® and the related Point2®
fluid chemistry tests for amylase, CEA, and glucose. In the event Novitas ultimately restricts coverage for the PancraGEN®
test, the Company’s liquidity could be negatively impacted.
U.S. Food and Drug
Administration Regulation of LDTs
While subject to oversight by
CMS through its enforcement of the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), the Food and Drug Administration
(“FDA”) has claimed regulatory authority over laboratories that produce LDTs, a type of in vitro diagnostic test that is designed,
manufactured and used within a single laboratory. The FDA has regulatory responsibility over, among other areas, instruments, test kits,
reagents and other devices used in clinical laboratories to perform diagnostic testing in the United States.
Historically, the FDA has exercised
enforcement discretion over most LDTs. On April 29, 2024, however, the FDA published a final rule on LDTs, in which the FDA outlines its
plans to end enforcement discretion for many LDTs in five stages over a four-year period. In Phase 1 (effective May 6, 2025), clinical
laboratories running LDTs will be required to comply with medical device (adverse event) reporting and correction/removal reporting requirements,
as well as requirements for maintenance of complaint files under the FDA’s quality systems regulation (QSR). In Phase 2 (effective
May 6, 2026), clinical laboratories will be required to comply with all other device requirements (e.g., registration/listing, labeling,
investigational use), except for the remaining QSR requirements and premarket review. In Phase 3 (effective May 6, 2027), clinical laboratories
will be required to comply with all remaining applicable QSR requirements. In Phase 4 (effective November 6, 2027), clinical laboratories
will be required to comply with premarket review requirements for high-risk tests (i.e., tests subject to the premarket approval (PMA)
requirement). Finally, in Phase 5 (effective May 6, 2028), clinical laboratories will be required to comply with premarket review requirements
for moderate- and low-risk tests (i.e., tests subject to the de novo or 510(k) requirement).
Under the final rule, several
types of tests will be eligible for some degree of continued enforcement discretion. For example, LDTs approved by the New York State
Department of Health will be exempt from premarket review requirements but will remain subject to the requirements of Phases 1 through
3. Similarly, LDTs first marketed prior to May 6, 2024 that are not subsequently modified, or are modified only in certain limited ways,
will be exempt from the premarket review and most quality systems requirements, but will remain subject to the requirements of Phases
1 and 2. The FDA notes, however, that it retains discretion to pursue enforcement action for violations of the Federal Food, Drug and
Cosmetic Act at any time and intends to do so when appropriate. The FDA further explains that it may update any of the enforcement discretion
policies set forth in the final rule as circumstances warrant or if the circumstances that inform those policies change, consistent with
the FDA’s good guidance practices.
To the extent the FDA ultimately
regulates certain LDTs, our LDTs may be subject to certain additional regulatory requirements. Complying with the FDA’s requirements
can be expensive, time-consuming, and subject us to significant or unanticipated delays. Insofar as we may be required to obtain premarket
clearance or approval to perform or continue performing an LDT, we cannot assure you that we will be able to obtain such authorization.
Even if we obtain regulatory clearance or approval where required, such authorization may not be for the intended uses that we believe
are commercially attractive or are critical to the commercial success of our tests. As a result, the application of the FDA’s requirements
to our tests could materially and adversely affect our business, financial condition, and results of operations.
Failure to comply with applicable
requirements could result in a range of enforcement actions by the FDA, such as warning letters, civil monetary penalties, injunctions,
criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown of operations, and denial of or
challenges to applications for clearance or approval, as well as significant adverse publicity.
Legislative proposals have also
been introduced that, if enacted, would potentially supersede the final rule. In March 2017, members of Congress posted a discussion draft
of “The Diagnostics Accuracy and Innovation Act”. The discussion draft included language that, if enacted, would have established
a new regulatory framework for the oversight of in vitro clinical tests (“IVCTs”) which include LDTs. In March 2020, members
of Congress introduced “The Verifying Accurate, Leading-edge IVCT Development (VALID) Act.” This bill has been re-introduced
in substantially similar forms over the years, and, most recently in March 2023. Under the most recent version of the VALID Act, a risk-based
approach would be used to regulate IVCTs while grandfathering many existing IVCTs from certain requirements. Each test will be classified
as high-risk, moderate-risk, or low-risk. Pre-market review will be required for high-risk tests. To market a high-risk IVCT, reasonable
assurance of analytical and clinical validity for the intended use must be established. Under VALID, a precertification process would
be established which will allow a laboratory to establish that the facilities, methods, and controls used in the development of certain
IVCTs meet quality system requirements. If pre-certified, IVCTs falling within the scope of a certification order will not be subject
to pre-market review. The new regulatory framework would include quality control and post-market reporting requirements. The FDA would
have the authority to withdraw from the market IVCTs if there is a reasonable likelihood that such tests will cause death or serious adverse
health consequences (among other criteria). Failure to comply with applicable regulatory requirements could result in enforcement action
by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. However,
we cannot predict if this (or any other bill) will be enacted in its current (or any other) form and cannot quantify the effect of such
proposals on our business.
Whether via statute, regulation,
or sub-regulatory action, any FDA effort to end enforcement discretion for LDTs is likely to continue to be met with resistance by certain
sections of industry. Multiple lawsuits have been filed challenging the April 2024 LDT final rule, in which the plaintiffs argue that
the FDA lacks authority to regulate LDTs as medical devices. We cannot predict the likelihood of success of these or any other such actions,
nor can we quantify the effect of such efforts on our business.
Revenue Recognition
Clinical services derive revenues
from the performance of proprietary assays or tests. Our performance obligation is fulfilled upon completion, review and release of test
results to the customer, at which time we bill third-party payers or direct-bill payers for the tests performed. Under Accounting Standards
Codification 606, revenue is recognized based upon the estimated transaction price or net realizable value (“NRV”), which
is determined based on historical collection rates by each payer category for each proprietary test offered. To the extent that the transaction
price includes variable consideration, for all third party and direct-bill payers and proprietary tests, we estimate the amount of variable
consideration that should be included in the transaction price using the expected value method based on historical experience.
The ultimate amounts received
from the third-party and direct-bill payers and related estimated reimbursement rates are regularly reviewed and we adjust the NRV’s
and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we
adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known.
Cost of Revenue
Cost of revenue consists primarily
of the costs associated with operating our laboratory and other costs directly related to our tests. Personnel costs, which constitute
the largest portion of cost of services, include all labor-related costs, such as salaries, bonuses, fringe benefits and payroll taxes
for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty
expenses, and facility expenses.
CONDENSED CONSOLIDATED RESULTS OF OPERATIONS
The following table sets forth,
for the periods indicated, certain statements of operations data. The trends illustrated in this table may not be indicative of future
results.
Condensed Consolidated Results of Continuing Operations
for the Quarter Ended September 30, 2024 Compared to the Quarter Ended September 30, 2023 (unaudited, in thousands)
| |
Three Months Ended September 30, | |
| |
2024 | | |
2024 | | |
2023 | | |
2023 | |
| |
| | |
% to | | |
| | |
% to | |
| |
| | |
revenue | | |
| | |
revenue | |
| |
| | |
| | |
| | |
| |
Revenue, net | |
$ | 12,295 | | |
| 100.0 | % | |
$ | 9,078 | | |
| 100.0 | % |
Cost of revenue | |
| 4,789 | | |
| 39.0 | % | |
| 4,124 | | |
| 45.4 | % |
Gross profit | |
| 7,506 | | |
| 61.0 | % | |
| 4,954 | | |
| 54.6 | % |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Sales and marketing | |
| 2,864 | | |
| 23.3 | % | |
| 2,498 | | |
| 27.5 | % |
Research and development | |
| 199 | | |
| 1.6 | % | |
| 149 | | |
| 1.6 | % |
General and administrative | |
| 2,538 | | |
| 20.6 | % | |
| 2,124 | | |
| 23.4 | % |
Acquisition related amortization expense | |
| - | | |
| 0.0 | % | |
| 199 | | |
| 2.2 | % |
Total operating expenses | |
| 5,601 | | |
| 45.6 | % | |
| 4,970 | | |
| 54.7 | % |
| |
| | | |
| | | |
| | | |
| | |
Operating income (loss) | |
| 1,905 | | |
| 15.5 | % | |
| (16 | ) | |
| -0.2 | % |
Interest accretion expense | |
| (4 | ) | |
| 0.0 | % | |
| (26 | ) | |
| -0.3 | % |
Note payable interest | |
| (141 | ) | |
| -1.1 | % | |
| (230 | ) | |
| -2.5 | % |
Other expense, net | |
| (394 | ) | |
| -3.2 | % | |
| (252 | ) | |
| -2.8 | % |
Income (loss) from continuing operations before tax | |
| 1,366 | | |
| 11.1 | % | |
| (524 | ) | |
| -5.8 | % |
Provision for income taxes | |
| 4 | | |
| 0.0 | % | |
| 4 | | |
| 0.0 | % |
Income (loss) from continuing operations | |
| 1,362 | | |
| 11.1 | % | |
| (528 | ) | |
| -5.8 | % |
| |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations, net of tax | |
| (82 | ) | |
| -0.7 | % | |
| (86 | ) | |
| -0.9 | % |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) | |
$ | 1,280 | | |
| 10.4 | % | |
$ | (614 | ) | |
| -6.8 | % |
Revenue, net
Revenue, net for the three months
ended September 30, 2024 increased by $3.2 million, or 35%, to $12.3 million, compared to $9.1 million for the three months ended September
30, 2023. The increase in net revenue was largely driven by increased test volumes as compared to the prior year.
Cost of revenue
Consolidated cost of revenue
for the three months ended September 30, 2024 was $4.8 million, as compared to $4.1 million for the three months ended September 30, 2023.
As a percentage of revenue, cost of revenue decreased to 39% for the three months ended September 30, 2024 from 45% for the three months
ended September 30, 2023. This decrease was due to the increase in revenue mentioned above.
Gross profit
Consolidated gross profit
was approximately $7.5 million for the three months ended September 30, 2024 and $5.0 million for the three months ended September
30, 2023. The gross profit percentage increased to 61% for the three months ended September 30, 3024 from 55% for the three months
ended September 30, 2023, respectively. This improvement was primarily due to the increase in revenue discussed above, which
resulted in fixed costs becoming a smaller percentage of cost of revenue which in turn improved the gross profit percentage.
Sales and marketing expense
Sales and marketing expense was
approximately $2.9 million for the three months ended September 30, 2024 and $2.5 million for the three months ended September 30, 2023.
The increase was primarily attributable to increased headcount and related employee costs. As
a percentage of revenue, sales and marketing expense was 23% for the three months ended September 30, 2024 as compared to 28% for the
three months ended September 30, 2023.
Research and development
Research and development expense
was approximately $0.2 million for the three months ended September 30, 2024 and $0.1 million for the three months ended September 30,
2023. As a percentage of revenue, research and development expense was approximately 2% in both periods.
General and administrative
General and administrative expense
was approximately $2.5 million for the three months ended September 30, 2024 and $2.1 million for the three months ended September 30,
2023. The increase can be primarily attributed to an increase in employee costs and legal and professional
fees during the quarter.
Acquisition amortization expense
During
the three months ended September 30, 2023, we recorded amortization expense of approximately
$0.2 million, which was related to intangible assets associated with prior acquisitions. There was no amortization expense during the
three months ended September 30, 2024.
Operating income (loss)
Operating income from continuing
operations was $1.9 million for the three months ended September 30, 2024 as compared to an operating loss from continuing operations
of $0.02 million for the three months ended September 30, 2023. The increase in operating income from continuing operations was primarily
attributable to the increases in revenue and gross profit discussed above.
Provision for income taxes
Income tax expense was approximately
$4,000 for both the three months ended September 30, 2024 and the three months ended September 30, 2023.
Loss from discontinued operations, net of tax
We had a loss from discontinued
operations of approximately $0.1 million for both the three months ended September 30, 2024 and for the three months ended September 30,
2023, respectively.
Condensed Consolidated Results of Continuing Operations
for the Nine Months Ended September 30, 2024 Compared to the Nine Months Ended September 30, 2023 (unaudited, in thousands)
| |
Nine Months Ended September 30, | |
| |
2024 | | |
2024 | | |
2023 | | |
2023 | |
| |
| | |
% to | | |
| | |
% to | |
| |
| | |
revenue | | |
| | |
revenue | |
| |
| | |
| | |
| | |
| |
Revenue, net | |
$ | 34,610 | | |
| 100.0 | % | |
$ | 29,931 | | |
| 100.0 | % |
Cost of revenue | |
| 13,602 | | |
| 39.3 | % | |
| 12,163 | | |
| 40.6 | % |
Gross profit | |
| 21,008 | | |
| 60.7 | % | |
| 17,768 | | |
| 59.4 | % |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Sales and marketing | |
| 8,571 | | |
| 24.8 | % | |
| 7,444 | | |
| 24.9 | % |
Research and development | |
| 483 | | |
| 1.4 | % | |
| 484 | | |
| 1.6 | % |
General and administrative | |
| 6,918 | | |
| 20.0 | % | |
| 7,515 | | |
| 25.1 | % |
Acquisition related amortization expense | |
| - | | |
| 0.0 | % | |
| 834 | | |
| 2.8 | % |
Total operating expenses | |
| 15,972 | | |
| 46.1 | % | |
| 16,277 | | |
| 54.4 | % |
| |
| | | |
| | | |
| | | |
| | |
Operating income | |
| 5,036 | | |
| 14.6 | % | |
| 1,491 | | |
| 5.0 | % |
Interest accretion expense | |
| (34 | ) | |
| -0.1 | % | |
| (92 | ) | |
| -0.3 | % |
Note payable interest | |
| (514 | ) | |
| -1.5 | % | |
| (682 | ) | |
| -2.3 | % |
Other expense, net | |
| (406 | ) | |
| -1.2 | % | |
| (408 | ) | |
| -1.4 | % |
Income from continuing operations before tax | |
| 4,082 | | |
| 11.8 | % | |
| 309 | | |
| 1.0 | % |
Provision for income taxes | |
| 12 | | |
| 0.0 | % | |
| 12 | | |
| 0.0 | % |
Income from continuing operations | |
| 4,070 | | |
| 11.8 | % | |
| 297 | | |
| 1.0 | % |
| |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations, net of tax | |
| (260 | ) | |
| -0.8 | % | |
| (385 | ) | |
| -1.3 | % |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) | |
$ | 3,810 | | |
| 11.0 | % | |
$ | (88 | ) | |
| -0.3 | % |
Revenue, net
Revenue, net for the nine months
ended September 30, 2024 increased by $4.7 million, or 16%, to $34.6 million, compared to $29.9 million for the nine months ended September
30, 2023. The increase in net revenue was largely driven by increased test volumes as compared to the prior year.
Cost of revenue
Consolidated cost of revenue
for the nine months ended September 30, 2024 was $13.6 million, as compared to $12.2 million for the nine months ended September 30, 2023.
As a percentage of revenue, cost of revenue was approximately 39% for the nine months ended September 30, 2024 as compared to 41% for
the nine months ended September 30, 2023.
Gross profit
Consolidated gross profit was
approximately $21.0 million for the nine months ended September 30, 2024 and $17.8 million for the nine months ended September 30, 2023.
The gross profit percentage was approximately 61% for the nine months ended September 30, 3024 and 59% for the nine months ended September
30, 2023. The increase was primarily due to the increase in revenue discussed above.
Sales and marketing expense
Sales and marketing expense was
approximately $8.6 million for the nine months ended September 30, 2024 and $7.4 million for the nine months ended September 30, 2023.
The increase was primarily due to increased employee costs. As a percentage of revenue, sales and marketing expense was approximately
25% in both periods.
Research and development
Research and development expense
was approximately $0.5 million for both the nine months ended September 30, 2024 and September 30, 2023, respectively. As a percentage
of revenue, research and development expense decreased to 1% from 2% in the comparable prior year period.
General and administrative
General and administrative expense
was approximately $6.9 million for the nine months ended September 30, 2024 and $7.5 million for the three months ended September 30,
2023. The decrease can be primarily attributed to a decrease in legal and related professional fees.
Acquisition amortization expense
During
the nine months ended September 30, 2023, we recorded amortization expense of approximately
$0.8 million, which was related to intangible assets associated with prior acquisitions. There was no amortization expense during the
nine months ended September 30, 2024.
Operating income
Operating income from continuing
operations was $5.0 million for the nine months ended September 30, 2024 as compared to operating income from continuing operations of
$1.5 million for the nine months ended September 30, 2023. The increase in operating income from continuing operations was primarily attributable
to the increase in revenue and gross profit discussed above.
Provision for income taxes
Income tax expense was approximately
$12,000 for both the nine months ended September 30, 2024 and September 30, 2023.
Loss from discontinued operations, net of tax
We had a loss from discontinued
operations of approximately $0.3 million for the nine months ended September 30, 2024 and a loss from discontinued operations of approximately
$0.4 million for the nine months ended September 30, 2023.
Non-GAAP Financial Measures
In addition to the United States
generally accepted accounting principles (“GAAP”) results provided throughout this document, we have provided certain non-GAAP
financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented
in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business
and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows
investors to view our financial results in the way that management views financial results.
In this Quarterly Report on Form
10-Q, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of
the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash
stock based compensation, interest and taxes, and other non-cash expenses including change in fair value of notes payable and warrant
liability. The table below includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial
measure.
Reconciliation of Adjusted EBITDA (Unaudited)
($ in thousands)
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Income (loss) from continuing operations (GAAP Basis) | |
$ | 1,362 | | |
$ | (528 | ) | |
$ | 4,070 | | |
$ | 297 | |
Depreciation and amortization | |
| 85 | | |
| 241 | | |
| 205 | | |
| 954 | |
Stock-based compensation | |
| 86 | | |
| 152 | | |
| 218 | | |
| 501 | |
Taxes expense | |
| 4 | | |
| 4 | | |
| 12 | | |
| 12 | |
Interest accretion expense | |
| 4 | | |
| 26 | | |
| 34 | | |
| 92 | |
Note payable interest | |
| 141 | | |
| 230 | | |
| 514 | | |
| 682 | |
Interest income | |
| (10 | ) | |
| (21 | ) | |
| (40 | ) | |
| (34 | ) |
Change in fair value of note payable | |
| 404 | | |
| 259 | | |
| 445 | | |
| 400 | |
Adjusted EBITDA | |
$ | 2,076 | | |
$ | 363 | | |
$ | 5,458 | | |
$ | 2,904 | |
LIQUIDITY AND CAPITAL RESOURCES
In October 2021, the Company
entered into a Loan and Security Agreement with BroadOak, providing for a term loan in the aggregate principal amount of $8,000,000 (the
“Term Loan”). Funding of the Term Loan took place on November 1, 2021. The Term Loan was scheduled to mature upon the earlier
of (i) October 31, 2024 or (ii) the occurrence of a change in control, and bears interest at the rate of 9% per annum. The Term Loan is
secured by a security interest in substantially all of the Company’s and its subsidiaries’ assets and was subordinate to the
Company’s former $7,500,000 revolving credit facility with Comerica Bank. The Term Loan has an origination fee of 3% of the Term
Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs
on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the
change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii)
30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the
Term Loan, or if the Term Loan is repaid on its maturity date. Upon receipt of the term loan, the proceeds were used to repay in full
at their maturity the notes extended by Ampersand and 1315 Capital discussed above. See Note 13, Notes Payable, for more details.
In May 2022, the Company issued a Convertible Note to BroadOak, pursuant to which BroadOak funded a term loan in the aggregate principal
amount of $2.0 million which was converted into a subordinated term loan and was added to the outstanding balance of the Term Loan. See
Note 13, Notes Payable, for more details.
On October 24, 2023, the Company
entered into a Second Amendment to the Loan and Security Agreement with BroadOak (the “Second Amendment”). The primary changes
to the Term Loan were as follows:
|
● |
The Company made a one-time payment in an aggregate amount equal to $2,500,000, on October 30, 2023 and applied the payment in full satisfaction of the $3,000,000 Terminal Payment (as defined in the Term Loan). See Note 13, Notes Payable, regarding the Terminal Payment. |
|
|
|
|
● |
Effective November 1, 2023, the interest rate under the Term Loan was reduced from 9% to 8% through the maturity date of October 31, 2024 or earlier, upon the occurrence of a change in control (“Loan Maturity Date”). |
|
|
|
|
● |
The Company has the option to request an extension of the Loan Maturity Date in writing no less than sixty days prior to the Loan Maturity Date. If BroadOak agreed to the extension, the Loan Maturity Date would automatically be extended. |
On March 29, 2024, the Company
entered into a Third Amendment to the Loan and Security Agreement with BroadOak (the “Third Amendment”), extending the loan
maturity date to June 30, 2025. The primary changes to the Second Amendment were as follows:
|
● |
The maturity date was extended to June 30, 2025. |
|
|
|
|
● |
Beginning April 1, 2024, the Company will make $500,000 monthly payments with the remaining loan balance due on the new maturity date. |
The Term Loan contains affirmative
and negative restrictive covenants, including restrictions on certain mergers, acquisitions, investments and encumbrances which could
adversely affect our ability to conduct our business. The Term Loan also contains customary events of default. The balance of the loan
at September 30, 2024 was $5.9 million.
For the nine months ended September
30, 2024, we had operating income from continuing operations of $5.0 million. As of the nine months ended September 30, 2024, we had cash
and cash equivalents of $2.1 million, total current assets of $11.1 million and current liabilities of $18.8 million. As of November 1,
2024, we had approximately $1.8 million of cash and cash equivalents.
During the nine months ended
September 30, 2024, net cash provided by operating activities was $3.5 million. The main component of cash provided by operating activities
was our net income of $3.8 million, partially offset by an increase in accounts receivable of $2.3 million. During
the nine months ended September 30, 2023, net cash provided by operating activities was $2.6 million. The main component of cash provided
by operating activities included non-cash expenses of $2.0 million.
During
the nine months ended September 30, 2024, net cash used in investing activities was approximately $0.7 million which pertained to upgrades
to the lab and the purchase of lab equipment. During the nine months ended September 30, 2023, net cash provided by investing activities
was $0.1 million.
For the nine months ended September
30, 2024, cash used in financing activities was $4.1 million, which were payments made on the BroadOak Term Loan. For the nine months
ended September 30, 2023, cash used in financing activities was $2.5 million, which were payments made on the Comerica Revolving Line
of Credit.
We intend to meet our ongoing
capital needs by using our available cash generated from operations as well as through targeted margin improvement; collection of accounts
receivable; containment of costs; and the potential use of other financing options and other strategic alternatives.
The Company continues to explore
various strategic alternatives, dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances,
business development and other sources in order to provide additional liquidity. With the Company’s delisting of its common stock
from Nasdaq in February 2021, our ability to raise additional capital on terms acceptable to the Company has been adversely impacted.
There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable to the Company.
On October 10, 2024, Ampersand
and 1315 Capital exchanged 47,000 shares of Series B Preferred Stock for 47,000 shares of Series C Preferred Stock (the “Exchange”).
See Note 18, Subsequent Events. The Company believes that the 47,000 shares of Series C Preferred Stock will constitute stockholders’
equity under generally accepted accounting principles. The Exchange is the first significant step for the Company to seek an uplisting
of its common stock to Nasdaq. Other steps may need to be taken in order to satisfy Nasdaq listing requirements, including meeting Nasdaq’s
stockholder equity and minimum bid price requirements. The Company believes that a Nasdaq listing would assist it in raising additional
capital, increasing investor interest and trading volume in its common stock, and pursuing acquisitions. No assurance
can be given that a Nasdaq listing will be achieved.
Further, along with many laboratories,
we may be affected by the Proposed LCD DL39365, which is currently under consideration by our local Medicare Administrative Contractor,
Novitas. If finalized, this Proposed LCD, which governs “Genetic Testing for Oncology,” could impact the existing Medicare
coverage for one of our molecular tests, PancraGEN®. On June 5, 2023 we announced that Novitas issued the final LCD of
Genetic Testing for Oncology (L39365) which, if finalized, would have established non-coverage for the Company’s widely used PancraGEN®
test effective July 17, 2023. On July 6, 2023, Novitas announced that it would not be implementing the final Genetic Testing for
Oncology LCD (L39365) as scheduled on July 17, 2023. Novitas then issued a new virtually identical proposed LCD affecting the same companies
and tests and reaching the same conclusions as noted in the previously rescinded LCD on July 27, 2023. In response, the Company participated
in a public meeting presentation and submitted detailed written comments supporting the use of PancraGEN®. The timing and
content of any final implemented LCD is uncertain at this time; the process could potentially take a year or longer from issuance of the
updated proposed LCD to reach a conclusion. On July 29, 2024 the Company announced that CMS granted Novitas an undefined extension to
the final decision for the LCD. As a result, we are able to continue offering PancraGEN® and the related Point2®
fluid chemistry tests for amylase, CEA, and glucose. In the event Novitas ultimately restricts coverage for the PancraGEN®
test, the Company’s liquidity could be negatively impacted.
Inflation
We do not believe that inflation
had a significant impact on our results of operations for the periods presented. However, inflation and supply chain disruptions, whether
caused by restrictions or slowdowns in shipping or logistics, increases in demand for certain goods used in our operations, or otherwise,
could impact our operations in the near term.
Critical Accounting Policies
See Note 5, Summary of Significant
Accounting Policies and Note 17, Recent Accounting Standards to the Interim Financial Statements included elsewhere in this
Quarterly Report on Form 10-Q for information regarding newly adopted and recent accounting pronouncements. See also Note 1, Nature
of Business and Significant Accounting Policies to our financial statements included in our Annual Report on Form 10-K for the year
ended December 31, 2023, as amended, for a discussion of our critical accounting policies. There have been no material changes to such
critical accounting policies. We believe our most critical accounting policies include accounting for revenue recognition, leases, income taxes and stock-based compensation expense.
Off-Balance Sheet Arrangements
None.
Subsequent Event
On October 10th, 2024, the Company, Ampersand and
1315 Capital (the “Investors”) entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to which
the Investors exchanged an aggregate of 47,000 shares of the Company’s existing Series B Preferred Stock of the Company comprised
of 28,000 shares of Series B Preferred Stock held by Ampersand and 19,000 shares of Series B Preferred Stock held by 1315 Capital, which
represented all of the Company’s issued and outstanding Series B Preferred Stock, for 47,000 newly created shares of Series C Preferred
Stock, at an issuance price per share of $1,000. In the Exchange, Ampersand received 28,000 shares of Series C Preferred Stock and 1315
received 19,000 shares of Series C Preferred Stock.
The Series C Preferred Stock is convertible into the
Company’s common stock at a conversion price of $2.02 per share of common stock (subject to further adjustment in the event of any
stock dividend, stock split, combination, or other similar recapitalization affecting such shares) which was the closing price of the
common stock on the date of the Exchange Agreement. The Series C Preferred Stock does not have a liquidation preference over the common
stock in the event of a sale or dissolution of the Company, does not have director designation rights and includes limited customary protective
provisions. The Series B Preferred Stock had a conversion price of $6.00 per share of common stock and included additional protective
provisions not applicable to the Series C Preferred Stock, including (i) limitations on the Board of Directors of the Company to declare
dividends, (ii) director designation rights for each of the Investors, (iii) liquidation rights of holders upon “deemed liquidation”
events, including a liquidation preference over the common stock, (iv) limitations on the ability to authorize, issue or create debt securities,
(v) limitations on the ability to enter into mergers or acquisitions and (vi) limitations on the ability to conduct public offerings of
the Company’s common stock. The Series C Preferred Stock is convertible into 23,267,326 shares of common stock.
The closing of the transactions contemplated by the Exchange Agreement
occurred on October 11, 2024, following the satisfaction of customary conditions set forth in the Exchange Agreement and did not result
in the receipt of any cash proceeds by the Company.
Item 3. Quantitative and Qualitative Disclosures
About Market Risk
As a smaller reporting company,
we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our principal executive officer
and principal financial officer evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term
“disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and
other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s
rules and forms. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of
possible controls and procedures. Disclosure controls and procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated
and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate,
to allow timely decisions regarding required disclosure.
Based
on management’s evaluation of the Company’s disclosure controls and procedures, the principal executive officer and principal
financial officer of the Company identified a material weakness in the Company’s internal control over financial reporting in the
quarterly period ended March 31, 2024 related to the timing of revenue recognition based on the Company’s revenue recognition policy
and have concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2024 as a result
of such material weakness in the Company’s internal control over financial reporting.
The
Company has adopted a remediation plan, pursuant to which the Company plans to amend its internal controls to mitigate the material weakness,
which was identified by management, including by updating its procedures regarding the testing of revenue recognition, and reviewing the
procedures which ensure that revenue is recorded in the period in which it is earned. The Company believes implementation of these processes
and appropriate testing of their effectiveness will remediate the material weakness in the Company’s internal control over financial
reporting.
Changes in Internal Controls over Financial Reporting
Other
than the material weakness and the adoption of the remediation plan discussed above, there has been no change in our internal control
over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter covered
by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 1A. Risk Factors
Not applicable as we are a smaller reporting company.
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
None.
Item 6. Exhibits
Exhibit No. |
|
Description |
|
|
|
3.1 |
|
Conformed version of Certificate of Incorporation of Interpace Biosciences, Inc., as amended most recently by the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock effective October 11, 2024. |
|
|
|
3.2 |
|
Amended and Restated Bylaws of Interpace Biosciences, Inc., incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 14, 2019. |
|
|
|
10.1 |
|
Series C Preferred Stock Exchange Agreement incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 15, 2024. |
|
|
|
10.2 |
|
Amended and Restated Investor Rights Agreement incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on October 15, 2024. |
|
|
|
10.3 |
|
Termination of Support Agreement between Interpace Biosciences and 1315 Capital incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K filed with the SEC on October 15, 2024. |
|
|
|
31.1* |
|
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
31.2* |
|
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
|
|
32.1+ |
|
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
32.2+ |
|
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
101.INS |
|
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document. |
101.CAL |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document. |
101.LAB |
|
Inline XBRL Taxonomy Extension Label Linkbase Document. |
101.PRE |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101). |
* |
Filed Herewith. |
|
|
+ |
Exhibits 32.1 and 32.2 are being furnished herewith and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference to any registration statement or other document filed under the Securities Act or the Exchange Act, except as otherwise stated in any such filing. |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: November 8, 2024 |
Interpace Biosciences, Inc. |
|
(Registrant) |
|
|
|
/s/ Thomas W. Burnell |
|
Thomas W. Burnell |
|
President and Chief Executive Officer |
|
(Principal Executive Officer) |
|
|
Date: November 8, 2024 |
/s/ Christopher McCarthy |
|
Christopher McCarthy |
|
Chief Financial Officer |
|
(Principal Financial Officer) |
Exhibit
3.1
Certificate
of Incorporation
of
Professional
Detailing, Inc.
The
undersigned, being a natural person, solely for the purpose of organizing a corporation under the provisions and subject to the
requirements of the laws of the State of Delaware (particularly Chapter 1, Title 8 of the Delaware Code and the acts amendatory
thereof and supplemental thereto, and known, identified and referred to as the “General Corporation Law of the State of
Delaware”), hereby certifies that:
FIRST:
The name of the corporation is Professional Detailing, Inc. (hereinafter called the “Corporation’’).
SECOND:
The address of the registered office of the Corporation in the State of Delaware is 9 East Loockerman Street, Dover, Delaware,
Kent County, 19901. The name of the registered agent of the Corporation at such address is National Registered Agents, Inc. The
Corporation’s principle executive offices are located at 599 MacArthur Boulevard, Mahwah, New Jersey 07430.
THIRD:
The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the
General Corporation Law of the State of Delaware.
FOURTH:
The total number of shares of all classes of stock which this Corporation shall have authority to issue is 35,000,000 shares,
consisting of (i) 30,000,000 shares of Common Stock, $.01 par value per share (“Common Stock”), and (ii) 5,000,000
shares of Preferred Stock, $.01 par value per share (“Preferred Stock”).
The
following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions
thereof in respect of each class of capital stock of this Corporation.
(a)
Common Stock.
1.
General. All shares of Common Stock are of one class. All authorized and outstanding shares of Common Stock are to be fully
paid and non-assessable. The Common Stock has no preemptive, conversion or other subscription rights to subscribe for any shares
of any class of stock of this Corporation whether now or hereafter authorized. The holders of Common Stock are entitled to one
vote for each share held of record on all matters submitted to a vote of stockholders. The voting, dividend and liquidation rights
of the holders of the Common Stock are subject to and qualified by the rights of the holders of the Preferred Stock of any series
as may be designated by the Board of Directors upon any issuance of the Preferred Stock of any series.
2.
No Pre-emptive Rights. No holder of any of the shares of the Common Stock of the Corporation, whether now or hereafter
authorized and issued, shall be entitled as of right to purchase or subscribe for (1) any unissued stock of any class, or (2)
any additional shares of any class to be issued by reason of any increase of the authorized capital stock of the Corporation of
any class, or (3) bonds, certificates of indebtedness, debentures or other securities convertible into stock of the Corporation,
or carrying any right to purchase stock of any class, but any such unissued stock or such additional authorized issue of any stock
or of other securities convertible into stock, or carrying any right to purchase stock, may be issued and disposed of pursuant
to resolution of the Board of Directors to such persons, firms, partnerships, corporations, associations or other entities and
upon such terms as may be deemed advisable by the Board of Directors in the exercise of its discretion.
3.
Voting. The holders of the Common Stock are entitled to one vote for each share held at all meetings of stockholders. There
shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the
number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the stock of this Corporation
entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law of the State of Delaware.
4.
Dividends. Dividends may be declared and paid on the Common Stock from funds lawfully available therefor as and when determined
by the Board of Directors and subject to any preferential dividend rights of any then outstanding Preferred Stock.
5.
Liquidation- Upon the dissolution or liquidation of this Corporation, whether voluntary or involuntary, holders of Common
Stock will be entitled to receive all assets of this Corporation available for distribution to its stockholders, subject to any
preferential rights of any then outstanding Preferred Stock.
(b)
Preferred Stock.
1.
General. The Board of Directors, in the exercise of its discretion, is authorized to issue the undesignated Preferred Stock
in one or more series, to determine the powers, preferences and rights, and qualifications, limitations or restrictions, granted
to or imposed upon any wholly unissued series of undesignated Preferred Stock, and to fix the number of shares constituting any
series and the designation of such series, without any further vote or action by the stockholders
2.
No Pre-emptive Rights. No holder of any of the shares of any series of Preferred Stock of the Corporation, whether now
or hereafter authorized and issued, shall be entitled as of right to purchase or subscribe for (1) any unissued stock of any class,
or (2) any additional shares of any class to be issued by reason of any increase of the authorized capital stock of the Corporation
of any class, or (3) bonds, certificates of indebtedness, debentures or other securities convertible into stock of the Corporation,
or carrying any right to purchase stock of any class, but any such unissued stock or such additional authorized issue of any stock
or of other securities convertible into stock, or carrying any right to purchase stock, may be issued and disposed of pursuant
to resolution of the Board of Directors to such persons, firms, partnerships, corporations, associations or other entities and
upon such terms as may be deemed advisable by the Board of Directors in the exercise of its discretion.
FIFTH:
The name and the mailing address of the incorporator are as follows:
Name |
|
Mailing
Address |
Terence
O’Brien |
|
Morse,
Zelnick, Rose & Lander, LLP 450 Park Avenue New York, New York 10022 |
SIXTH:
The powers of the incorporator are to terminate upon the filing of the Certificate of Incorporation.
SEVENTH:
(a) The management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of Directors.
The phrase “whole Board” and the phrase “total number of directors” shall be deemed to have the same meaning,
to wit, the total number of directors which the Corporation would have if there were no vacancies. The original or other Bylaws
of the Corporation may be adopted, amended or repealed by the initial directors. After the original or other Bylaws of the Corporation
have been adopted, amended, or repealed, as the case may be, in accordance with the provisions of Section 109 of the General Corporation
Law of the State of Delaware, and after the Corporation has received any payment for any of its stock, the power to adopt, amend,
or repeal the Bylaws of the Corporation may be exercised by the Board of Directors of the Corporation.
(b)
Until the consummation of an initial public offering (an “IPO”) of the Common Stock under the Securities Act of 1933,
as amended (the “Act”), the Corporation shall have one or more directors, the number of directors to be determined
from time to time by vote of a majority of the directors then in office. Immediately upon the consummation of an IPO, the following
provisions shall apply:
1.
Number of Directors. The number of directors of the Corporation shall not be less than one. The exact number of directors
within the limitations specified in the preceding sentence shall be fixed from time to time by, or in the manner provided in,
the Corporation’s Bylaws.
2.
Classes of Directors. The Board of Directors shall be and is divided into three classes: Class I, Class II and Class III.
No one class shall have more than one director more than any other class. If a fraction is contained in the quotient arrived at
by dividing the designated number of directors by three, then if such fraction is one-third, the extra director shall be a member
of Class II, and if such fraction is two-thirds, one of the extra directors shall be a member of Class II and one of the extra
directors shall be a member of Class III, unless otherwise provided from time to time by resolution adopted by the Board of Directors.
The persons who shall serve as the initial Class I, Class II and Class III directors upon consummation of the IPO may be designated
by the Board of Directors prior to such IPO.
3.
Election of Directors/Terms of Office. Election of directors need not be by written ballot except as and to the extent
provided in the Bylaws of the Corporation. Except as otherwise provided herein, each director shall serve for a term ending on
the date of the third annual meeting of the stockholders following the annual meeting at which such director was elected. A director
shall hold office until the annual meeting for the year in which his term expires and until his successor shall be elected and
shall qualify, subject, however, to prior death, resignation, retirement, disqualification or removal from office for cause. Each
initial Class I director shall serve for a one year term; each initial Class II director shall serve for a two year term; and
each initial Class III director shall serve for a three year term. Notwithstanding the foregoing, the term of each director shall
be subject to the election and qualification of his successor and to his earlier death, resignation or removal.
4.
Allocation of Directors among Classes in the Event of Increases or Decreases in the Number of Directors. In the event of
any increase or decrease in the authorized number of directors, (i) each director then serving as such shall nevertheless continue
as a director of the class of which he is a member and (ii) the newly created or eliminated directorships resulting from such
increase or decrease shall be apportioned among the three classes of directors so as to ensure that no one class has more than
one director more than any other class. To the extent possible, consistent with the foregoing rule, any newly created directorships
shall be added to those classes whose terms of office are to expire at the latest dates following such allocation, and any newly
eliminated directorships shall be subtracted from those classes whose terms of offices are to expire at the earliest dates following
such allocation, unless otherwise provided from time to time by resolution adopted by the Board of Directors.
5.
Preferred Stock Directors. Notwithstanding the foregoing, whenever the holders of any one or more classes or series of
Preferred Stock issued by the Corporation shall have the right to vote separately by class or series to elect directors at an
annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such directorships
shall be governed by the terms of this Certificate of Incorporation applicable thereto, and such directors so elected shall not
be divided into classes provided by this Article Seventh, unless expressly provided by such terms.
6.
Removal. Directors of the Corporation may be removed only for cause by the affirmative vote of the holders of at least
two-thirds of the shares of capital stock of the Corporation issued and outstanding and entitled to vote generally in the election
of directors.
7.
Vacancies. Any vacancy in the Board of Directors, however occurring, including a vacancy resulting from an enlargement
of the Board of Directors, shall be filled only by a vote of a majority of directors then in office, although less than a quorum,
or by a sole remaining director. A director elected to fill a vacancy shall be elected to hold office until the next election
of the class for which such director shall have been chosen, subject to the election and qualification of his successor and to
his earlier death, resignation or removal.
8.
Stockholder Nominations and Introductions of Business. Advance notice of stockholder nominations for election of directors
and other business to be brought by stockholders before either an annual or special meeting of stockholders shall be given in
the manner provided by the Bylaws of the Corporation.
9.
Committees. Wherever the term “Board of Directors” is used in this Certificate of Incorporation, such term
shall mean the Board of Directors of the Corporation; provided, however that to the extent any committee of directors of the Board
of Directors exists, such committee may exercise any right or authority of the Board of Directors under this Certificate of Incorporation.
10.
Amendments to Article. Notwithstanding any other provision of law, this Certificate of Incorporation or the Bylaws of the
Corporation, each as amended, and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote
of the holders of at least seventy-five percent (75%) of the shares of capital stock of the Corporation issued and outstanding
and entitled to vote generally in the election of directors shall be required to amend or repeal or to adopt any provision inconsistent
with this Article SEVENTH.
EIGHTH:
The Corporation is to have perpetual existence.
NINTH:
Whenever a compromise or arrangement is proposed between this Corporation and its creditors or any class of them and/or
between this Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware
may, on the application in a summary way of this Corporation or of any creditor or stockholder thereof or on the application of
any receiver or receivers appointed for this Corporation under § 291 of Title 8 of the Delaware Code or on the application
of trustees in dissolution or of any receiver or receivers appointed for this Corporation under § 279 of Title 8 of the Delaware
Code order a meeting of the creditors or class of creditors, and/or of the stockholder or class of stockholders of this Corporation,
as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths
in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this Corporation, as the
case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as consequence of such compromise
or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to which the
said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders or class
of stockholders, of this Corporation, as the case may be, and also on this Corporation.
TENTH:
Whenever the Corporation shall be authorized to issue only one class of stock each outstanding share shall entitle the holder
thereof to notice of, and the right to vote at, any meeting of stockholders. Whenever the Corporation shall be authorized to issue
more than one class of stock no outstanding share of any class of stock which is denied voting power under the provisions of the
Certificate of Incorporation shall entitle the holder thereof to the right to vote at any meeting of stockholders except as the
provisions of paragraph (c)(2) of Section 242 of the General Corporation Law of the State of Delaware shall otherwise require;
provided, that no share of any such class which is otherwise denied voting power shall entitle the holder thereof to vote upon
the increase or decrease in the number of authorized shares of said class.
ELEVENTH:
A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages
for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to
the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which
the director derived an improper personal benefit.
TWELFTH:
(a) Right to Indemnification. Each person who was or is made a party or is threatened to be made a party to or
is involved in any action, suit, claim or proceeding, whether civil, criminal, administrative or investigative (hereinafter a
“proceeding”), by reason of the fact that he or she, or a person of whom he or she is the legal representative,
is or was a director or officer, of the Corporation or is or was serving at the request of the Corporation as a director, officer,
employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with
respect to employee benefit plans, whether the basis of such proceeding is alleged action in an official capacity as a director,
officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified
and held harmless by the Corporation to the fullest extent authorized by the Delaware General Corporation Law, as the same exists
or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation
to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against
all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts
paid or to be paid in settlement) reasonably incurred or suffered by such person in connection therewith and such indemnification
shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his
or her heirs, executors and administrators: provided, however, that, except as provided in paragraph (b) hereof, the Corporation
shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person
only if such proceeding (or part thereof) was authorized by the Board of Directors. The right to indemnification conferred in
this Section shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending
any such proceeding in advance of its final disposition: provided, however, that, if the Delaware General Corporation Law requires,
the payment of such expenses incurred by a director or officer (in his or her capacity as a director or officer and not in any
other capacity in which service was or is rendered by such person while a director or officer, including, without limitation,
service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to
the Corporation of an undertaking, by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately
be determined that such director or officer is not entitled to be indemnified under this Section or otherwise. The Corporation
may, by action of its Board of Directors, provide indemnification to employees and agents of the Corporation with the same scope
and effect as the foregoing indemnification of directors and officers mentioned in this Article Twelfth. Notwithstanding the indemnification
provisions throughout the Certificate of Incorporation, the Corporation, shall not be obligated, contractually or otherwise, to
indemnify its directors and officers with respect to proceedings initiated or brought by any officer or director and not by way
of defense, or, for any amounts paid in settlement of any proceeding against any officer or director, without the prior written
consent of the Company.
(b)
Right of Claimant to Bring Suit. If a claim under paragraph (a) of this Article is not paid in full by the Corporation
within thirty days after a written claim has been received by the Corporation, the claimant may at any time thereafter bring suit
against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be
entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action
brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required
undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standards of conduct
which make it permissible under the Delaware General Corporation Law for the Corporation to indemnify the claimant for the amount
claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including
its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement
of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard
of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the Corporation (including its Board
of Directors, independent legal counsel, or its stockholders) that the claimant has not met such applicable standard or conduct,
shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.
(c)
Non-Exclusivity of Rights. The right to indemnification and the payment of expenses incurred in defending a proceeding
in advance of its final disposition conferred in this Article shall not be exclusive of any other right which any person may have
or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote of stockholders
or disinterested directors or otherwise.
(d)
Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee
or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any such expense,
liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability
or loss under the Delaware General Corporation Law.
THIRTEENTH:
From time to time any of the provisions of this Certificate of Incorporation may be amended, altered or repealed, and
other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted in the manner and
at the time prescribed by said laws, and all rights at any time conferred upon the stockholders of the Corporation by this Certificate
of Incorporation are granted subject to the provisions of this Article Thirteenth.
FOURTEENTH:
Meetings of the stockholders may be held within or without the State of Delaware, as the Bylaws, amendments thereto, or
amendments to this Certificate of Incorporation may provide. The books of the Corporation may be kept outside of the State of
Delaware at such place or places as may be designated from time to time by the Board of Directors or by the Bylaws, and amendments
thereto, or by the amendments to this Certificate of Incorporation.
FIFTEENTH:
At any time during which a class of capital stock of this Corporation is registered under Section 12 of the Securities
Exchange Act of 1934 or any similar successor statute, stockholders of this Corporation may not take any action by written consent
in lieu of a meeting. Notwithstanding any other provisions of law, this Certificate of Incorporation or the Bylaws of this Corporation,
and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least
seventy-five percent (75%) of the shares of capital stock of this Corporation issued and outstanding and entitled to vote generally
in the election of directors shall be required to amend or repeal, or to adopt any provision inconsistent with, this Article Fifteenth.
SIXTEENTH:
Special meetings of stockholders may be called at any time by only the Chairman of the Board of Directors of the Corporation,
the Chief Executive Officer (or if there is no Chief Executive Officer, the President) or the Board of Directors of the Corporation.
Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated
in the notice of meeting. Notwithstanding any other provision of law, the Certificate of Incorporation or the Bylaws of the Corporation,
and notwithstanding the fact that a lesser percentage may be specified by law, the affirmative vote of the holders of at least
seventy-five percent (75%) of the shares of capital stock of the Corporation issued and outstanding and entitled to vote generally
in the election of directors shall be required to amend or repeal, or to adopt any provision inconsistent with this Article Sixteenth.
Dated:
February 10, 1998
|
/s/
Terence O’Brien |
|
Terence
O’Brien, Incorporator |
CERTIFICATE
OF MERGER
OF
PROFESSIONAL
DETAILING, INC.
[a
New Jersey Corporation]
AND
PROFESSIONAL
DETAILING, INC.
[a
Delaware Corporation]
It
is hereby certified that:
1.
The constituent business corporations participating in the merger herein certified are:
(i)
Professional Detailing, Inc., which is incorporated under the laws of the State of New Jersey (“PDI-NJ”); and
(ii)
Professional Detailing, Inc., which is incorporated under the laws of the State of Delaware (“PDI-Del”).
2.
The Plan of Merger has been approved, adopted, certified, executed, and acknowledged by each of the aforesaid constituent corporations
in accordance with the provisions of subsection (c) of Section 252 of the Delaware General Corporation Law, to wit, by PDI-NJ
in accordance with the laws of the State of New Jersey and by PDI-Del in the same manner as is provided in Section 251 of the
Delaware General Corporation Law.
3.
The name of the surviving corporation in the merger herein certified is Professional Detailing, Inc., a Delaware corporation,
which will continue its existence as said surviving corporation under its present name upon the effective date of said merger
pursuant to the provisions of the Delaware General Corporation Law.
4.
The Certificate of Incorporation of PDI-Del. as now in force and effect, shall continue to be the Certificate of Incorporation
of said surviving corporation until amended and changed pursuant to the provisions of the Delaware General Corporation Law,
5.
The executed Plan of Merger between the aforesaid constituent corporations is on file at the principal place of business of the
aforesaid surviving corporation, the address of which is as follows:
599
MacArthur Boulevard
Mahwah,
New Jersey 07430
6.
A copy of the aforesaid Plan of Merger will be furnished by the aforesaid surviving corporation, on request, and without cost,
to any stockholder of each of the aforesaid constituent corporations.
7.
The authorized capital stock of PDI-NJ consists of 2,500 shares without par value.
8.
The merger of PDI-NJ with and into PDI-Del shall be effective immediately upon the filing of this Certificate of Merger.
Executed
on this 13th day of May, 1998
|
PROFESSIONAL
DETAILING, INC. |
|
A
Delaware Corporation |
|
|
|
|
By: |
/s/
Charles T. Saldarini |
|
|
President
and Chief Executive Officer |
CERTIFICATE
OF AMENDMENT
OF
CERTIFICATE OF INCORPORATION
OF
PROFESSIONAL
DETAILING, INC.
(Pursuant
to Section 242 of
the
Delaware General Corporation Law)
Professional
Detailing, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General
Corporation Law (the “DGCL”) does hereby certifies that:
1.
The name of the corporation is Professional Detailing, Inc.
2.
The Board of Directors of the Corporation duly adopted resolutions setting forth two (2) proposed amendments (the “Amendments”)
to the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”), declaring the Amendments’
advisability to its stockholders, and directing that the Amendments be considered at the year 2001 annual meeting of the stockholders
of the Corporation. At the year 2001 annual meeting of stockholders of the Corporation, a majority of the stockholders approved
the Amendments. The Amendments provide as follows:
(i)
That Article First of the Certificate of Incorporation shall be amended to read in its entirety as follows:
“FIRST:
The name of the corporation is PDI, Inc. (hereinafter called the “corporation”)”;
and
(ii)
That the first paragraph of Article Fourth of the Certificate of Incorporation shall be amended to read in its entirety as follows:
“FOURTH:
The total number of shares of all classes of stock which this corporation shall have authority to issue is 105,000,000, consisting
of (i) 100,000,000 shares of common stock, $.01 par value per share (“Common Stock”) and (ii) 5,000,000 shares of
preferred stock, $.01 par value per share (the “Preferred Stock”).”
3.
The Amendments herein certified have been duly adopted in accordance with the provisions of Section 242 of the DGCL by the Board
of Directors.
4.
This Certificate of Amendment shall become effective as of 8:00 a.m., Eastern Standard Time, on October 1, 2001.
Executed
on this 28th day of September, 2001.
|
Professional
Detailing, Inc. |
|
|
|
|
By: |
/s/
Bernard C. Boyle |
|
|
Bernard
C. Boyle |
|
|
Executive
Vice President and Chief Financial Officer |
CERTIFICATE
OF OWNERSHIP AND MERGER
OF
LIFECYCLE
VENTURES, INC.
(a
Delaware corporation)
INTO
PDI,
INC.
(a
Delaware corporation)
PDI,
Inc. (hereinafter referred to as the “Corporation”), a corporation organized and existing under and by virtue of the
Delaware General Corporation Law, does hereby certify:
1.
The Corporation is a business corporation of the State of Delaware.
2.
The Corporation is the owner of all of the outstanding shares of the stock of LifeCycle Ventures, Inc. (hereinafter referred to
as “LCV”), which is also a business corporation of the State of Delaware.
3.
On December 21, 2001, the Board of Directors of the Corporation adopted the following resolutions to merge LCV into the Corporation:
|
RESOLVED: |
That
LCV be merged into this Corporation, and that all of the estate, property, rights, privileges, powers and franchises of LCV
be vested in and held and enjoyed by this Corporation as fully and entirely and without change or diminution as the same were
before held and enjoyed by LCV in its name. |
|
|
|
|
RESOLVED: |
That
this Corporation shall assume all of the obligations of LCV. |
|
|
|
|
RESOLVED: |
That
this Corporation shall cause to be executed and filed and/or recorded the documents prescribed by the laws of the State of
Delaware and by the laws of any other appropriate jurisdiction and will cause to be performed all necessary acts within the
State of Delaware and within any other appropriate jurisdiction. |
|
|
|
|
RESOLVED: |
That
the merger of LCV into the Corporation shall be effective as of 11:59 p.m. December 31, 2001. |
Executed
on this 24th day of December, 2001.
|
PDI,
INC. |
|
|
|
|
By: |
/s/
Bernard C. Boyle |
|
|
Bernard
C. Boyle, Executive Vice President, Secretary and Chief Financial Officer |
CERTIFICATE
OF AMENDMENT
TO
THE CERTIFICATE OF INCORPORATION OF
PDI,
INC.
PDI,
Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law
of the state of Delaware, does hereby certify that:
1.
The name of the Corporation is PDI, Inc.
2.
The Board of Directors of the Corporation duly adopted resolutions approving and setting forth this proposed amendment (the “Amendment”)
to the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”), declaring the Amendment’s
advisability to its stockholders, and directing that the Amendment be considered at the 2012 annual meeting of the stockholders
of the Corporation. At the annual meeting of the stockholders of the Corporation held on June 5, 2012, holders of a majority of
the outstanding shares of the Corporation’s common stock, being the only outstanding class of the Corporation’s capital
stock entitled to vote, voted in favor of the adoption of the Amendment.
3.
The Amendment provides as follows:
The
first paragraph of ARTICLE FOURTH of the Corporation’s Certificate of Incorporation is amended to read as follows:
FOURTH:
The total number of shares of all classes of stock which this corporation shall have authority to issue is 45,000,000, consisting
of (i) 40,000,000 shares of common stock, par value $.01 per share (“Common Stock”), and 5,000,000 shares of preferred
stock, par value $.01 per share (“Preferred Stock”).
4.
The Amendment herein certified has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance
with the provisions of Section 242 of the General Corporation Law of the state of Delaware.
IN
WITNESS WHEREOF, this Certificate of Amendment to the Certificate of Incorporation of PDI, Inc. has been executed as of this
5th day of June, 2012.
|
PDI,
Inc. |
|
|
|
By: |
/s/
Nancy Lurker |
|
Name: |
Nancy
Lurker |
|
Title: |
Chief
Executive Officer |
STATE
OF DELAWARE
CERTIFICATE
OF OWNERSHIP
SUBSIDIARY
INTO PARENT
Section
253
CERTIFICATE
OF OWNERSHIP
MERGING
TVG
1, INC.
INTO
PDI,
Inc.
(Pursuant
to Section 253 of the General Corporation Law of Delaware)
PDI,
Inc., a corporation incorporated on the 10th day of February, 1998, pursuant to the provisions of the General Corporation Law
of the State of Delaware;
DOES
HEREBY CERTIFY that this corporation owns 90% of the capital stock of TVG 1, Inc., a corporation incorporated on the 19th day
of September, 1986, A.D., pursuant to the provisions of the State of Delaware, and that this corporation, by a resolution of its
Board of Directors duly adopted on the 24th day of December, 2014, A.D., determined to and did merge into itself said TVG 1, Inc.,
which resolution is in the following words to wit:
WHEREAS
this corporation lawfully owns 90% of the outstanding stock of TVG 1, Inc., a corporation organized and exiting under the laws
of the State of Delaware, and
WHEREAS
this corporation desires to merge into itself the said TVG 1, Inc., and to be possessed of all the estate, property, rights, privileges
and franchises of said corporation,
NOW,
THEREFORE, BE IT RESOLVED, that this corporation merge into itself said TVG 1, Inc. and assumes all of its liabilities and obligations,
and
FURTHER
RESOLVED, that an authorized officer of this corporation be and he/she is hereby directed to make and execute a certificate of
ownership setting forth a copy of the resolution to merge said TVG 1, Inc. and assume its liabilities and obligations, and the
date of adoption thereof, and to file the same in the office of the Secretary of State of Delaware, and a certified copy thereof
in the office of the Recorder of Deeds of Kent County; and
FURTHER
RESOLVED, that the officers of this corporation be and they hereby are authorized and directed to do all acts and things whatsoever,
whether within or without the State of Delaware; which may be in any way necessary or proper to effect said merger.
IN
WITNESS WHEREOF, said parent corporation has caused its corporate seal to be affixed and this certificate to be signed by an authorized
officer this 29th day of December, 2014 A.D.
|
By: |
/s/
Graham Miao |
|
|
Authorized
Officer |
|
Name: |
Graham
Miao |
|
|
Print
or Type |
|
Title: |
Chief
Financial Officer & EVP |
(Insert
if applicable)
FURTHER
RESOLVED, that ___________________________ relinquishes its corporate name and assumes in place thereof the name ____________________________________________________________.
CERTIFICATE
OF AMENDMENT
TO
THE CERTIFICATE OF INCORPORATION OF
PDI,
INC.
PDI,
Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law
of the State of Delaware, does hereby certify that:
1.
The name of the Corporation is PDI, Inc.
2.
The Board of Directors of the Corporation duly adopted resolutions approving and setting forth this proposed amendment (the “Amendment”)
to the Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”), declaring
the Amendment’s advisability, and directing that the Amendment be considered at a special meeting of the stockholders of
the Corporation. Thereafter a special meeting of the stockholders of the Corporation was held, at which holders of a majority
of the outstanding shares of the Corporation’s common stock, being the only outstanding class of the Corporation’s
capital stock entitled to vote, voted in favor of the adoption of the Amendment.
3.
The Amendment provides as follows:
That
the first paragraph of ARTICLE FOURTH of the Corporation’s Certificate of Incorporation is amended to read in its entirety
as follows:
FOURTH:
The total number of shares of all classes of stock which this corporation shall have authority to issue is 105,000,000, consisting
of (i) 100,000,000 shares of common stock, par value $.01 per share (“Common Stock”), and (ii) 5,000,000 shares of
preferred stock, par value $.01 per share (“Preferred Stock”).
4.
The Amendment herein certified has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance
with the provisions of Section 242 of the General Corporation Law of the State of Delaware.
IN
WITNESS WHEREOF, this Certificate of Amendment to the Certificate of Incorporation of PDI, Inc. has been executed as of this 22nd
day of December.
|
PDI,
Inc. |
|
|
|
|
By: |
/s/
Nancy Lurker |
|
Name: |
Nancy
Lurker |
|
Title: |
Chief
Executive Officer |
Signature
Page to Charter Amendment re: Authorized Shares
CERTIFICATE
OF AMENDMENT
TO
THE CERTIFICATE OF INCORPORATION OF
PDI,
INC.
PDI,
Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law
of the State of Delaware, does hereby certify that:
1.
The name of the Corporation is PDI, Inc.
2.
The Board of Directors of the Corporation duly adopted resolutions approving and setting forth this proposed amendment (the “Amendment”)
to the Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”), declaring
the Amendment’s advisability, and directing that the Amendment be considered at a special meeting of the stockholders of
the Corporation. Thereafter a special meeting of the stockholders of the Corporation was held, at which holders of a majority
of the outstanding shares of the Corporation’s common stock, being the only outstanding class of the Corporation’s
capital stock entitled to vote, voted in favor of the adoption of the Amendment.
3.
The Amendment provides as follows:
That
ARTICLE FIRST of the Corporation’s Certificate of Incorporation is amended to read in its entirety as follows:
FIRST:
The name of the corporation is Interpace Diagnostics Group, Inc. (hereinafter called the “Corporation”).
4.
The Amendment herein certified has been duly adopted by the Board of Directors and stockholders of the Corporation in accordance
with the provisions of Section 242 of the General Corporation Law of the State of Delaware.
IN
WITNESS WHEREOF, this Certificate of Amendment to the Certificate of Incorporation of PDI, Inc. has been executed as of this 22nd
day of December, 2015.
|
PDI,
Inc. |
|
|
|
|
By: |
/s/
Nancy Lurker |
|
Name: |
Nancy
Lurker |
|
Title: |
Chief
Executive Officer |
Signature
Page to Charter Amendment re: Name Change
CERTIFICATE
OF AMENDMENT
TO
THE
CERTIFICATE
OF INCORPORATION
OF
INTERPACE
DIAGNOSTICS GROUP, INC.
INTERPACE
DIAGNOSTICS GROUP, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the
“Corporation”), does hereby certify as follows:
FIRST:
At the Effective Time, as defined below, of this Certificate of Amendment pursuant to Section 242 of the General Corporation Law
of the State of Delaware, each ten (10) shares of the Corporation’s common stock, par value $.01 per share, issued and outstanding
immediately prior to the Effective Time (the “Old Common Stock”) shall automatically without further action on the
part of the Corporation or any holder of Old Common Stock, be reclassified, combined, converted and changed into one (1) fully
paid and nonassessable share of common stock, par value $.01 per share (the “New Common Stock”), subject to the treatment
of fractional share interests as described below (the “reverse stock split”). The conversion of the Old Common Stock
into New Common Stock will be deemed to occur at the Effective Time. From and after the Effective Time, certificates representing
the Old Common Stock shall represent the number of shares of New Common Stock into which such Old Common Stock shall have been
converted pursuant to this Certificate of Amendment. Holders who otherwise would be entitled to receive fractional share interests
of New Common Stock upon the effectiveness of the reverse stock split shall be entitled to receive a cash payment in lieu of any
fractional share created as a result of such reverse stock split equal to (i) the average closing price of the Old Common Stock
as reported by The NASDAQ Capital Market for the five trading days immediately preceding the effective date of the reverse stock
split by (ii) the amount of the fractional share.
SECOND:
The foregoing amendment shall be effective at 5:00 p.m. (EST) on December 28, 2016 (the “Effective Time”).
THIRD:
That the stockholders of the Corporation have duly approved the foregoing amendment in accordance with the provisions of Section
242 of the General Corporation Law of the State of Delaware.
IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly adopted and executed in its corporate name
and on its behalf by its duly authorized officer as of the 28th day of December, 2016.
|
INTERPACE
DIAGNOSTICS GROUP, INC. |
|
|
|
|
By: |
/s/
Jack E. Stover |
|
Name: |
Jack
E. Stover |
|
Title: |
President
& CEO |
STATE
OF DELAWARE
CERTIFICATE
OF CHANGE OF REGISTERED AGENT
AND/OR
REGISTERED OFFICE
The
corporation, organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows:
4.
The name of the corporation is INTERPACE DIAGNOSTICS GROUP, INC.
5.
The Registered Office of the corporation in the State of Delaware is changed to 251 Little Falls Drive, in the City of Wilmington,
DE, County of New Castle, Zip Code 19808. The name of the Registered Agent at such address upon whom process against this Corporation
may be served is Corporation Service Company.
6.
The foregoing change to the registered office/agent was adopted by a resolution of the Board of Directors of the corporation.
|
By: |
/s/
James E. Early |
|
|
Authorized
Officer |
|
|
|
|
Name |
James
E. Early |
|
|
Print
or Type |
INTERPACE
DIAGNOSTICS GROUP, INC.
CERTIFICATE
OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS
OF
SERIES
A CONVERTIBLE PREFERRED STOCK
AND
SERIES
A-1 CONVERTIBLE PREFERRED STOCK
PURSUANT
TO SECTION 151 OF THE
DELAWARE
GENERAL CORPORATION LAW
INTERPACE
DIAGNOSTICS GROUP, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions
of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance
with Section 151 of the DGCL, the following resolution was duly adopted by the Board of Directors of the Corporation on July 12,
2019:
RESOLVED,
pursuant to authority expressly set forth in the Certificate of Incorporation of the Corporation (the “Certificate
of Incorporation”), the issuance of a series of Preferred Stock designated as the Series A Convertible Preferred
Stock, par value $0.01 per share, of the Corporation and the issuance of a series of Preferred Stock designated as the Series
A-1 Convertible Preferred Stock, par value $0.01 per share, of the Corporation is each hereby authorized and the designation,
number of shares, powers, preferences, rights, qualifications, limitations and restrictions thereof (in addition to any provisions
set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series) are hereby
fixed, and this Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock and
Series A-1 Convertible Preferred Stock is hereby approved as follows:
SERIES
A AND SERIES A-1 CONVERTIBLE PREFERRED STOCK
Section
1. Definitions. For the purposes hereof, the following terms shall have the following meanings:
“Additional
Shares of Common Stock” shall mean all shares of Common Stock issued (or, pursuant to Section 9(e) below, deemed
to be issued) by the Corporation after the Issuance Date, other than: (a) shares of Common Stock, Options or Convertible Securities
issued as a dividend or distribution on Senior Preferred Stock; (b) shares of Common Stock, Options or Convertible Securities
issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by Section
9(a), Section 9(b) or Section 9(c); (c) shares of Common Stock or Options issued to employees or directors of, or consultants
or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board
of Directors of the Corporation, including the approval of at least one Series A Director; (d) shares of Common Stock or Convertible
Securities actually issued upon the exercise of Options or shares of Common Stock actually issued upon the conversion or exchange
of Convertible Securities, in each case, provided such issuance is pursuant to the terms of an Option or Convertible Security
that is issued and outstanding prior to the Issuance Date (clauses a – d collectively, “Exempted Securities”).
“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls,
is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the
Securities Act. With respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by
the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser.
“Business
Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.
“Commission”
means the U.S. Securities and Exchange Commission.
“Common
Stock” means the Corporation’s common stock, par value $0.01 per share.
“Conversion
Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series A Preferred
Stock in accordance with the terms hereof.
“Convertible
Securities” shall mean any evidences of indebtedness, shares or other securities directly or indirectly convertible
into or exchangeable for Common Stock, but excluding Options.
“Deemed
Liquidation” shall mean (a) a merger or consolidation in which (i) the Corporation is a constituent party or (ii)
a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such
merger or consolidation, except any such merger or consolidation involving the Corporation or a subsidiary in which the shares
of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are
converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at
least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation; or (2) if the surviving
or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation,
the parent corporation of such surviving or resulting corporation; or (b) the sale, lease, transfer, exclusive license or other
disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation
of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether
by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the
Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease,
transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.
“DGCL”
shall mean the Delaware General Corporation Law.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Holder”
means any holder of Senior Preferred Stock.
“Issuance
Date” means July 15, 2019.
“Minimum
Price” means the lower of (a) the closing price of Common Stock (as reflected on Nasdaq.com) on the Trading Day
immediately preceding the Issuance Date; or (b) the average closing price of the Common Stock (as reflected on Nasdaq.com) for
the five Trading Days immediately preceding the Issuance Date.
“Net
Revenue” means the consolidated net revenue recognized by the Corporation as set forth on the Corporation’s
audited consolidated statement of operations for the twelve month period ended December 31, 2020, as reported by the Corporation
on Form 10-K as filed with the Commission, in each case, solely to the extent such consolidated net revenue arises from the Corporation’s
clinical testing business (which for the avoidance of doubt will exclude any products or services acquired or licensed by the
Corporation or any of its direct or indirect subsidiaries from and after the Issuance Date, including pursuant to that certain
Secured Creditor Asset Purchase Agreement, entered into by a subsidiary of the Corporation on the Issuance Date).
“Option”
shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.
“Person”
means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Preferred
Stock” means the Corporation’s preferred stock, par value $0.01 per share.
“Series
A Adjustment Amount” means an amount equal to the product, of: (a) three cents ($0.03); multiplied by (b) (the amount,
if any, by which the Net Revenue is less than Thirty Four Million Dollars ($34,000,000)) divided by 1,000,000; provided, however,
in no event will the Series A Adjustment Amount equal an amount greater than twenty one cents $0.21 per share (it being understood
that the Series A Adjustment Amount shall be subject to appropriate adjustment in the event of any stock dividend, stock split,
combination or other similar recapitalization affecting such shares).
“Series
A Conversion Price” means an amount initially equal to eighty cents ($0.80) (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares) minus the Series
A Adjustment Amount, subject to adjustment as provided herein.
“Series
A Conversion Ratio” means, for each share of Series A Preferred Stock, the ratio obtained by dividing the Series
A Liquidation Amount of such share by the Series A Conversion Price.
“Series
A Liquidation Value” means an amount equal to the Series A Liquidation Amount divided by the number of shares of
Series A Preferred Stock outstanding.
“Series
A-1 Liquidation Value” means an amount equal to the Series A-1 Liquidation Amount divided by the number of shares
of Series A-1 Preferred Stock outstanding.
“Series
A Mandatory Conversion Price” means an amount equal to eighty cents ($0.80) minus the Series A Adjustment Amount.
“Series
A Minimum Voting Ratio” means, for each share of Series A Preferred Stock, the ratio obtained by dividing the Stated
Value by Eighty Cents ($0.80) (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization affecting such shares).
“Stated
Value” means $100,000 per share.
“Threshold
Amount” means 19.99% of the number of shares of Common Stock outstanding immediately prior to the issuance of Senior
Preferred Stock on the Issuance Date.
“Trading
Day” means a day on which the Common Stock is traded for any period on a principal securities exchange or if the
Common Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities
market on which the Common Stock is then being traded.
Section
2. Designation, Amount and Par Value; Assignment.
(a)
The first series of Preferred Stock designated by this Certificate of Designation shall be designated as the Corporation’s
Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and the number of shares so designated
shall be 270. The second series of Preferred Stock designated by this Certificate of Designation shall be designated as the Corporation’s
Series A-1 Convertible Preferred Stock (the “Series A-1 Preferred Stock” and together with the Series
A Preferred Stock, the “Senior Preferred Stock”) and the number of shares so designated shall be 80. The Senior
Preferred Stock shall have a par value of $0.01 per share.
(b)
The Corporation shall register shares of the Senior Preferred Stock, upon records to be maintained by the Corporation for that
purpose (the “Senior Preferred Stock Register”), in the name of the Holders thereof from time to time.
The Corporation may deem and treat the registered Holder of shares of Senior Preferred Stock as the absolute owner thereof for
the purpose of any conversion thereof and for all other purposes. Shares of Senior Preferred Stock may be issued solely in book-entry
form or, if requested by any Holder, such Holder’s shares may be issued in certificated form. The Corporation shall register
the transfer of any shares of Senior Preferred Stock in the Senior Preferred Stock Register, upon surrender of the certificates
(if applicable) evidencing such shares to be transferred, duly endorsed by the Holder thereof, to the Corporation at its address
specified herein. Upon any such registration or transfer, a new certificate (or book-entry notation, if applicable) evidencing
the shares of Senior Preferred Stock so transferred shall be issued to the transferee and a new certificate (or book-entry notation,
if applicable) evidencing the remaining portion of the shares not so transferred, if any, shall be issued to the transferring
Holder, in each case, within two (2) Business Days. The provisions of this Certificate of Designation are intended to be for the
benefit of all Holders from time to time and shall be enforceable by any such Holder.
Section
3. Dividends.
(a)
From and after the third (3rd) anniversary of the Issuance Date, each share of Series A-1 Preferred Stock shall accrue dividends
at the rate per annum of twelve percent (12%) of the Stated Value plus the amount of previously declared or accrued, and not previously
paid dividends (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization affecting such shares) (the “Series A-1 Accruing Dividends”). The Series A-1 Accruing
Dividends shall accrue from day to day, whether or not declared, and shall be cumulative and be compounded quarterly; provided,
however, that except as set forth in the following sentence of this Section 3(a) such Series A-1 Accruing Dividends shall
be payable only when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such
Series A-1 Accruing Dividends. The Corporation shall not declare, pay or set aside any dividends on shares of any other class
or series of capital stock of the Corporation (other than the Series A Accruing Dividend and dividends on shares of Common Stock
payable in shares of Common Stock) unless the Holders of the Series A-1 Preferred Stock then outstanding shall first receive,
or simultaneously receive, a dividend on each outstanding share of Series A-1 Preferred Stock in an amount at least equal to the
sum of (i) the amount of the aggregate Series A-1 Accruing Dividends then accrued on such share of Series A-1 Preferred Stock
and not previously paid, plus (ii) (A) in the case of a dividend on Common Stock or any class or series that is convertible into
Common Stock, that dividend per share of Series A-1 Preferred Stock as would equal the product of (1) the dividend payable on
each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into
Common Stock and (2) the number of shares of Common Stock issuable had such share of Series A-1 Preferred Stock been converted
into Series A Preferred Stock pursuant to Section 7 immediately prior to such dividend and immediately thereafter and effective
prior to the consummation of such dividend each such share of Series A Preferred Stock had been converted to Common Stock pursuant
to Section 8 without regard to the Exchange Cap, in each case calculated on the record date for determination of holders entitled
to receive such dividend or (B) in the case of a dividend on any class or series that is not convertible into Common Stock, at
a rate per share of Series A-1 Preferred Stock determined by (1) dividing the amount of the dividend payable on each share of
such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares)
and (2) multiplying such fraction by an amount equal to the Stated Value; provided that, if the Corporation declares, pays or
sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend
payable to the holders of Series A-1 Preferred Stock pursuant to this Section 3(a) shall be calculated based upon the dividend
on the class or series of capital stock that would result in the highest Series A-1 Preferred Stock dividend. Notwithstanding
anything to the contrary herein, the Corporation shall not declare, pay or set aside a dividend on Series A-1 Preferred Stock
consisting of Common Stock prior to the Nasdaq Approval Date.
(b)
From and after the initial issuance date of a share of Series A Preferred Stock, including the date of conversion of any shares
of Series A-1 Preferred Stock into Series A Preferred Stock, each such share of Series A Preferred Stock shall accrue dividends
at the rate per annum of six percent (6%) of the Stated Value plus the amount of previously declared or accrued, and not previously
paid dividends (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization affecting such shares) (the “Series A Accruing Dividends”). The Series A Accruing Dividends
shall accrue from day to day, whether or not declared, and shall be cumulative and be compounded quarterly; provided, however,
that except as set forth in the following sentence of this Section 3(b) such Series A Accruing Dividends shall be payable only
when, as, and if declared by the Board of Directors and the Corporation shall be under no obligation to pay such Series A Accruing
Dividends. The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital
stock of the Corporation (other than the Series A-1 Accruing Dividend and dividends on shares of Common Stock payable in shares
of Common Stock) unless the Holders of the Series A Preferred Stock then outstanding shall first receive, or simultaneously receive,
a dividend on each outstanding share of Series A Preferred Stock in an amount at least equal to the sum of (i) the amount of the
aggregate Series A Accruing Dividends then accrued on such share of Series A Preferred Stock and not previously paid, plus (ii)
(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per
share of Series A Preferred Stock as would equal the product of (1) the dividend payable on each share of such class or series
determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2) the number of
shares of Common Stock issuable upon conversion of a share of Series A Preferred Stock pursuant to Section 8 without regard to
the Exchange Cap, in each case calculated on the record date for determination of holders entitled to receive such dividend or
(B) in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series
A Preferred Stock determined by (1) dividing the amount of the dividend payable on each share of such class or series of capital
stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event
of any stock dividend, stock split, combination or other similar recapitalization affecting such shares) and (2) multiplying such
fraction by an amount equal to the Stated Value; provided that, if the Corporation declares, pays or sets aside, on the same date,
a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the Holders
of Series A Preferred Stock pursuant to this Section 3(b) shall be calculated based upon the dividend on the class or series of
capital stock that would result in the highest Series A Preferred Stock dividend. Notwithstanding anything to the contrary herein,
the Corporation shall not declare, pay or set aside a dividend on Series A Preferred Stock consisting of Common Stock prior to
the Nasdaq Approval Date.
Section
4. Voting Rights.
(a)
Non-Voting Series A-1 Preferred Stock. The Series A-1 Preferred Stock shall have no voting rights.
(b)
General Series A Preferred Stock Voting Rights. From and after the Issuance Date until the earlier of: (i) the day following
the Next Meeting Date (as defined below); and (ii) six (6) months following the Issuance Date (the “Voting Date”),
the Series A Preferred Stock shall have no voting rights (the “Voting Block”); provided, however, that
the Voting Block shall not apply to Section 4(c)(i), Section 4(c)(ii), Section 4(c)(iii), Section 4(c)(iv), Section 4(c)(vi),
Section 4(d) or Section 4(e); provided, further, that from and after the day following the Next Meeting Date, the Voting Block
shall not apply. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting
of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each Holder of outstanding shares
of Series A Preferred Stock shall be entitled to cast the number of votes equal to the lesser of: (a) the number of whole shares
of Common Stock into which the shares of Series A Preferred Stock held by such Holder are convertible as of the record date for
determining stockholders entitled to vote on such matter; and (b) the number of whole shares of Common Stock equal to the number
of shares of Series A Preferred Stock held by such Holder as of the record date for determining stockholders entitled to vote
on such matter multiplied by the Series A Minimum Voting Ratio; provided, however, that at any meeting of stockholders
of the Corporation (or by written consent of stockholders in lieu of meeting) pursuant to which the record date for determining
the stockholders entitled to vote at such meeting (or by written consent) occurs prior to the Nasdaq Approval Date, each share
of Series A Preferred Stock that exceeds the Exchange Cap shall have no voting rights (the “Voting Cap”);
provided, further, that from and after the Nasdaq Approval Date, the Voting Cap shall not apply. Except as provided
by law or by the other provisions of this Certificate of Designation, Holders of Series A Preferred Stock shall vote together
with the holders of Common Stock as a single class and on an as-converted to Common Stock basis.
(c)
Directors.
(i)
After the Nasdaq Approval Date, for so long as at least 135 shares of Series A Preferred Stock remain outstanding that are not
subject to the Voting Cap (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization affecting such shares) or if the Holders of Series A Preferred obtain an exemption to the Voting Cap
from the Nasdaq Capital Market with respect to the right to appoint directors of the Corporation, the Holders of record of the
shares of Series A Preferred Stock, exclusively and as a separate class, shall be entitled to elect three (3) directors of the
Corporation.
(ii)
After the Nasdaq Approval Date, for so long as at least 90 shares of Series A Preferred Stock remain outstanding that are not
subject to the Voting Cap (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization affecting such shares) or if the Holders of Series A Preferred obtain an exemption to the Voting Cap
from the Nasdaq Capital Market with respect to the right to appoint directors of the Corporation, the Holders of record of the
shares of Series A Preferred Stock, exclusively and as a separate class, shall be entitled to elect two (2) directors of the Corporation.
(iii)
For so long as at least 45 shares of Series A Preferred Stock remain outstanding that are not subject to the Voting Cap (subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting
such shares), the Holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, shall be entitled
to elect one (1) director of the Corporation (each director elected pursuant to this Section 4(c) shall hereinafter referred to
as a “Series A Director”).
(iv)
If the Corporation is unable to redeem for cash in compliance with Section 6 all of the shares of Senior Preferred Stock subject
to a Redemption Notice in compliance with applicable law, the Holders of record of the shares of Series A Preferred Stock, exclusively
and as a separate class, shall be entitled to elect a majority of the directors of the Corporation then in-office.
(v)
The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Series A Preferred
Stock), exclusively and voting together as a single class, shall, subject to the rights of any additional series of Preferred
Stock that may be established from time to time, be entitled to elect the balance of the total number of directors of the Corporation.
At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of
the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing
such director.
(vi)
Any director elected pursuant to this Section 4(c) may be removed without cause by, and only by, the affirmative vote of the holders
of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special
meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. A vacancy in any directorship
filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders
of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this
Section 4(c).
(d)
Protective Provisions. Notwithstanding anything in this Certificate of Designation to the contrary, for so long as any
shares of the Senior Preferred Stock remain outstanding, the following actions may only be taken by the Corporation or any of
its direct or indirect subsidiaries with the written consent of Holders representing a majority of the outstanding shares of Senior
Preferred Stock (voting as a single class):
(i)
amend, waive, alter or repeal the preferences, rights, privileges or powers of the Holders of the Senior Preferred Stock;
(ii)
amend, alter or repeal any provision of this Certificate of Designation in a manner that is adverse to the Holders of Senior Preferred
Stock;
(iii)
authorize, create or issue any equity securities senior to or pari passu with either series of the Senior Preferred Stock; or
(iv)
increase or decrease the number of directors constituting the Board.
(e)
Additional Protective Provisions. Notwithstanding anything in this Certificate of Designation to the contrary, for so long
as either: (i) at least 105 shares of Senior Preferred Stock remain outstanding (subject to appropriate adjustment in the event
of any stock dividend, stock split, combination or other similar recapitalization affecting such shares); or (ii) at least 28
shares of Series A-1 Preferred Stock remain outstanding (subject to appropriate adjustment in the event of any stock dividend,
stock split, combination or other similar recapitalization affecting such shares), the following actions may only be taken by
the Corporation or any of its direct or indirect subsidiaries with the written consent with the consent of Holders representing
a majority of the outstanding shares of Senior Preferred Stock (voting as a single class):
(A)
(1) authorize, create or issue any debt securities for borrowed money or funded debt pursuant to which the Corporation or any
of its direct or indirect subsidiaries issues shares, warrants or any other convertible security in the same transaction or a
series of related transactions; or (2) authorize, create or issue any debt securities for borrowed money or funded debt pursuant
to which the Corporation or any of its direct or indirect subsidiaries does not issue shares, warrants or any other convertible
security in the same transaction or a series of related transactions exceeding $4.5 million initially (the “Debt Threshold”),
excluding, however: (w) any capitalized and operating leases entered into by the Corporation or its direct or indirect subsidiaries
in the ordinary course of business consistent with past practice; and (x) any debt incurred by the Corporation pursuant to the
terms of the Corporation’s existing term loan and credit facility with Silicon Valley Bank as it is proposed to be expanded
on the Issuance Date on similar terms with Silicon Valley Bank or another comparable credit facility provider subsequent to the
Issuance Date; provided, that if the aggregate consolidated revenue recognized by the Corporation and its direct or indirect subsidiaries
(the “Combined Revenue”) as reported by the Corporation on Form 10-K as filed with the Commission for
any fiscal year ending after the Issuance Date exceeds $45 million dollars, the Debt Threshold for the following fiscal year shall
increase to an amount equal to: (y) ten percent (10%); multiplied by (z) the Combined Revenue as reported by the Corporation on
Form 10-K as filed with the Commission for the previous fiscal year;
(B)
merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess
of $20 million (the “Acquisition Threshold”); provided, that the Acquisition Threshold shall increase
on a straight line basis to an amount up to $40 million, but in no event greater than $40 million, to the extent Combined Revenue
for the then-most recently completed quarterly period as reported by the Corporation on Form 10-K as filed with the Commission
or Form 10-Q as filed with the Commission, as applicable, falls between the Combined Revenue for the Corporation’s fiscal
quarter ended on September 30, 2019, and 100% greater than the Combined Revenue for the Corporation’s fiscal quarter ended
on September 30, 2019;
(C)
materially change the nature of the business of the Corporation or any of its direct or indirect subsidiaries as it is proposed
to be conducted as of the Issuance Date.;
(D)
consummate any Liquidation (as defined below);
(E)
transfer, by sale, exclusive license or otherwise, material intellectual property rights of the Corporation or any of its direct
or indirect subsidiaries, other than licenses, transfers or sales of products accomplished in the ordinary course of business
consistent with past practice;
(F)
declare or pay any cash dividend or make any cash distribution on any equity interests of the Corporation other than the Senior
Preferred Stock;
(G)
repurchase or redeem any shares of capital stock of the Corporation, except for: (1) the redemption of the Senior Preferred Stock
pursuant to Section 5(e) or Section 6; or (2) repurchases of Common Stock under agreements previously approved by the Board of
Directors of the Corporation with employees, consultants, advisors or others who performed services for the Corporation or any
direct or indirect subsidiary in connection with the cessation of such employment or service;
(H)
incur any additional individual debt, indebtedness for borrowed money or other additional liabilities pursuant to which the Corporation
or any of its direct or indirect subsidiaries issues shares, warrants or any other convertible security in the same transaction
or a series of related transactions; or (b) incur any individual debt, indebtedness for borrowed money or other liabilities pursuant
to which the Corporation or any of its direct or indirect subsidiaries does not issue shares, warrants or any other convertible
security in the same transaction or a series of related transactions in excess of the Debt Threshold (in each case, excluding:
(i) any capitalized and operating leases entered into by the Corporation or its direct or indirect subsidiaries in the ordinary
course of business consistent with past practice; (ii) any debt incurred by the Corporation pursuant to the terms of the Corporation’s
existing term loan and credit facility with Silicon Valley Bank as it is proposed to be expanded on the Issuance Date on similar
terms with Silicon Valley Bank or another comparable credit facility provider subsequent to the Issuance Date; and (iii) any purchase
money financing in connection with the acquisition of equipment or otherwise); or
(I)
change any accounting methods or practices of the Corporation or any of its direct or indirect subsidiaries, except for those
changes required by GAAP or applicable regulatory agencies or authorities, including but not limited to the Securities and Exchange
Commission and the Financial Accounting Standards Board, in each case, as consented to by the Corporation’s independent
auditors.
(f)
Notwithstanding the foregoing, nothing in Section 4(e) shall restrict the Corporation’s ability to adopt an at-the-market
offering of its Common Stock or other public offering of Common Stock registered with the Commission on Form S-3 for up to $5
million worth of the Common Stock (“Permitted Financings”); provided, however, that Permitted
Financings will not include any transaction or series of related transactions pursuant to which the Corporation issues warrants
or any other convertible security without the written consent of Holders representing a majority of the outstanding shares of
Senior Preferred Stock.
Section
5. Liquidation.
(a)
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation (a
“Liquidation”), the Holders of shares of Series A-1 Preferred Stock then outstanding shall be entitled
to be paid out of the assets of the Corporation available for distribution to its stockholders (on a pari passu basis with the
holders of any class or series of Preferred Stock ranking on liquidation on a parity with the Series A-1 Preferred Stock), and
before any payment shall be made to the Holders of Series A Preferred Stock, Common Stock or any other class or series of Preferred
Stock ranking on liquidation junior to the Series A-1 Preferred Stock by reason of their ownership thereof, an amount per share
of Series A-1 Preferred Stock equal to the greater of (based on the date of the related Liquidation): (a) from and after the Issuance
Date until the second (2nd) anniversary of the Issuance Date, two times (2x) the Stated Value of such share of Series A-1 Preferred
Stock; (b) after the second (2nd) anniversary of the Issuance Date until the third (3rd) anniversary of the Issuance Date, two
and one-half times (2½x) the Stated Value of such share of Series A-1 Preferred Stock; or (c) from and after the third
(3rd) anniversary of the Issuance Date three times (3x) the Stated Value of such share of Series A-1 Preferred Stock, plus any
Series A-1 Accruing Dividends accrued but unpaid thereon, whether or not declared, together with any other dividends declared
but unpaid thereon or (ii) such amount per share as would have been payable in respect of such share had such share been converted
into Series A Preferred Stock pursuant to Section 7 immediately prior to such Liquidation and immediately thereafter and effective
prior to the consummation of such Liquidation each such share of Series A Preferred Stock had been converted to Common Stock pursuant
to Section 8 without regard to the Exchange Cap (the amount payable in respect of shares of Series A-1 Preferred Stock pursuant
to this sentence is hereinafter referred to as the “Series A-1 Liquidation Amount”). If upon any such
Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Holders
of shares of Series A-1 Preferred Stock and any series of Preferred Stock ranking on liquidation on a parity with the Series A-1
Preferred Stock the full amount to which they shall be entitled under this Section 5(a), the Holders of shares of Series A-1 Preferred
Stock and any series of Preferred Stock ranking on liquidation on a parity with the Series A-1 Preferred Stock shall share ratably
in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be
payable in respect of the shares of Series A-1 Preferred Stock held by them upon such distribution if all amounts payable on or
with respect to such shares were paid in full.
(b)
In the event of any Liquidation, the Holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid
out of the assets of the Corporation available for distribution to its stockholders (on a pari passu basis with the holders of
any class or series of Preferred Stock ranking on liquidation on a parity with the Series A Preferred Stock), and before any payment
shall be made to the holders of Common Stock or any other class or series of Preferred Stock ranking on liquidation junior to
the Series A Preferred Stock by reason of their ownership thereof, an amount per share of Series A Preferred Stock equal to the
greater of (i) the Stated Value of such share of Series A Preferred Stock, plus any Series A Accruing Dividends accrued but unpaid
thereon, whether or not declared, together with any other dividends declared but unpaid thereon, or (ii) such amount per share
as would have been payable had each such share been converted into Common Stock pursuant to Section 8 immediately prior to such
Liquidation without regard to the Exchange Cap, (the amount payable in respect of shares of Series A Preferred Stock pursuant
to this sentence is hereinafter referred to as the “Series A Liquidation Amount”). If upon any such
Liquidation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Holders
of shares of Series A Preferred Stock and any series of Preferred Stock ranking on liquidation on a parity with the Series A Preferred
Stock the full amount to which they shall be entitled under this Section 5(b), the Holders of shares of Series A Preferred Stock
and any series of Preferred Stock ranking on liquidation on a parity with the Series A Preferred Stock shall share ratably in
any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable
in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid
in full.
(c)
In the event of any Liquidation, after the payment of all preferential amounts required to be paid to the Holders of shares of
Series A-1 Preferred Stock, Series A Preferred Stock and any other series of Preferred Stock ranking on liquidation senior to
the Common Stock, the remaining assets of the Corporation available for distribution to its stockholders shall be distributed
among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.
(d)
The Corporation shall not have the power to effect a Deemed Liquidation unless the definitive agreement regarding such transaction
provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital
stock of the Corporation in accordance with Section 5 of this Certificate of Designation.
(e)
If following a Deemed Liquidation the Corporation does not effect a dissolution of the Corporation under the General Corporation
Law within sixty (60) days after such Deemed Liquidation, then (i) the Corporation shall send a written notice to each Holder
of Senior Preferred Stock no later than the sixtieth (60th) day after the Deemed Liquidation advising such Holders of their right
(and the requirements to be met to secure such right) pursuant to the terms of the following clause (ii) to require the redemption
of such shares of Senior Preferred Stock, and (ii) if the Holders of a majority of the then outstanding shares of Senior Preferred
Stock so request in a written instrument delivered to the Corporation not later than sixty (60) days after receipt of such notice,
the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation (net of any retained liabilities
associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors of the Corporation)
(the “Net Proceeds”), to the extent legally available therefor, on the one hundred fiftieth (150th)
day after such Deemed Liquidation, to redeem all outstanding shares of Senior Preferred Stock at a price per share equal to the
Series A-1 Liquidation Value or Series A Liquidation Value, as applicable. Notwithstanding the foregoing, in the event of a redemption
pursuant to the preceding sentence, if the Net Proceeds are not sufficient to redeem all outstanding shares of Senior Preferred
Stock and of any other series of Preferred Stock ranking on redemption on parity with the Senior Preferred Stock that is required
to then be redeemed, or if the Corporation does not have sufficient lawfully available funds to effect such redemption, the Corporation
shall first redeem a pro rata portion of each Holder’s shares of Series A Preferred Stock and any such other series of Preferred
Stock ranking on redemption on a parity with the Series A Preferred Stock to the fullest extent of such Net Proceeds or such lawfully
available funds, as the case may be, based on the respective amounts which would otherwise be payable in respect of the shares
to be redeemed if the legally available funds were sufficient to redeem all such shares. If upon any such redemption, the assets
of the Corporation lawfully available to effect such redemption shall be insufficient to pay the Holders of shares of Series A
Preferred Stock and any series of Preferred Stock ranking on redemption on a parity with the Series A Preferred Stock, the full
amount to which they shall be entitled under this Section 5(e), the Holders of shares of Series A Preferred Stock and any series
of Preferred Stock ranking on redemption on a parity with the Series A Preferred Stock shall share ratably in any distribution
of the assets lawfully available for such redemption in proportion to the respective amounts which would otherwise be payable
in respect of the shares held by them upon such redemption if all amounts payable on or with respect to such shares were paid
in full, and shall redeem the remaining shares to have been redeemed as soon as practicable after the Corporation has funds legally
available therefor. Thereafter, the Corporation shall next redeem a pro rata portion of each Holder’s shares of Series A-1
Preferred Stock and any such other series of Preferred Stock ranking on redemption on parity with the Series A-1 Preferred Stock
to the fullest extent of such Net Proceeds or such lawfully available funds, as the case may be, based on the respective amounts
which would otherwise be payable in respect of the shares to be redeemed if the legally available funds were sufficient to redeem
all such shares. If upon any such redemption, the assets of the Corporation lawfully available to effect such redemption shall
be insufficient to pay the Holders of shares of Series A-1 Preferred Stock and any series of Preferred Stock ranking on redemption
on a parity with the Series A-1 Preferred Stock, the full amount to which they shall be entitled under this Section 5(e), the
Holders of shares of Series A-1 Preferred Stock and any series of Preferred Stock ranking on redemption on a parity with the Series
A-1 Preferred Stock shall share ratably in any distribution of the assets lawfully available for such redemption in proportion
to the respective amounts which would otherwise be payable in respect of the shares held by them upon such redemption if all amounts
payable on or with respect to such shares were paid in full, and shall redeem the remaining shares to have been redeemed as soon
as practicable after the Corporation has funds legally available therefor. The provisions of Section 6(b) below shall apply, with
such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Senior Preferred Stock
pursuant to this Section 5(e). Prior to the distribution or redemption provided for in this Section 5(e), the Corporation shall
not expend or dissipate the consideration received for such Deemed Liquidation, except to discharge expenses incurred in connection
with such Deemed Liquidation or in the ordinary course of business consistent with past practice.
(f)
The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any Liquidation Event shall be the
cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring
person, firm or other entity; provided, that the value of any such non-cash property, rights or securities shall be determined
in good faith by the Board of Directors of the Corporation.
Section
6. Redemption.
(a)
If the Corporation shall have failed to obtain the Nasdaq Approval on, or prior to, the third (3rd) anniversary of the Issuance
Date (the “Triggering Event Date”), each Holder shall have the right (the “Redemption Right”)
beginning on the date following the Triggering Event Date to require the Corporation to redeem all of the shares of Series A Preferred
Stock, if any, then held by such Holder that are convertible into a number of shares of Common Stock that exceeds the Exchange
Cap and all of the shares of Series A-1 Preferred Stock then held by such Holder by delivering written notice thereof to the Corporation
(the “Redemption Notice”) together with the applicable certificates, if any, representing such shares
of Senior Preferred Stock which Redemption Notice shall indicate that Holder is electing to redeem such shares of Senior Preferred
Stock. Each of the shares of Senior Preferred Stock subject to redemption by the Corporation pursuant to this Section 6(a) shall
be redeemed by the Corporation at a price equal to the Series A-1 Liquidation Value or Series A Liquidation Value, as applicable.
Payment of the Series A-1 Liquidation Value or Series A Liquidation Value, as applicable, required by this Section 6(a) shall
be made in accordance with the provisions of Section 6(b). Notwithstanding anything to the contrary in this Section 6(a), until
the Series A Liquidation Value for each share of Series A Preferred Stock subject to a Redemption Notice is paid in full, such
shares of Series A Preferred Stock that have not been so redeemed under this Section 6(a) may be converted, in whole or in part,
by Holder into Common Stock pursuant to Section 8; provided, that the Corporation shall not be obligated to pay Holder
the Series A Liquidation Value in respect of any shares of Senior Preferred Stock subject to a Redemption Notice that are so converted
into shares of Common Stock.
(b)
If a Holder submits a Redemption Notice in accordance with Section 6(a), the Corporation shall pay such Holder an amount equal
to the aggregate Series A-1 Liquidation Value or Series A Liquidation Value, as applicable, payable in respect of all Senior Preferred
Stock held by such Holder to be redeemed pursuant to Section 6(a) by wire transfer of immediately available funds to the account(s)
designated in the Redemption Notice as soon as reasonably practicable, but in no event later than sixty (60) days, following the
date of such Redemption Notice. Upon payment of the aggregate Series A-1 Liquidation Value or Series A Liquidation Value, as applicable,
in respect of any shares of Senior Preferred Stock subject to a Redemption Notice, such shares of Senior Preferred Stock will
be automatically cancelled without any further action on the part of the Corporation, Holder or any other Person and such cancelled
shares of Senior Preferred Stock shall no longer be issued and outstanding shares of capital stock of the Corporation. In the
event that the Corporation does not pay to Holder any portion of the Series A-1 Liquidation Value or Series A Liquidation Value,
as applicable, in respect of shares of Senior Preferred Stock subject to a Redemption Notice in full within the time period required
for any reason (including, without limitation, to the extent such payment is prohibited pursuant to applicable law), at any time
thereafter and until the Corporation pays such Series A-1 Liquidation Value or Series A Liquidation Value, as applicable, in full,
such Holder shall have the option, in lieu of redemption, to require the Corporation to promptly return to such Holder all or
any of the shares of Senior Preferred Stock subject to a Redemption Notice that were submitted for redemption and for which the
applicable Series A-1 Liquidation Value or Series A Liquidation Value, as applicable, has not been paid. Upon the Corporation’s
receipt of such notice, (A) the Redemption Notice shall be null and void with respect to such shares of Senior Preferred Stock,
and (B) the Corporation shall immediately return the applicable certificate, if any, or issue a new, to Holder (unless such shares
of Senior Preferred Stock are held in book-entry form, in which case the Corporation shall deliver evidence to such Holder that
a book-entry for such shares of Senior Preferred Stock then exists).
Section
7. Conversion of Series A-1 Preferred Stock into Series A Preferred Stock.
(a)
Automatic Conversion of Series A-1 Preferred Stock into Series A Preferred Stock. If the Corporation obtains the Nasdaq
Approval at any time prior to the eighteen (18) month anniversary of the Issuance Date, on the date that the Corporation obtains
such Nasdaq Approval (the “Nasdaq Approval Date”), each share of Series A-1 Preferred Stock shall automatically
be converted into one share of Series A Preferred Stock.
(b)
No Conversion of Series A-1 Preferred Stock into Common Stock. Shares of Series A-1 Preferred Stock shall not be convertible
into shares of Common Stock.
Section
8. Conversion of Series A Preferred Stock into Common Stock.
(a)
Conversion of Series A Preferred Stock into Common Stock at Option of Holder. Subject to Section 8(c) below, each share
of Series A Preferred Stock shall be convertible, at any time and from time to time from and after the Issuance Date, at the option
of the Holder thereof, into a number of shares of Common Stock equal to the product of the Series A Conversion Ratio and the number
of shares of Series A Preferred Stock to be converted. Holders shall effect conversions of Series A Preferred Stock into Common
Stock by providing the Corporation with the form of conversion notice attached hereto as Annex A (a “Notice
of Conversion”), duly completed and executed. Provided the Corporation’s transfer agent is participating in
the Depository Trust Corporation (“DTC”) Fast Automated Securities Transfer program, the Notice of Conversion
may specify, at the Holder’s election, whether the applicable Conversion Shares shall be credited to the DTC participant
account nominated by the Holder through DTC’s Deposit Withdrawal Agent Commission system (a “DWAC Delivery”).
The “Optional Conversion Date”, or the date on which a conversion shall be deemed effective, shall be
defined as the Trading Day after the Trading Date that the Notice of Conversion, completed and executed, is sent by facsimile
or other electronic transmission to, and received during regular business hours by, the Corporation; provided that the original
certificate(s) (if any) representing such shares of Series A Preferred Stock being converted, duly endorsed, and the accompanying
Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all other cases, the Optional
Conversion Date shall be defined as the Trading Day after the Trading Date on which the original shares of Series A Preferred
Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation.
(b)
Mandatory Conversion of Series A Preferred Stock into Common Stock. If at any time after the Corporation shall have obtained
the Nasdaq Approval, the Corporation consummates the sale of shares of Common Stock to the public in a firm-commitment underwritten
public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, pursuant to which
(A) the price per share of the Common Stock in such offering is at least the Series A Mandatory Conversion Price (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares)
and such offering results in at least $25 million in proceeds, net of the underwriting discount and commissions, to the Corporation
and the Common Stock continues to be listed for trading on the Nasdaq Capital Market or another Exchange such as NYSE (such offering,
an “Underwritten Offering”, and the date of the consummation of such Underwritten Offering is referred
to herein as the “Mandatory Conversion Date” and together with each Optional Conversion Date, a “Conversion
Date”), (i) all outstanding shares of Series A Preferred Stock shall automatically be converted into shares of Common
Stock, at the then effective Series A Conversion Ratio and (ii) such shares may not be reissued by the Corporation. The provisions
of Section 8(d) shall apply, with such necessary changes in the details thereof as are necessitated by the context, to the conversion
of shares of Series A Preferred Stock into Common Stock pursuant to this Section 8(b). Notwithstanding the foregoing, an Underwritten
Offering shall not include, and shares of Series A Preferred Stock will not automatically convert to shares of Common Stock upon
the consummation of, any Underwritten Offering that includes the issuance of warrants to purchase capital stock of the Corporation
or any other Convertible Security.
(c)
Series A Conversion Limitation. Notwithstanding anything herein to the contrary, from and after the Issuance Date until
the Voting Date, the Corporation shall not effect any conversion of the Series A Preferred (the “Exchange Block”);
provided, however, that from and after the Voting Date, the Exchange Block shall not apply. From and after the Voting
Date, the Corporation shall not effect any conversion of the Series A Preferred Stock into Common Stock, and a Holder shall not
have the right to convert any portion of the Series A Preferred Stock into Common Stock, if the issuance of such shares of Common
Stock would exceed the aggregate number of shares of Common Stock which the Corporation may issue upon conversion of the Series
A Preferred Stock under applicable Nasdaq Marketplace rules (the number of shares of Common Stock which may be issued without
violating such rules, the “Exchange Cap”), except that the Exchange Cap shall not apply in the event
that the Corporation obtains the approval of its stockholders as required by applicable Nasdaq Marketplace rules for issuances
of shares of Common Stock without regard to the Exchange Cap (the “Nasdaq Approval”). Within six (6)
months following the Issuance Date, the Corporation shall call a meeting (the date that such meeting is completed, the “Next
Meeting Date”) of the Corporation’s stockholders for the purpose of soliciting the Nasdaq Approval for the
issuance of the full amount of shares of Common Stock issuable upon the conversion of the Series A Preferred Stock, including
the Series A Preferred Stock issuable upon conversion of the Series A-1 Preferred Stock, authorized and designated under this
Certificate of Designation without regard to the Exchange Cap.
(d)
Mechanics of Conversion of Series A Preferred Stock into Common Stock.
(i)
Delivery of Certificate or Electronic Issuance Upon Conversion. Not later than three (3) Trading Days after the applicable
Conversion Date (the “Share Delivery Date”), the Corporation shall (a) deliver, or cause to be delivered,
to the converting Holder or recipient of the Conversion Shares a physical certificate or certificates representing the number
of Conversion Shares set forth in a Notice of Conversion being acquired upon the conversion of shares of Series A Preferred Stock,
or (b) in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting
the DTC participant account nominated by the Holder through DTC’s DWAC system. If in the case of any Notice of Conversion
such certificate or certificates are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not
electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be
entitled to elect to rescind such Conversion Notice by written notice to the Corporation at any time on or before its receipt
of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event
the Corporation shall promptly return to such Holder any original Series A Preferred Stock certificate delivered to the Corporation
and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares
of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series A Preferred Stock unsuccessfully
tendered for conversion to the Corporation.
(ii)
Obligation Absolute. Subject to Section 8(c) hereof and subject to Holder’s right to rescind a Conversion Notice
pursuant to Section 8(d)(i) above, the Corporation’s obligation to issue and deliver the Conversion Shares upon conversion
of Series A Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or
inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment
against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any
breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation
of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation
of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Nothing herein shall limit a Holder’s
right to pursue actual damages for the Corporation’s failure to deliver Conversion Shares within the period specified herein
and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief; provided that Holder shall not receive duplicate damages
for the Corporation’s failure to deliver Conversion Shares within the period specified herein. The exercise of any such
rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.
(iii)
Compensation for Buy-In on Failure to Timely Deliver Certificates Upon Conversion. If the Corporation fails to deliver
to a Holder (or its transferee) the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, in each
case that represent shares of Common Stock by the Share Delivery Date pursuant to Section 8(d)(i) (other than a failure caused
by incorrect or incomplete information provided by Holder to the Corporation), and if after such Share Delivery Date such Holder
is required to or otherwise purchases (in an open market transaction or otherwise), shares of Common Stock to deliver in satisfaction
of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such
Share Delivery Date (a “Buy-In”), then the Corporation shall (A) pay in cash to such Holder (in addition
to any other remedies available to or elected by such Holder) the amount by which (x) such Holder’s total purchase price
(including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate
number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual
sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions)
and (B) at the option of such Holder, either reissue (if surrendered) the shares of Series A Preferred Stock equal to the number
of shares of Series A Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock
that would have been issued if the Corporation had timely complied with its delivery requirements under Section 8(d)(i). For example,
if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
conversion of shares of Series A Preferred Stock with respect to which the actual sale price (including any brokerage commissions)
giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation
shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading
Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable
confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder’s right to
pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Corporation’s failure to timely deliver certificates representing shares of
Common Stock upon conversion of the shares of Series A Preferred Stock as required pursuant to the terms hereof; provided, however,
that the Holder shall not be entitled to both (i) require the reissuance of the shares of Series A Preferred Stock submitted for
conversion for which such conversion was not timely honored and (ii) receive the number of shares of Common Stock that would have
been issued if the Corporation had timely complied with its delivery requirements under Section 8(d)(i).
(iv)
Not later than two (2) Business Days after the Nasdaq Approval Date, the Corporation shall issue to each Holder the number of
shares of Series A Preferred Stock being acquired upon the conversion of shares of Series A-1 Preferred Stock held by such Holder
pursuant to Section 7(a) solely in book-entry form or, if requested by any Holder, such shares may be issued in certificated form.
(e)
Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will, at all times reserve and keep available
out of its authorized and unissued shares of Series A Preferred Stock for the sole purpose of issuance upon conversion of the
Series A-1 Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the
Holders of the Series A-1 Preferred Stock, not less than such aggregate number of shares of the Series A Preferred Stock as shall
be issuable upon the conversion of all outstanding shares of Series A-1 Preferred Stock. The Corporation covenants that all shares
of Series A Preferred Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, non-assessable
and free and clear of all liens and other encumbrances. The Corporation covenants that it will, at all times reserve and keep
available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series
A Preferred Stock, including all shares of Series A Preferred Stock issuable upon conversion of shares of Series A-1 Preferred
Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series
A Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account
the adjustments of Section 9) upon the conversion of all outstanding shares of Series A Preferred Stock, including all shares
of Series A Preferred Stock issuable upon conversion of shares of Series A-1 Preferred Stock. The Corporation covenants that all
shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, non-assessable
and free and clear of all liens and other encumbrances.
(f)
Fractional Shares No fractional shares or scrip representing fractional shares of Series A Preferred Stock shall be issued
upon the conversion of the Series A-1 Preferred Stock. As to any fraction of a share of Series A Preferred Stock which a Holder
would otherwise be entitled to receive upon such conversion, the Corporation shall pay a cash adjustment in respect of such final
fraction in an amount equal to such fraction multiplied by the Stated Value. No fractional shares or scrip representing fractional
shares of Common Stock shall be issued upon the conversion of the Series A Preferred Stock. As to any fraction of a share of Common
Stock which a Holder would otherwise be entitled to receive upon such conversion, the Corporation shall pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the Series A Conversion Price.
(g)
Transfer Taxes. The issuance of certificates (or book entry notations) for shares of Series A Preferred Stock upon conversion
of the Series A-1 Preferred Stock and the issuance of certificates (or book entry notations) for shares of the Common Stock upon
conversion of the Series A Preferred Stock, in each case, shall be made without charge to any Holder for any documentary stamp
or similar taxes that may be payable in respect of the issue or delivery of such certificates (or such book entry notation), provided
that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance
and delivery of any such certificate (or such book entry notation) upon conversion in a name other than that of the registered
Holder(s) of such shares of Series A-1 Preferred Stock or Series A Preferred Stock, as applicable, and the Corporation shall not
be required to issue or deliver such certificates (or such book entry notation) unless or until the Person or Persons requesting
the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of
the Corporation that such tax has been paid.
(h)
Status as Stockholder. Upon each Conversion Date and Mandatory Conversion Date: (i) the shares of Series A Preferred Stock
being converted shall be deemed converted into shares of Common Stock; and (ii) the Holder’s rights as a holder of such
converted shares of Series A Preferred Stock shall cease and terminate, excepting only the right to receive certificates (or book
entry notations) for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity
to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases,
the Holder shall retain all of its rights and remedies for the Corporation’s failure to convert Series A Preferred Stock.
From and after the Nasdaq Approval Date: (i) the shares of Series A-1 Preferred Stock shall be deemed converted into shares of
Series A Preferred Stock; and (ii) the Holder’s rights as a Holder of such converted shares of Series A-1 Preferred Stock
shall cease and terminate, excepting only the right to receive certificates (or book entry notations) for such shares of Series
A Preferred Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure
by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its
rights and remedies for the Corporation’s failure to convert Series A-1 Preferred Stock.
Section
9. Certain Adjustments.
(a)
Stock Dividends and Stock Splits. If the Corporation, at any time while any shares of Series A Preferred Stock are outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock with respect to
the then outstanding shares of Common Stock; (ii) subdivides outstanding shares of Common Stock into a larger number of shares;
or (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares,
then the Series A Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event (excluding any treasury shares of the Corporation).
Any adjustment made pursuant to this Section 9(a) shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date
in the case of a subdivision or combination.
(b)
Adjustments for Other Dividends and Distributions. In the event the Corporation at any time or from time to time after
the Issuance Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive,
a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock
in respect of outstanding shares of Common Stock) or in other property and the provisions of Section 3 do not apply to such dividend
or distribution, then and in each such event the Holders of Senior Preferred Stock shall receive, simultaneously with the distribution
to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the
amount of such securities or other property as they would have received if all outstanding shares of Series A Preferred Stock,
including if all shares of Series A-1 Preferred Stock shall have been converted to Series A Preferred Stock, had been converted
into Common Stock on the date of such event.
(c)
Adjustment for Merger or Reorganization, etc. Subject to the provisions of Section 5, if there shall occur any reorganization,
recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Series
A Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by
Section 9(a), Section 9(b), Section 9(e) or Section 9(f)), then, following any such reorganization, recapitalization, reclassification,
consolidation or merger, each share of Series A Preferred Stock shall thereafter be convertible in lieu of the Common Stock into
which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of
the number of shares of Common Stock of the Corporation issuable upon conversion of one share of Series A Preferred Stock immediately
prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive
pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors
of the Corporation) shall be made in the application of the provisions in this Certificate of Designation with respect to the
rights and interests thereafter of the Holders of the Series A Preferred Stock, to the end that the provisions set forth in this
Certificate of Designation (including provisions with respect to changes in and other adjustments of the Series A Conversion Price)
shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable
upon the conversion of the Series A Preferred Stock.
(d)
No Adjustment of Series A Conversion Price. No adjustment in the Series A Conversion Price shall be made as the result
of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Holders
representing a majority of the Senior Preferred Stock (voting as a single class) then-outstanding agreeing that no such adjustment
shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.
(e)
Deemed Issue of Additional Shares of Common Stock.
(i)
If the Corporation at any time or from time to time after the Issuance Date shall issue any Options or Convertible Securities
(excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination
of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number
of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability,
convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number)
issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange
of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or,
in case such a record date shall have been fixed, as of the close of business on such record date.
(ii)
If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Series A Conversion
Price pursuant to the terms of Section 9(f), are revised as a result of an amendment to such terms or any other adjustment pursuant
to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution
or similar provisions of such Option or Convertible Security pursuant to which an adjustment has already been made under this
Section 9(e)) to provide for either (1) any increase or decrease in the number of shares of Common Stock issuable upon the exercise,
conversion and/or exchange of any such Option or Convertible Security or (2) any increase or decrease in the consideration payable
to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective,
the Series A Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence
of a record date with respect thereto) shall be readjusted to such Series A Conversion Price as would have obtained had such revised
terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing,
no readjustment pursuant to this Section 9(e)(ii) shall have the effect of increasing the Series A Conversion Price to an amount
which exceeds the lower of (i) the Series A Conversion Price in effect immediately prior to the original adjustment made as a
result of the issuance of such Option or Convertible Security, or (ii) the Series A Conversion Price that would have resulted
from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a
result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.
(iii)
If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted
Securities), the issuance of which did not result in an adjustment to the Series A Conversion Price pursuant to the terms of Section
9(f) (either because the consideration per share (determined pursuant to Section 9(g)) of the Additional Shares of Common Stock
subject thereto was equal to or greater than the Series A Conversion Price then in effect, or because such Option or Convertible
Security was issued before the Issuance Date), are revised after the Issuance Date as a result of an amendment to such terms or
any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to
such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security pursuant to which an adjustment
has already been made under this Section 9(e)) to provide for either (1) any increase in the number of shares of Common Stock
issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2) any decrease in the consideration
payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended
or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in Section 9(e)(ii))
shall be deemed to have been issued effective upon such increase or decrease becoming effective.
(iv)
Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof)
which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Series A Conversion
Price pursuant to the terms of Section 9(f), the Series A Conversion Price shall be readjusted to such Series A Conversion Price
as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.
(v)
If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security,
or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such
Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment
to the Series A Conversion Price provided for in this Section 9(e) shall be effected at the time of such issuance or amendment
based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any
subsequent adjustments shall be treated as provided in clauses (ii) and (iii) of this Section 9(e)). If the number of shares of
Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration
payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option
or Convertible Security is issued or amended, any adjustment to the Series A Conversion Price that would result under the terms
of this Section 9(e) at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or
amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating
such adjustment to the Series A Conversion Price that such issuance or amendment took place at the time such calculation can first
be made.
(f)
Adjustment of Series A Conversion Price Upon Issuance of Additional Shares of Common Stock. In the event the Corporation
shall at any time after the Issuance Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock
deemed to be issued pursuant to Section 9(e)), without consideration or for a consideration per share less than the Series A Conversion
Price in effect immediately prior to such issuance or deemed issuance, then the Series A Conversion Price shall be reduced, concurrently
with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:
CP2
= CP1* (A + B) ÷ (A + C).
For
purposes of the foregoing formula, the following definitions shall apply:
“CP2”
shall mean the Series A Conversion Price in effect immediately after such issuance or deemed issuance of Additional Shares of
Common Stock.
“CP1”
shall mean the Series A Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares
of Common Stock;
“A”
shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional
Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options
outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including
the Series A Preferred Stock into Common Stock, including the shares of Series A-1 Preferred Stock into Series A Preferred Stock)
outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);
“B”
shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been
issued or deemed issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the
Corporation in respect of such issue by CP1); and
“C”
shall mean the number of such Additional Shares of Common Stock issued in such transaction.
(g)
Determination of Consideration. For purposes of this Certificate of Designation, the consideration received by the Corporation
for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows: (i) such consideration
shall: (A) insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding
amounts paid or payable for accrued interest; (B) insofar as it consists of property other than cash, be computed at the fair
market value thereof at the time of such issue, as determined in good faith by the Board of Directors of the Corporation; and
(C) in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the
Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in
clauses (A) and (B) above, as determined in good faith by the Board of Directors of the Corporation.
(h)
Options and Convertible Securities. The consideration per share received by the Corporation for Additional Shares of Common
Stock deemed to have been issued pursuant to Section 9(e), relating to Options and Convertible Securities, shall be determined
by dividing: (i) the total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options
or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating
thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation
upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for
Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible
Securities, by (ii) the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard
to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the
conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such
Options for Convertible Securities and the conversion or exchange of such Convertible Securities.
(i)
Multiple Closing Dates. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock
that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Series A
Conversion Price pursuant to the terms of Section 9(f), then, upon the final such issuance, the Series A Conversion Price shall
be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving
effect to any additional adjustments as a result of any such subsequent issuances within such period).
(j)
Calculations. All calculations under this Certificate of Designation shall be made to the nearest cent or the nearest 1/100th
of a share, as the case may be. For purposes of this Section 9, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation)
issued and outstanding.
(k)
Notice to the Holders.
(i)
Adjustment to Series A Conversion Price. Whenever the Series A Conversion Price is adjusted pursuant to any provision of
this Section 9, the Corporation shall promptly deliver to each Holder a notice setting forth the Series A Conversion Ratio after
such adjustment and setting forth a brief statement of the facts requiring such adjustment.
(ii)
Other Notices. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required
in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party,
any Liquidation, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) consent of the Holders of Senior Preferred Stock is required pursuant to Section 4(d) or Section 4(e), then, in each case,
the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of the shares of Series
A Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books
of the Corporation, at least ten (10) calendar days prior to the applicable record or effective date hereinafter specified, a
notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights
or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer, Liquidation or share exchange is expected to become effective or close, and the date as
of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such notice.
Section
10. Miscellaneous.
(a)
Lost or Mutilated Stock Certificates. If a Holder’s certificate representing shares of Series A Preferred Stock or
Series A-1 Preferred Stock, if applicable, shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver,
if requested by the Holder, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or
in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series A Preferred Stock or Series
A-1 Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction
of such certificate, and of the ownership thereof, reasonably satisfactory to the Corporation and, in each case, customary and
reasonable indemnity, if requested, without the requirement to post a bond. Applicants for a new certificate under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the
Corporation may prescribe, without the requirement to post a bond.
(b)
Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall
not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of
this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict
adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive
that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this
Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this
Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Senior Preferred Stock
granted hereunder may be waived as to all shares of Senior Preferred Stock (and the Holders thereof) upon the written consent
of the Holders of a majority of the shares of Senior Preferred Stock (voting as a single class) then outstanding, unless a higher
percentage is required by the DGCL, in which case the written consent of the Holders of not less than such higher percentage shall
be required.
(c)
Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of
this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it
shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount
deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall
automatically be lowered to equal the maximum rate of interest permitted under applicable law.
(d)
Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day,
such payment shall be made on the next succeeding Business Day.
(e)
Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions hereof.
(f)
Status of Converted Senior Preferred Stock. If any shares of Senior Preferred Stock shall be converted or redeemed by the
Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated
as Series A Preferred Stock or Series A-1 Preferred Stock, as applicable.
********************
IN
WITNESS WHEREOF, Interpace Diagnostics Group, Inc., has caused this Certificate of Designation of Preferences, Rights and
Limitations of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock to be executed by its duly authorized
officer this 15th day of July, 2019.
|
INTERPACE
DIAGNOSTICS GROUP, INC. |
|
|
|
|
By: |
/s/
Jack E. Stover |
|
Name: |
Jack
E. Stover |
|
Title: |
President
& Chief Executive Officer |
[SIGNATURE
PAGE TO CERTIFICATE OF DESIGNATION]
CERTIFICATE
OF AMENDMENT
OF
CERTIFICATE
OF INCORPORATION
OF
INTERPACE
DIAGNOSTICS GROUP, INC.
Interpace
Diagnostics Group,
Inc.
(the “Corporation’’),
a corporation
organized and existing under
and by
virtue of the General Corporation
Law of
the State of Delaware (“DGCL”),
does hereby
certify:
FIRST:
That the board of directors
of the Corporation duly adopted resolutions
declaring
advisable the amendment of the
Certificate of Incorporation
of the Corporation.
The resolutions
setting forth
the proposed amendment are as
follows:
RESOLVED,
that Article
FIRST of the
Corporation’s
Certificate of Incorporation be
amended to read
in its entirety as
follows:
FIRST:
The name of
the Corporation
is Interpace
Biosciences, Inc. (hereinafter
called the “Corporation”).
SECOND:
That the
foregoing amendment
was duly adopted in accordance
with the provisions of §
242 of
the DGCL.
IN
WITNESS WHEREOF,
Interpace
Diagnostics Group, Inc.
has caused
this certificate to be signed
by a duly
authorized officer, this 12th
day of November,
2019.
|
|
/s/
Jack E. Stover |
|
Name: |
Jack
E. Stover |
|
Title: |
President
& Chief Executive Officer |
CERTIFICATE
OF AMENDMENT
TO THE
CERTIFICATE OF INCORPORATION
OF
INTERPACE BIOSCIENCES, INC.
Interpace
Biosciences, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law
of the State of Delaware, DOES HEREBY CERTIFY THAT:
FIRST:
The Board of Directors of the Corporation (the “Board of Directors”) has duly adopted resolutions proposing
and declaring advisable the following amendment to the Certificate of Incorporation of the Corporation (the “Certificate
of Incorporation”), directing that said amendment be submitted to the stockholders of the Corporation for consideration
thereof, and authorizing the Corporation to execute and file with the Secretary of State of the State of Delaware this Certificate
of Amendment of Certificate of Incorporation (this “Certificate of Amendment”).
SECOND:
At the Effective Time (as defined below), of this Certificate of Amendment pursuant to Section 242 of the General Corporation
Law of the State of Delaware, each ten (10) shares of the Corporation’s common stock, par value $0.01 per share, issued
and outstanding immediately prior to the Effective Time (the “Old Common Stock”) shall automatically without
further action on the part of the Corporation or any holder of Old Common Stock, be reclassified, combined, converted and changed
into one (1) fully paid and nonassessable share of common stock, par value $0.01 per share (the “New Common Stock”),
subject to the treatment of fractional share interests as described below (the “Reverse Stock Split”). The
conversion of the Old Common Stock into New Common Stock will be deemed to occur at the Effective Time. From and after the Effective
Time, certificates representing the Old Common Stock shall represent the number of shares of New Common Stock into which such
Old Common Stock shall have been converted pursuant to this Certificate of Amendment. No fractional shares shall be issued in
connection with the Reverse Stock Split. A holder of Common Stock who would otherwise be entitled to receive a fractional share
as a result of the Reverse Stock Split will receive one whole share of Common Stock in lieu of such fractional share.
THIRD:
The foregoing amendment shall be effective at 12.01 a.m. EST on Wednesday, January 15, 2020 (the “Effective Time”).
FOURTH:
That pursuant to resolution of the Board of Directors, the proposed amendment was submitted to the stockholders of the Corporation
for consideration at the special meeting of stockholders held on December 13, 2019 and was duly adopted by the stockholders of
the Corporation in accordance with the applicable provisions of Section 242 of the General Corporation Law of Delaware.
[Signature
page follows.]
IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be duly adopted and executed in its corporate
name and on its behalf by its duly authorized officer as of the 14th day of January, 2020.
|
INTERPACE
BIOSCIENCES, INC. |
|
|
|
|
By: |
/s/
Jack E. Stover _ |
|
Name: |
Jack
E. Stover |
|
Title: |
President
and Chief Executive Officer |
[Signature
Page to Certificate of Amendment]
INTERPACE
BIOSCIENCES, INC.
CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS
OF
SERIES
B CONVERTIBLE PREFERRED STOCK
PURSUANT
TO SECTION 151 OF THE
DELAWARE GENERAL CORPORATION LAW
INTERPACE
BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions
of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance
with Section 151 of the DGCL, the following resolution was duly adopted by the Board of Directors of the Corporation on January
14, 2020:
RESOLVED,
pursuant to authority expressly set forth in the Certificate of Incorporation of the Corporation (the “Certificate
of Incorporation”), the issuance of a series of Preferred Stock designated as the Series B Convertible Preferred
Stock, par value $0.01 per share, of the Corporation is hereby authorized and the designation, number of shares, powers, preferences,
rights, qualifications, limitations and restrictions thereof (in addition to any provisions set forth in the Certificate of Incorporation
that are applicable to the Preferred Stock of all classes and series) are hereby fixed, and this Certificate of Designation of
Preferences, Rights and Limitations of Series B Convertible Preferred Stock is hereby approved as follows:
SERIES
B CONVERTIBLE PREFERRED STOCK
Section
1. Definitions. For the purposes hereof, the following terms shall have the following meanings:
“1315
Capital” means 1315 Capital II, L.P., a Delaware limited partnership, including its successors and assigns.
“Ampersand”
means Ampersand 2018 Limited Partnership, a Delaware limited partnership, including its successors and assigns.
“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls,
is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the
Securities Act. With respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by
the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser.
“Business
Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States
or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.
“Commission”
means the U.S. Securities and Exchange Commission.
“Common
Stock” means the Corporation’s common stock, par value $0.01 per share.
“Conversion
Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Preferred
Stock in accordance with the terms hereof.
“Convertible
Securities” shall mean any evidences of indebtedness, shares or other securities directly or indirectly convertible
into or exchangeable for Common Stock, but excluding Options.
“Deemed
Liquidation” shall mean (a) a merger or consolidation in which (i) the Corporation is a constituent party or (ii)
a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such
merger or consolidation, except any such merger or consolidation involving the Corporation or a subsidiary in which the shares
of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are
converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at
least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation; or (2) if the surviving
or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation,
the parent corporation of such surviving or resulting corporation; or (b) the sale, lease, transfer, exclusive license or other
disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation
of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether
by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the
Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease,
transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation.
“DGCL”
shall mean the Delaware General Corporation Law.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Holder”
means any holder of Series B Preferred Stock.
“Issuance
Date” means January 15, 2020.
“Option”
shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.
“Person”
means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Preferred
Stock” means the Corporation’s preferred stock, par value $0.01 per share.
“Series
B Conversion Price” means an amount initially equal to six dollars ($6.00) (subject to appropriate adjustment in
the event of any stock dividend, stock split, combination or other similar recapitalization affecting such shares).
“Series
B Conversion Ratio” means, for each share of Series B Preferred Stock, the ratio obtained by dividing the Series
B Liquidation Amount of such share by the Series B Conversion Price.
“Series
B Liquidation Amount” has the meaning set forth in Section 5(a).
“Series
B Liquidation Value” means an amount equal to the Series B Liquidation Amount divided by the number of shares of
Series B Preferred Stock outstanding.
“Series
B Mandatory Conversion Price” means an amount equal to twelve dollars ($12.00).
“Stated
Value” means $1,000 per share.
“Trading
Day” means a day on which the Common Stock is traded for any period on a principal securities exchange or if the
Common Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities
market on which the Common Stock is then being traded.
Section
2. Designation, Amount and Par Value; Assignment.
(a)
The Preferred Stock designated by this Certificate of Designation shall be designated as the Corporation’s Series B Convertible
Preferred Stock (the “Series B Preferred Stock”) and the number of shares so designated shall be 47,000.
(b)
The Corporation shall register shares of the Series B Preferred Stock, upon records to be maintained by the Corporation for that
purpose (the “Series B Preferred Stock Register”), in the name of the Holders thereof from time to time.
The Corporation may deem and treat the registered Holder of shares of Series B Preferred Stock as the absolute owner thereof for
the purpose of any conversion thereof and for all other purposes. Shares of Series B Preferred Stock may be issued solely in book-entry
form or, if requested by any Holder, such Holder’s shares may be issued in certificated form. The Corporation shall register
the transfer of any shares of Series B Preferred Stock in the Series B Preferred Stock Register, upon surrender of the certificates
(if applicable) evidencing such shares to be transferred, duly endorsed by the Holder thereof, to the Corporation at its address
specified herein. Upon any such registration or transfer, a new certificate (or book-entry notation, if applicable) evidencing
the shares of Series B Preferred Stock so transferred shall be issued to the transferee and a new certificate (or book-entry notation,
if applicable) evidencing the remaining portion of the shares not so transferred, if any, shall be issued to the transferring
Holder, in each case, within two (2) Business Days. The provisions of this Certificate of Designation are intended to be for the
benefit of all Holders from time to time and shall be enforceable by any such Holder.
Section
3. Dividends. Dividends may be declared and paid on the Series B Preferred Stock from funds lawfully available therefor
as and when determined by the Corporation’s Board of Directors. The Corporation shall not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common
Stock payable in shares of Common Stock) unless the Holders of the Series B Preferred Stock then outstanding shall first receive,
or simultaneously receive, a dividend on each outstanding share of Series B Preferred Stock in an amount at least equal to (A)
in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share
of Series B Preferred Stock as would equal the product of (1) the dividend payable on each share of such class or series determined,
if applicable, as if all shares of such class or series had been converted into Common Stock and (2) the number of shares of Common
Stock issuable upon conversion of a share of Series B Preferred Stock pursuant to Section 6, in each case calculated on the record
date for determination of holders entitled to receive such dividend or (B) in the case of a dividend on any class or series that
is not convertible into Common Stock, at a rate per share of Series B Preferred Stock determined by (1) dividing the amount of
the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series
of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization affecting such shares) and (2) multiplying such fraction by an amount equal to the Stated Value; provided that,
if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital
stock of the Corporation, the dividend payable to the Holders of Series B Preferred Stock pursuant to this Section 3 shall be
calculated based upon the dividend on the class or series of capital stock that would result in the highest Series B Preferred
Stock dividend.
Section
4. Voting Rights.
(a)
Series B Preferred Stock Voting Rights. On any matter presented to the stockholders of the Corporation for their action
or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting),
each Holder of outstanding shares of Series B Preferred Stock shall be entitled to cast the number of votes equal to the number
of whole shares of Common Stock into which the shares of Series B Preferred Stock held by such Holder are convertible as of the
record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions
of this Certificate of Designation, Holders of Series B Preferred Stock shall vote together with the holders of Common Stock as
a single class and on an as-converted to Common Stock basis.
(b)
Directors.
(i)
For so long as Ampersand holds at least sixty percent (60%) of the Series B Preferred Stock held by Ampersand as of the Issuance
Date, Ampersand shall be entitled to elect two (2) directors of the Corporation, provided that one (1) director elected by Ampersand
must qualify as an “independent director” under Rule 5605(a)(2) of the of the listing rules of the Nasdaq Stock Market
(or any successor rule) or under any similar rule promulgated by such other exchange on which the Corporation’s securities
are then listed or designated. For so long as Ampersand holds less than sixty percent (60%) of the Series B Preferred Stock held
by Ampersand as of the Issuance Date but at least forty percent (40%) of the Series B Preferred Stock held by Ampersand as of
the Issuance Date, Ampersand shall be entitled to elect one (1) director of the Corporation.
(ii)
For so long as 1315 Capital holds at least sixty percent (60%) of the Series B Preferred Stock held by 1315 Capital as of the
Issuance Date, 1315 Capital shall be entitled to elect two (2) directors of the Corporation, provided that one (1) director elected
by 1315 Capital must qualify as an “independent director” under Rule 5605(a)(2) of the of the listing rules of the
Nasdaq Stock Market (or any successor rule) or under any similar rule promulgated by such other exchange on which the Corporation’s
securities are then listed or designated. For so long as 1315 Capital holds less than sixty percent (60%) of the Series B Preferred
Stock held by 1315 Capital as of the Issuance Date but at least forty percent (40%) of the Series B Preferred Stock held by 1315
Capital as of the Issuance Date, 1315 Capital shall be entitled to elect one (1) director of the Corporation.
(iii)
The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Series B Preferred
Stock), exclusively and voting together as a single class, shall, subject to the rights of any additional series of Preferred
Stock that may be established from time to time, be entitled to elect the balance of the total number of directors of the Corporation.
At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of
the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing
such director.
(iv)
Any director elected pursuant to this Section 4(b) may be removed without cause by, and only by, the affirmative vote of the holders
of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special
meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders. A vacancy in any directorship
filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders
of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this
Section 4(b).
(c)
Protective Provisions. Notwithstanding anything in this Certificate of Designation to the contrary, for so long as any
shares of the Series B Preferred Stock remain outstanding, the following actions may only be taken by the Corporation or any of
its direct or indirect subsidiaries with the written consent of Holders representing at least seventy-five percent (75%) of the
outstanding shares of Series B Preferred Stock (voting as a single class):
(i)
amend, waive, alter or repeal the preferences, rights, privileges or powers of the Holders of the Series B Preferred Stock;
(ii)
amend, alter or repeal any provision of this Certificate of Designation in a manner that is adverse to the Holders of Series B
Preferred Stock;
(iii)
authorize, create or issue any equity securities senior to or pari passu with the Series B Preferred Stock; or
(iv)
increase or decrease the number of directors constituting the Board of Directors of the Corporation.
(d)
Additional Protective Provisions. Notwithstanding anything in this Certificate of Designation to the contrary, for so long
as at least thirty percent (30%) of the Series B Preferred Stock outstanding as of the Issuance Date remains outstanding (subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting
such shares), the following actions may only be taken by the Corporation or any of its direct or indirect subsidiaries with the
written consent with the consent of Holders representing at least seventy-five percent (75%) of the outstanding shares of Series
B Preferred Stock (voting as a single class):
(i)
(1) authorize, create or issue any debt securities for borrowed money or funded debt pursuant to which the Corporation or any
of its direct or indirect subsidiaries issues shares, warrants or any other convertible security in the same transaction or a
series of related transactions; or (2) authorize, create or issue any debt securities for borrowed money or funded debt pursuant
to which the Corporation or any of its direct or indirect subsidiaries does not issue shares, warrants or any other convertible
security in the same transaction or a series of related transactions exceeding $4.5 million initially (the “Debt Threshold”),
excluding, however: (i) any capitalized and operating leases entered into by the Corporation or its direct or indirect subsidiaries
in the ordinary course of business consistent with past practice and (ii) any debt incurred by the Corporation pursuant to the
terms of the Corporation’s existing term loan and credit facility with Silicon Valley Bank; provided, that if the aggregate
consolidated revenue recognized by the Corporation and its direct or indirect subsidiaries (the “Combined Revenue”)
as reported by the Corporation on Form 10-K as filed with the Commission for any fiscal year ending after the Issuance Date exceeds
$45 million dollars, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%);
multiplied by (y) the Combined Revenue as reported by the Corporation on Form 10-K as filed with the Commission for the previous
fiscal year;
(ii)
merge with or acquire all or substantially all of the assets of one or more other companies or entities with a value in excess
of $20 million (the “Acquisition Threshold”); provided, that the Acquisition Threshold shall increase
on a straight line basis to an amount up to $40 million, but in no event greater than $40 million, to the extent Combined Revenue
for the then-most recently completed quarterly period as reported by the Corporation on Form 10-K as filed with the Commission
or Form 10-Q as filed with the Commission, as applicable, falls between the Combined Revenue for the Corporation’s fiscal
quarter ended on September 30, 2019, and 100% greater than the Combined Revenue for the Corporation’s fiscal quarter ended
on September 30, 2019;
(iii)
materially change the nature of the business of the Corporation or any of its direct or indirect subsidiaries as it is proposed
to be conducted as of the Issuance Date.;
(iv)
consummate any Liquidation (as defined below);
(v)
transfer, by sale, exclusive license or otherwise, material intellectual property rights of the Corporation or any of its direct
or indirect subsidiaries, other than licenses, transfers or sales of products accomplished in the ordinary course of business
consistent with past practice;
(vi)
declare or pay any cash dividend or make any cash distribution on any equity interests of the Corporation other than the Series
B Preferred Stock;
(vii)
repurchase or redeem any shares of capital stock of the Corporation, except for: (1) the redemption of the Series B Preferred
Stock pursuant to Section 5(d); or (2) repurchases of Common Stock under agreements previously approved by the Board of Directors
of the Corporation with employees, consultants, advisors or others who performed services for the Corporation or any direct or
indirect subsidiary in connection with the cessation of such employment or service;
(viii)
(1) incur any additional individual debt, indebtedness for borrowed money or other additional liabilities pursuant to which the
Corporation or any of its direct or indirect subsidiaries issues shares, warrants or any other convertible security in the same
transaction or a series of related transactions; or (2) incur any individual debt, indebtedness for borrowed money or other liabilities
pursuant to which the Corporation or any of its direct or indirect subsidiaries does not issue shares, warrants or any other convertible
security in the same transaction or a series of related transactions in excess of the Debt Threshold (in each case, excluding:
(x) any capitalized and operating leases entered into by the Corporation or its direct or indirect subsidiaries in the ordinary
course of business consistent with past practice; (y) any debt incurred by the Corporation pursuant to the terms of the Corporation’s
existing term loan and credit facility with Silicon Valley Bank; and (z) any purchase money financing in connection with the acquisition
of equipment or otherwise);
(ix)
change any accounting methods or practices of the Corporation or any of its direct or indirect subsidiaries, except for those
changes required by GAAP or applicable regulatory agencies or authorities, including but not limited to the Securities and Exchange
Commission and the Financial Accounting Standards Board, in each case, as consented to by the Corporation’s independent
auditors; or
(x)
conduct a public offering of Common Stock registered with the Securities and Exchange Commission, including any at-the-market
offering of the Corporation’s Common Stock.
Section
5. Liquidation.
(a)
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation (a
“Liquidation”), the Holders of shares of Series B Preferred Stock then outstanding shall be entitled
to be paid out of the assets of the Corporation available for distribution to its stockholders (on a pari passu basis with the
holders of any class or series of Preferred Stock ranking on liquidation on a parity with the Series B Preferred Stock), and before
any payment shall be made to the holders of Common Stock or any other class or series of Preferred Stock ranking on liquidation
junior to the Series B Preferred Stock by reason of their ownership thereof, an amount per share of Series B Preferred Stock equal
to the greater of (i) the Stated Value of such share of Series B Preferred Stock, plus any dividends declared but unpaid thereon,
or (ii) such amount per share as would have been payable had each such share been converted into Common Stock pursuant to Section
6 immediately prior to such Liquidation, (the amount payable in respect of shares of Series B Preferred Stock pursuant to this
sentence is hereinafter referred to as the “Series B Liquidation Amount”). If upon any such Liquidation,
the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Holders of shares
of Series B Preferred Stock and any series of Preferred Stock ranking on liquidation on a parity with the Series B Preferred Stock
the full amount to which they shall be entitled under this Section 5(a), the Holders of shares of Series B Preferred Stock and
any series of Preferred Stock ranking on liquidation on a parity with the Series B Preferred Stock shall share ratably in any
distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable
in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid
in full.
(b)
In the event of any Liquidation, after the payment of all preferential amounts required to be paid to the Holders of shares of
Series B Preferred Stock and any other series of Preferred Stock ranking on liquidation senior to the Common Stock, the remaining
assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of shares of Common
Stock, pro rata based on the number of shares held by each such holder.
(c)
The Corporation shall not have the power to effect a Deemed Liquidation unless the definitive agreement regarding such transaction
provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital
stock of the Corporation in accordance with Section 5 of this Certificate of Designation.
(d)
If following a Deemed Liquidation the Corporation does not effect a dissolution of the Corporation under the General Corporation
Law within sixty (60) days after such Deemed Liquidation, then (i) the Corporation shall send a written notice to each Holder
of Series B Preferred Stock no later than the sixtieth (60th) day after the Deemed Liquidation advising such Holders of their
right (and the requirements to be met to secure such right) pursuant to the terms of the following clause (ii) to require the
redemption of such shares of Series B Preferred Stock, and (ii) if the Holders of at least seventy-five percent (75%) of the then
outstanding shares of Series B Preferred Stock so request in a written instrument delivered to the Corporation not later than
sixty (60) days after receipt of such notice, the Corporation shall use the consideration received by the Corporation for such
Deemed Liquidation (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good
faith by the Board of Directors of the Corporation) (the “Net Proceeds”), to the extent legally available
therefor, on the one hundred fiftieth (150th) day after such Deemed Liquidation, to redeem all outstanding shares of Series B
Preferred Stock at a price per share equal to the Series B Liquidation Value. Notwithstanding the foregoing, in the event of a
redemption pursuant to the preceding sentence, if the Net Proceeds are not sufficient to redeem all outstanding shares of Series
B Preferred Stock and of any other series of Preferred Stock ranking on redemption on parity with the Series B Preferred Stock
that is required to then be redeemed, or if the Corporation does not have sufficient lawfully available funds to effect such redemption,
the Corporation shall first redeem a pro rata portion of each Holder’s shares of Series B Preferred Stock and any such other
series of Preferred Stock ranking on redemption on a parity with the Series B Preferred Stock to the fullest extent of such Net
Proceeds or such lawfully available funds, as the case may be, based on the respective amounts which would otherwise be payable
in respect of the shares to be redeemed if the legally available funds were sufficient to redeem all such shares. If upon any
such redemption, the assets of the Corporation lawfully available to effect such redemption shall be insufficient to pay the Holders
of shares of Series B Preferred Stock and any series of Preferred Stock ranking on redemption on a parity with the Series B Preferred
Stock, the full amount to which they shall be entitled under this Section 5(d), the Holders of shares of Series B Preferred Stock
and any series of Preferred Stock ranking on redemption on a parity with the Series B Preferred Stock shall share ratably in any
distribution of the assets lawfully available for such redemption in proportion to the respective amounts which would otherwise
be payable in respect of the shares held by them upon such redemption if all amounts payable on or with respect to such shares
were paid in full, and shall redeem the remaining shares to have been redeemed as soon as practicable after the Corporation has
funds legally available therefor. Prior to the distribution or redemption provided for in this Section 5(d), the Corporation shall
not expend or dissipate the consideration received for such Deemed Liquidation, except to discharge expenses incurred in connection
with such Deemed Liquidation or in the ordinary course of business consistent with past practice.
(e)
The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any Liquidation Event shall be the
cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring
person, firm or other entity; provided, that the value of any such non-cash property, rights or securities shall be determined
in good faith by the Board of Directors of the Corporation.
Section
6. Conversion of Series B Preferred Stock into Common Stock.
(a)
Conversion of Series B Preferred Stock into Common Stock at Option of Holder.
Subject
to Section 6(c) below, each share of Series B Preferred Stock shall be convertible, at any time and from time to time from and
after the Issuance Date, at the option of the Holder thereof, into a number of shares of Common Stock equal to the product of
the Series B Conversion Ratio and the number of shares of Series B Preferred Stock to be converted. Holders shall effect conversions
of Series B Preferred Stock into Common Stock by providing the Corporation with the form of conversion notice attached hereto
as Annex A (a “Notice of Conversion”), duly completed and executed. Provided the Corporation’s
transfer agent is participating in the Depository Trust Corporation (“DTC”) Fast Automated Securities
Transfer program, the Notice of Conversion may specify, at the Holder’s election, whether the applicable Conversion Shares
shall be credited to the DTC participant account nominated by the Holder through DTC’s Deposit Withdrawal Agent Commission
system (a “DWAC Delivery”). The “Optional Conversion Date”, or the date on
which a conversion shall be deemed effective, shall be defined as the Trading Day after the Trading Date that the Notice of Conversion,
completed and executed, is sent by facsimile or other electronic transmission to, and received during regular business hours by,
the Corporation; provided that the original certificate(s) (if any) representing such shares of Series B Preferred Stock being
converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days
thereafter. In all other cases, the Optional Conversion Date shall be defined as the Trading Day after the Trading Date on which
the original shares of Series B Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are
received by the Corporation.
(b)
Mandatory Conversion of Series B Preferred Stock into Common Stock. If the Corporation consummates the sale of shares of
Common Stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under
the Securities Act of 1933, as amended, pursuant to which (A) the price per share of the Common Stock in such offering is at least
the Series B Mandatory Conversion Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination
or other similar recapitalization affecting such shares) and (B) such offering results in at least $25 million in proceeds, net
of the underwriting discount and commissions, to the Corporation and the Common Stock continues to be listed for trading on the
Nasdaq Capital Market or another Exchange such as NYSE (such offering, an “Underwritten Offering”, and
the date of the consummation of such Underwritten Offering is referred to herein as the “Mandatory Conversion Date”
and together with each Optional Conversion Date, a “Conversion Date”), (i) all outstanding shares of
Series B Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective Series B Conversion
Ratio and (ii) such shares may not be reissued by the Corporation. The provisions of Section 6(c) shall apply, with such necessary
changes in the details thereof as are necessitated by the context, to the conversion of shares of Series B Preferred Stock into
Common Stock pursuant to this Section 6(b). Notwithstanding the foregoing, an Underwritten Offering shall not include, and shares
of Series B Preferred Stock will not automatically convert to shares of Common Stock upon the consummation of, any Underwritten
Offering that includes the issuance of warrants to purchase capital stock of the Corporation or any other Convertible Security.
(c)
Mechanics of Conversion of Series B Preferred Stock into Common Stock.
(i)
Delivery of Certificate or Electronic Issuance Upon Conversion. Not later than three (3) Trading Days after the applicable
Conversion Date (the “Share Delivery Date”), the Corporation shall electronically transfer the number
of Conversion Shares set forth in a Notice of Conversion being acquired upon the conversion of shares of Series B Preferred Stock
by crediting the DTC participant account nominated by the Holder through DTC’s DWAC system. If in the case such shares are
not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall
be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt
of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event
the Corporation shall promptly return to such Holder any original Series B Preferred Stock certificate delivered to the Corporation
and such Holder shall promptly direct the return of any shares of Common Stock delivered to the Holder through the DWAC system,
representing the shares of Series B Preferred Stock unsuccessfully tendered for conversion to the Corporation.
(ii)
Obligation Absolute. Subject to Holder’s right to rescind a Notice of Conversion pursuant to Section 6(c)(i) above,
the Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series B Preferred Stock in accordance
with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same,
any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce
the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or
any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other
Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder
in connection with the issuance of such Conversion Shares. Nothing herein shall limit a Holder’s right to pursue actual
damages for the Corporation’s failure to deliver Conversion Shares within the period specified herein and such Holder shall
have the right to pursue all remedies available to it hereunder, at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief; provided that Holder shall not receive duplicate damages for the Corporation’s
failure to deliver Conversion Shares within the period specified herein. The exercise of any such rights shall not prohibit a
Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.
(iii)
Compensation for Buy-In on Failure to Timely Deliver Shares Upon Conversion. If the Corporation fails to effect a DWAC
Delivery that represents shares of Common Stock by the Share Delivery Date pursuant to Section 6(c)(i) (other than a failure caused
by incorrect or incomplete information provided by Holder to the Corporation), and if after such Share Delivery Date such Holder
is required to or otherwise purchases (in an open market transaction or otherwise), shares of Common Stock to deliver in satisfaction
of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such
Share Delivery Date (a “Buy-In”), then the Corporation shall (A) pay in cash to such Holder (in addition
to any other remedies available to or elected by such Holder) the amount by which (x) such Holder’s total purchase price
(including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate
number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual
sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions)
and (B) at the option of such Holder, either reissue (if surrendered) the shares of Series B Preferred Stock equal to the number
of shares of Series B Preferred Stock submitted for conversion or deliver to such Holder the number of shares of Common Stock
that would have been issued if the Corporation had timely complied with its delivery requirements under Section 6(c)(i). For example,
if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
conversion of shares of Series B Preferred Stock with respect to which the actual sale price (including any brokerage commissions)
giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation
shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading
Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable
confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder’s right to
pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Corporation’s failure to timely effect a DWAC Delivery representing shares
of Common Stock upon conversion of the shares of Series B Preferred Stock as required pursuant to the terms hereof; provided,
however, that the Holder shall not be entitled to both (i) require the reissuance of the shares of Series B Preferred Stock submitted
for conversion for which such conversion was not timely honored and (ii) receive the number of shares of Common Stock that would
have been issued if the Corporation had timely complied with its delivery requirements under Section 6(c)(i).
(d)
Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will, at all times reserve and keep available
out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Preferred
Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series
B Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account
the adjustments of Section 7) upon the conversion of all outstanding shares of Series B Preferred Stock. The Corporation covenants
that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, non-assessable
and free and clear of all liens and other encumbrances.
(e)
Fractional Shares. No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the
conversion of the Series B Preferred Stock. As to any fraction of a share of Common Stock which a Holder would otherwise be entitled
to receive upon such conversion, the Corporation shall pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the Series B Conversion Price.
(f)
Transfer Taxes. The issuance of book entry notations for shares of the Common Stock upon conversion of the Series B Preferred
Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of
the issue of such book entry notation, provided that the Corporation shall not be required to pay any tax that may be payable
in respect of any transfer involved in the issuance of such book entry notation upon conversion in a name other than that of the
registered Holder(s) of such shares of Series B Preferred Stock, and the Corporation shall not be required to issue such book
entry notation unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount
of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.
(g)
Status as Stockholder. Upon each Conversion Date and Mandatory Conversion Date: (i) the shares of Series B Preferred Stock
being converted shall be deemed converted into shares of Common Stock; and (ii) the Holder’s rights as a holder of such
converted shares of Series B Preferred Stock shall cease and terminate, excepting only the right to receive book entry notations
for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder
because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder
shall retain all of its rights and remedies for the Corporation’s failure to convert Series B Preferred Stock.
Section
7. Certain Adjustments.
(a)
Stock Dividends and Stock Splits. If the Corporation, at any time while any shares of Series B Preferred Stock are outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock with respect to
the then outstanding shares of Common Stock; (ii) subdivides outstanding shares of Common Stock into a larger number of shares;
or (iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares,
then the Series B Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common
Stock (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event (excluding any treasury shares of the Corporation).
Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the record date for the determination
of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date
in the case of a subdivision or combination.
(b)
Adjustments for Other Dividends and Distributions. In the event the Corporation at any time or from time to time after
the Issuance Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive,
a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock
in respect of outstanding shares of Common Stock) or in other property, then and in each such event the Holders of Series B Preferred
Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of
such securities or other property in an amount equal to the amount of such securities or other property as they would have received
if all outstanding shares of Series B Preferred Stock had been converted into Common Stock on the date of such event.
(c)
Adjustment for Merger or Reorganization, etc. Subject to the provisions of Section 5, if there shall occur any reorganization,
recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Series
B Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by
Section 7(a) or Section 7(b)), then, following any such reorganization, recapitalization, reclassification, consolidation or merger,
each share of Series B Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible
prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common
Stock of the Corporation issuable upon conversion of one share of Series B Preferred Stock immediately prior to such reorganization,
recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction;
and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors of the Corporation) shall be
made in the application of the provisions in this Certificate of Designation with respect to the rights and interests thereafter
of the Holders of the Series B Preferred Stock, to the end that the provisions set forth in this Certificate of Designation (including
provisions with respect to changes in and other adjustments of the Series B Conversion Price) shall thereafter be applicable,
as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of
the Series B Preferred Stock.
(d)
Calculations. All calculations under this Certificate of Designation shall be made to the nearest cent or the nearest 1/100th
of a share, as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation)
issued and outstanding.
(e)
Notice to the Holders.
(i)
Adjustment to Series B Conversion Price. Whenever the Series B Conversion Price is adjusted pursuant to any provision of
this Section 7, the Corporation shall promptly deliver to each Holder a notice setting forth the Series B Conversion Ratio after
such adjustment and setting forth a brief statement of the facts requiring such adjustment.
(ii)
Other Notices. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Corporation shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required
in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party,
any Liquidation, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) consent of the Holders of Series B Preferred Stock is required pursuant to Section 4(c) or Section 4(d), then, in each
case, the Corporation shall cause to be filed at each office or agency maintained for the purpose of conversion of the shares
of Series B Preferred Stock, and shall cause to be delivered to each Holder at its last address as it shall appear upon the stock
books of the Corporation, at least ten (10) calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights
or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer, Liquidation or share exchange is expected to become effective or close, and the date as
of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share
exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the
validity of the corporate action required to be specified in such notice.
Section
8. Miscellaneous.
(a)
Lost or Mutilated Stock Certificates. If a Holder’s certificate representing shares of Series B Preferred Stock shall
be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, if requested by the Holder, in exchange and
substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed
certificate, a new certificate for the shares of Series B Preferred Stock so mutilated, lost, stolen or destroyed, but only upon
receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership thereof, reasonably satisfactory
to the Corporation and, in each case, customary and reasonable indemnity, if requested, without the requirement to post a bond.
Applicants for a new certificate under such circumstances shall also comply with such other reasonable regulations and procedures
and pay such other reasonable third-party costs as the Corporation may prescribe, without the requirement to post a bond.
(b)
Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall
not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of
this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict
adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive
that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this
Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this
Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series B Preferred
Stock granted hereunder may be waived as to all shares of Series B Preferred Stock (and the Holders thereof) upon the written
consent of the Holders of at least seventy-five percent (75%) of the shares of Series B Preferred Stock (voting as a single class)
then outstanding, unless a higher percentage is required by the DGCL, in which case the written consent of the Holders of not
less than such higher percentage shall be required.
(c)
Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of
this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it
shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any interest or other amount
deemed interest due hereunder violates the applicable law governing usury, the applicable rate of interest due hereunder shall
automatically be lowered to equal the maximum rate of interest permitted under applicable law.
(d)
Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day,
such payment shall be made on the next succeeding Business Day.
(e)
Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions hereof.
(f)
Status of Converted Series B Preferred Stock. If any shares of Series B Preferred Stock shall be converted or redeemed
by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer
be designated as Series B Preferred Stock.
********************
IN
WITNESS WHEREOF, Interpace Biosciences, Inc., has caused this Certificate of Designation of Preferences, Rights and Limitations
of Series B Convertible Preferred Stock to be executed by its duly authorized officer this 14th day of January, 2020.
|
INTERPACE
BIOSCIENCES, INC. |
|
|
|
|
By: |
/s/
Jack E. Stover |
|
Name: |
Jack
E. Stover |
|
Title: |
President
& Chief Executive Officer |
[Signature
Page to Certificate of Designation]
ANNEX
A
NOTICE
OF CONVERSION
(TO
BE EXECUTED BY THE REGISTERED HOLDER
IN
ORDER TO CONVERT SHARES OF SERIES B PREFERRED STOCK)
The
undersigned Holder hereby irrevocably elects to convert the number of shares of Series B Preferred Stock indicated below, represented
by stock certificate No(s). _____ (the “Preferred Stock Certificates”), into shares of common stock, par value
$0.01 per share (the “Common Stock”), of Interpace Biosciences, Inc., a Delaware corporation (the “Corporation”),
as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will
pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed
to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock
(the “Certificate of Designation”) filed by the Corporation with the Delaware Secretary of State on January
14, 2020.
Conversion
calculations:
|
Date
to Effect Conversion: |
|
|
|
|
|
Number
of shares of Series B Preferred Stock owned prior to Conversion: |
|
|
|
|
|
Number
of shares of Series B Preferred Stock to be Converted: |
|
|
|
|
|
Number
of shares of Common Stock to be Issued: |
|
|
|
|
|
Address
for delivery of physical certificates: |
|
|
|
|
|
Or |
|
|
|
|
|
for
DWAC Delivery: |
|
|
|
|
|
DWAC
Instructions: |
|
|
|
|
|
Broker
no: |
|
|
|
|
|
Account
no: |
|
|
HOLDER |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
Date: |
|
INTERPACE
BIOSCIENCES, INC.
CERTIFICATE
OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS
OF
SERIES
C CONVERTIBLE PREFERRED STOCK
PURSUANT
TO SECTION 151 OF THE
DELAWARE
GENERAL CORPORATION LAW
INTERPACE
BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section
103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance with Section
151 of the DGCL, the following resolution was duly adopted by the Board of Directors of the Corporation on October 10, 2024:
RESOLVED,
pursuant to authority expressly set forth in the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”),
the issuance of a series of Preferred Stock designated as the Series C Convertible Preferred Stock, par value $0.01 per share, of the
Corporation is hereby authorized and the designation, number of shares, powers, preferences, rights, qualifications, limitations and
restrictions thereof (in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred
Stock of all classes and series) are hereby fixed, and this Certificate of Designation of Preferences, Rights and Limitations of Series
C Convertible Preferred Stock is hereby approved as follows:
SERIES
C CONVERTIBLE PREFERRED STOCK
Section
1. Definitions. For the purposes hereof, the following terms shall have the following meanings:
“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled
by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act. With
respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by the same investment manager
as such Purchaser will be deemed to be an Affiliate of such Purchaser.
“Business
Day” means any day except Saturday, Sunday, any day which shall be a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
“Commission”
means the U.S. Securities and Exchange Commission.
“Common
Stock” means the Corporation’s common stock, par value $0.01 per share.
“Conversion
Shares” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series C Preferred Stock
in accordance with the terms hereof.
“Convertible
Securities” shall mean any evidences of indebtedness, shares or other securities directly or indirectly convertible into
or exchangeable for Common Stock, but excluding Options.
“DGCL”
shall mean the Delaware General Corporation Law.
“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Holder”
means any holder of Series C Preferred Stock.
“Issuance
Date” means October 11, 2024.
“Option”
shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.
“Person”
means any individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.
“Preferred
Stock” means the Corporation’s preferred stock, par value $0.01 per share.
“Series
C Conversion Price” means an amount initially equal to $2.02 (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization affecting such shares).
“Series
C Conversion Ratio” means, for each share of Series C Preferred Stock, the ratio obtained by dividing the Stated Value
of such share by the Series C Conversion Price.
“Stated
Value” means $1,000 per share.
“Trading
Day” means a day on which the Common Stock is traded for any period on a principal securities exchange or if the Common
Stock is not traded on a principal securities exchange, on a day that the Common Stock is traded on another securities market on which
the Common Stock is then being traded.
Section
2. Designation, Amount and Par Value; Assignment.
(a)
The Preferred Stock designated by this Certificate of Designation shall be designated as the Corporation’s Series C Convertible
Preferred Stock (the “Series C Preferred Stock”) and the number of shares so designated shall be 52,000.
(b)
The Corporation shall register shares of the Series C Preferred Stock, upon records to be maintained by the Corporation for that purpose
(the “Series C Preferred Stock Register”), in the name of the Holders thereof from time to time. The Corporation
may deem and treat the registered Holder of shares of Series C Preferred Stock as the absolute owner thereof for the purpose of any conversion
thereof and for all other purposes. Shares of Series C Preferred Stock may be issued solely in book-entry form or, if requested by any
Holder, such Holder’s shares may be issued in certificated form. The Corporation shall register the transfer of any shares of Series
C Preferred Stock in the Series C Preferred Stock Register, upon surrender of the certificates (if applicable) evidencing such shares
to be transferred, duly endorsed by the Holder thereof, to the Corporation at its address specified herein. Upon any such registration
or transfer, a new certificate (or book-entry notation, if applicable) evidencing the shares of Series C Preferred Stock so transferred
shall be issued to the transferee and a new certificate (or book-entry notation, if applicable) evidencing the remaining portion of the
shares not so transferred, if any, shall be issued to the transferring Holder, in each case, within two (2) Business Days. The provisions
of this Certificate of Designation are intended to be for the benefit of all Holders from time to time and shall be enforceable by any
such Holder.
Section
3. Dividends. Dividends may be declared and paid on the Series C Preferred Stock from funds lawfully available therefor as
and when determined by the Corporation’s Board of Directors.
Section
4. Voting Rights.
(a)
Series C Preferred Stock Voting Rights. On any matter presented to the stockholders of the Corporation for their action or consideration
at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each Holder of outstanding
shares of Series C Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock
into which the shares of Series C Preferred Stock held by such Holder are convertible as of the record date for determining stockholders
entitled to vote on such matter. Except as provided by law or by the other provisions of this Certificate of Designation, Holders of
Series C Preferred Stock shall vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock
basis.
(b)
Protective Provisions. Notwithstanding anything in this Certificate of Designation to the contrary, for so long as any shares
of the Series C Preferred Stock remain outstanding, the following actions may only be taken by the Corporation or any of its direct or
indirect subsidiaries with the written consent of each Holder of the outstanding shares of Series C Preferred Stock:
(i)
amend, waive, alter or repeal the preferences, rights, privileges or powers of the Holders of the Series C Preferred Stock;
(ii)
amend, alter or repeal any provision of this Certificate of Designation in a manner that is adverse to the Holders of Series C Preferred
Stock; or
(iii)
authorize, create or issue any equity securities senior to or pari passu with the Series C Preferred Stock;
Section
5. Liquidation.
In
the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation (a “Liquidation”),
the Holders of shares of Series C Preferred Stock then outstanding on an as-converted basis shall be entitled to be paid out of the assets
of the Corporation available for distribution to its stockholders on a pari passu basis with the holders of the Common Stock of the Company.
Section
6. Conversion of Series C Preferred Stock into Common Stock.
(a)
Conversion of Series C Preferred Stock into Common Stock at Option of Holder. Subject to Section 6(b) below, each share of Series
C Preferred Stock shall be convertible, at any time and from time to time from and after the Issuance Date, at the option of the Holder
thereof, into a number of shares of Common Stock equal to the product of the Series C Conversion Ratio and the number of shares of Series
C Preferred Stock to be converted. Holders shall effect conversions of Series C Preferred Stock into Common Stock by providing the Corporation
with the form of conversion notice attached hereto as Annex A (a “Notice of Conversion”), duly
completed and executed. Provided the Corporation’s transfer agent is participating in the Depository Trust Corporation (“DTC”)
Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder’s election, whether the applicable
Conversion Shares shall be credited to the DTC participant account nominated by the Holder through DTC’s Deposit Withdrawal Agent
Commission system (a “DWAC Delivery”). The “Optional Conversion Date”, or the date
on which a conversion shall be deemed effective, shall be defined as the Trading Day after the Trading Date that the Notice of Conversion,
completed and executed, is sent by facsimile or other electronic transmission to, and received during regular business hours by, the
Corporation; provided that the original certificate(s) (if any) representing such shares of Series C Preferred Stock being converted,
duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In
all other cases, the Optional Conversion Date shall be defined as the Trading Day after the Trading Date on which the original shares
of Series C Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation.
(b)
Mandatory Conversion of Series C Preferred Stock into Common Stock. Immediately prior to the listing of the Common Stock on The
Nasdaq Stock Market, all outstanding shares of Series C Preferred Stock owned by each Holder shall automatically convert (a “Mandatory
Conversion”) into a number of shares of Common Stock equal to the product of the Series C Conversion Ratio and the number
of shares of Series C Preferred Stock owned by such Holder. The Trading Day that the Common Stock is listed for trading on The Nasdaq
Stock Market is referred to herein as the “Mandatory Conversion Date” and together with each Optional Conversion
Date, a “Conversion Date. Such shares of Series C Preferred Stock may not be reissued by the Corporation.
(c)
Mechanics of Conversion of Series C Preferred Stock into Common Stock.
(i)
Delivery of Certificate or Electronic Issuance Upon Conversion. Not later than one (1) Trading Day after the applicable Conversion
Date (the “Share Delivery Date”), the Corporation shall electronically transfer the number of Conversion Shares
being acquired upon the conversion of shares of Series C Preferred Stock by crediting the DTC participant account nominated by the Holder
through DTC’s DWAC system. If in the case of a conversion to which Section 6(a) applies such shares are not electronically delivered
to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such
Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for
Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder
any original Series C Preferred Stock certificate delivered to the Corporation and such Holder shall promptly direct the return of any
shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series C Preferred Stock unsuccessfully
tendered for conversion to the Corporation.
(ii)
Obligation Absolute. The Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series C
Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder
to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any
action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such
Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other
Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection
with the issuance of such Conversion Shares. Nothing herein shall limit a Holder’s right to pursue actual damages for the Corporation’s
failure to deliver Conversion Shares within the period specified herein and such Holder shall have the right to pursue all remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief; provided
that Holder shall not receive duplicate damages for the Corporation’s failure to deliver Conversion Shares within the period specified
herein. The exercise of any such rights shall not prohibit a Holder from seeking to enforce damages pursuant to any other Section hereof
or under applicable law.
(d)
Reservation of Shares Issuable Upon Conversion. The Corporation covenants that it will, at all times reserve and keep available
out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series C Preferred
Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series C Preferred
Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of
Section 7) upon the conversion of all outstanding shares of Series C Preferred Stock. The Corporation covenants that all shares of Common
Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid, non-assessable and free and clear
of all liens and other encumbrances.
(e)
Fractional Shares. No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the conversion
of the Series C Preferred Stock. As to any fraction of a share of Common Stock which a Holder would otherwise be entitled to receive
upon such conversion, the Corporation shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Series C Conversion Price.
(f)
Transfer Taxes. The issuance of book entry notations for shares of the Common Stock upon conversion of the Series C Preferred
Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue
of such book entry notation, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any
transfer involved in the issuance of such book entry notation upon conversion in a name other than that of the registered Holder(s) of
such shares of Series C Preferred Stock, and the Corporation shall not be required to issue such book entry notation unless or until
the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established
to the satisfaction of the Corporation that such tax has been paid.
(g)
Status as Stockholder. Upon each Conversion Date: (i) the shares of Series C Preferred Stock being converted shall be deemed converted
into shares of Common Stock; and (ii) the Holder’s rights as a holder of such converted shares of Series C Preferred Stock shall
cease and terminate, excepting only the right to receive book entry notations for such shares of Common Stock and to any remedies provided
herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of
this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation’s failure
to convert Series C Preferred Stock.
Section
7. Certain Adjustments.
(a)
Stock Dividends and Stock Splits. If the Corporation, at any time while any shares of Series C Preferred Stock are outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock with respect to the then
outstanding shares of Common Stock; (ii) subdivides outstanding shares of Common Stock into a larger number of shares; or (iii) combines
(including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Series C Conversion
Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury
shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common
Stock outstanding immediately after such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this
Section 7(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.
(b)
Adjustments for Other Dividends and Distributions. In the event the Corporation at any time or from time to time after the Issuance
Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other
distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding
shares of Common Stock) or in other property, then and in each such event the Holders of Series C Preferred Stock shall receive, simultaneously
with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount
equal to the amount of such securities or other property as they would have received if all outstanding shares of Series C Preferred
Stock had been converted into Common Stock on the date of such event.
(c)
Adjustment for Merger or Reorganization, etc. Subject to the provisions of Section 5, if there shall occur any reorganization,
recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Series C
Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by Section 7(a)
or Section 7(b)), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of
Series C Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event
into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation
issuable upon conversion of one share of Series C Preferred Stock immediately prior to such reorganization, recapitalization, reclassification,
consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as
determined in good faith by the Board of Directors of the Corporation) shall be made in the application of the provisions in this Certificate
of Designation with respect to the rights and interests thereafter of the Holders of the Series C Preferred Stock, to the end that the
provisions set forth in this Certificate of Designation (including provisions with respect to changes in and other adjustments of the
Series C Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property
thereafter deliverable upon the conversion of the Series C Preferred Stock.
(d)
Calculations. All calculations under this Certificate of Designation shall be made to the nearest cent or the nearest 1/100th
of a share, as the case may be. For purposes of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued
and outstanding.
(e)
Notice to the Holders.
(i)
Adjustment to Series C Conversion Price. Whenever the Series C Conversion Price is adjusted pursuant to any provision of this
Section 7, the Corporation shall promptly deliver to each Holder a notice setting forth the Series C Conversion Ratio after such adjustment
and setting forth a brief statement of the facts requiring such adjustment.
(ii)
Other Notices. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation shall
authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, or (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Corporation is a party, any Liquidation, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash or property, then, in each case, the Corporation shall cause to be
filed at each office or agency maintained for the purpose of conversion of the shares of Series C Preferred Stock, and shall cause to
be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least ten (10) calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are
to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer, Liquidation or share exchange
is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be
entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.
Section
8. Miscellaneous.
(a)
Lost or Mutilated Stock Certificates. If a Holder’s certificate representing shares of Series C Preferred Stock shall be
mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, if requested by the Holder, in exchange and substitution
for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a
new certificate for the shares of Series C Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence
of such loss, theft or destruction of such certificate, and of the ownership thereof, reasonably satisfactory to the Corporation and,
in each case, customary and reasonable indemnity, if requested, without the requirement to post a bond. Applicants for a new certificate
under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party
costs as the Corporation may prescribe, without the requirement to post a bond.
(b)
Waiver. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate
as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of
Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term
of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder)
of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver
by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary,
any provision contained herein and any right of the Holders of Series C Preferred Stock granted hereunder may be waived as to all shares
of Series C Preferred Stock (and the Holders thereof) upon the written consent of the Holders of at least seventy-five percent (75%)
of the shares of Series C Preferred Stock (voting as a single class) then outstanding, unless a higher percentage is required by the
DGCL, in which case the written consent of the Holders of not less than such higher percentage shall be required.
(c)
Severability. If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate
of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain
applicable to all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder
violates the applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the
maximum rate of interest permitted under applicable law.
(d)
Next Business Day. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment
shall be made on the next succeeding Business Day.
(e)
Headings. The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation
and shall not be deemed to limit or affect any of the provisions hereof.
(f)
Status of Converted Series C Preferred Stock. If any shares of Series C Preferred Stock shall be converted or redeemed by the
Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated
as Series C Preferred Stock.
********************
IN
WITNESS WHEREOF, Interpace Biosciences, Inc., has caused this Certificate of Designation of Preferences, Rights and Limitations of
Series C Convertible Preferred Stock to be executed by its duly authorized officer this 10th day of October, 2024.
|
INTERPACE
BIOSCIENCES, INC. |
|
|
|
|
|
|
|
By: |
/s/
Thomas W. Burnell |
|
Name:
|
Thomas
W. Burnell |
|
Title: |
Chairman,
President and Chief Executive Officer |
[Signature
Page to Certificate of Designation]
ANNEX
A
NOTICE
OF CONVERSION
(TO
BE EXECUTED BY THE REGISTERED HOLDER
IN
ORDER TO CONVERT SHARES OF SERIES C PREFERRED STOCK)
The
undersigned Holder hereby irrevocably elects to convert the number of shares of Series C Preferred Stock indicated below, represented
by stock certificate No(s). _____ (the “Preferred Stock Certificates”), into shares of common stock, par value
$0.01 per share (the “Common Stock”), of Interpace Biosciences, Inc., a Delaware corporation (the “Corporation”),
as of the date written below. If securities are to be issued in the name of a person other than the undersigned, the undersigned will
pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed
to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock
(the “Certificate of Designation”) filed by the Corporation with the Delaware Secretary of State on 0.
Conversion
calculations:
|
Date
to Effect Conversion: |
|
|
|
|
|
Number
of shares of Series C Preferred Stock owned prior to Conversion: |
|
|
|
|
|
Number
of shares of Series C Preferred Stock to be Converted: |
|
|
|
|
|
Number
of shares of Common Stock to be Issued: |
|
|
|
|
|
Address
for delivery of physical certificates: |
|
|
|
|
|
Or |
|
|
|
|
|
for
DWAC Delivery: |
|
|
|
|
|
DWAC
Instructions: |
|
|
|
|
|
Broker
no: |
|
|
|
|
|
Account
no: |
|
|
HOLDER |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
Date: |
|
Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Thomas W. Burnell, certify that:
|
1. |
I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 of Interpace Biosciences, Inc. (the “registrant”); |
|
|
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
|
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 8, 2024 |
/s/ Thomas W. Burnell |
|
Chief Executive Officer |
|
(Principal Executive Officer) |
Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Christopher McCarthy, certify that:
|
1. |
I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 of Interpace Biosciences, Inc. (the “registrant”); |
|
|
|
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
|
|
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 8, 2024 |
/s/ Christopher McCarthy |
|
Chief Financial Officer |
|
(Principal Financial Officer) |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Interpace
Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Thomas W. Burnell, as Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 8, 2024 |
/s/ Thomas W. Burnell |
|
Chief Executive Officer |
|
(Principal Executive Officer) |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Interpace
Biosciences, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Christopher McCarthy as Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge,
that:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: November 8, 2024 |
/s/ Christopher McCarthy |
|
Chief Financial Officer |
|
(Principal Financial Officer) |
v3.24.3
Cover - $ / shares
|
9 Months Ended |
|
Sep. 30, 2024 |
Nov. 01, 2024 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Sep. 30, 2024
|
|
Document Fiscal Period Focus |
Q3
|
|
Document Fiscal Year Focus |
2024
|
|
Current Fiscal Year End Date |
--12-31
|
|
Entity File Number |
000-24249
|
|
Entity Registrant Name |
Interpace
Biosciences, Inc.
|
|
Entity Central Index Key |
0001054102
|
|
Entity Tax Identification Number |
22-2919486
|
|
Entity Incorporation, State or Country Code |
DE
|
|
Entity Address, Address Line One |
Waterview
Plaza
|
|
Entity Address, Address Line Two |
Suite 310
|
|
Entity Address, Address Line Three |
2001 Route 46
|
|
Entity Address, City or Town |
Parsippany
|
|
Entity Address, State or Province |
NJ
|
|
Entity Address, Postal Zip Code |
07054
|
|
City Area Code |
(855)
|
|
Local Phone Number |
776-6419
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
4,404,795
|
Entity Listing, Par Value Per Share |
$ 0.01
|
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 3 such as an Office Park
+ References
+ Details
Name: |
dei_EntityAddressAddressLine3 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe par value per share of security quoted in same currency as Trading currency. Example: '0.01'.
+ References
+ Details
Name: |
dei_EntityListingParValuePerShare |
Namespace Prefix: |
dei_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands |
Sep. 30, 2024 |
Dec. 31, 2023 |
Current assets: |
|
|
Cash and cash equivalents |
$ 2,113
|
$ 3,498
|
Accounts receivable, net of allowance for credit loss of $26 and $0, respectively |
7,293
|
4,983
|
Other current assets |
1,704
|
1,841
|
Total current assets |
11,110
|
10,322
|
Property and equipment, net |
1,352
|
790
|
Operating lease right of use assets |
1,532
|
1,864
|
Other long-term assets |
45
|
45
|
Total assets |
14,039
|
13,021
|
Current liabilities: |
|
|
Accounts payable |
1,701
|
1,544
|
Accrued salary and bonus |
1,687
|
1,969
|
Other accrued expenses |
9,033
|
8,201
|
Note payable at fair value, current |
5,688
|
5,100
|
Current liabilities of discontinued operations |
660
|
660
|
Total current liabilities |
18,769
|
17,474
|
Operating lease liabilities, net of current portion |
1,189
|
1,472
|
Note payable at fair value |
|
4,243
|
Other long-term liabilities |
5,227
|
4,968
|
Total liabilities |
25,185
|
28,157
|
Commitments and contingencies (Note 8) |
|
|
Redeemable preferred stock, $.01 par value; 5,000,000 shares authorized,47,000 shares Series B issued and outstanding |
46,536
|
46,536
|
Stockholders’ deficit: |
|
|
Common stock, $.01 par value; 100,000,000 shares authorized; 4,532,991 and 4,447,489 shares issued, respectively; 4,404,795 and 4,351,445 shares outstanding, respectively |
406
|
405
|
Additional paid-in capital |
188,363
|
188,146
|
Accumulated deficit |
(244,405)
|
(248,215)
|
Treasury stock, at cost (128,196 and 96,044 shares, respectively) |
(2,046)
|
(2,008)
|
Total stockholders’ deficit |
(57,682)
|
(61,672)
|
Total liabilities and stockholders’ deficit |
(32,497)
|
(33,515)
|
Total liabilities, preferred stock and stockholders’ deficit |
$ 14,039
|
$ 13,021
|
X |
- DefinitionLiabilities And Stockholders Equity Excluding Preferred Stock.
+ References
+ Details
Name: |
IDXG_LiabilitiesAndStockholdersEquityExcludingPreferredStock |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapitalCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashAndCashEquivalentsAtCarryingValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11
+ Details
Name: |
us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherLiabilitiesNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.E.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
+ Details
Name: |
us-gaap_TemporaryEquityCarryingAmountAttributableToParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1
+ Details
Name: |
us-gaap_TreasuryStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.24.3
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
|
Sep. 30, 2024 |
Dec. 31, 2023 |
Allowance for credit loss |
$ 26,000
|
$ 0
|
Temporary equity, par value |
$ 0.01
|
$ 0.01
|
Temporary equity, shares authorized |
5,000,000
|
5,000,000
|
Common stock, par value |
$ 0.01
|
$ 0.01
|
Common stock, shares authorized |
100,000,000
|
100,000,000
|
Common stock, shares issued |
4,532,991
|
4,447,489
|
Common stock, shares outstanding |
4,404,795
|
4,351,445
|
Treasury stock, shares |
128,196
|
96,044
|
Series B Preferred Stock [Member] |
|
|
Temporary equity, shares issued |
47,000
|
47,000
|
Temporary equity, shares outstanding |
47,000
|
47,000
|
X |
- DefinitionAmount of allowance for credit loss on accounts receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquityParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquitySharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquitySharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquitySharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1
+ Details
Name: |
us-gaap_TreasuryStockCommonShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands |
3 Months Ended |
9 Months Ended |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Income Statement [Abstract] |
|
|
|
|
Revenue, net |
$ 12,295
|
$ 9,078
|
$ 34,610
|
$ 29,931
|
Cost of revenue |
4,789
|
4,124
|
13,602
|
12,163
|
Gross profit |
7,506
|
4,954
|
21,008
|
17,768
|
Operating expenses: |
|
|
|
|
Sales and marketing |
2,864
|
2,498
|
8,571
|
7,444
|
Research and development |
199
|
149
|
483
|
484
|
General and administrative |
2,538
|
2,124
|
6,918
|
7,515
|
Acquisition related amortization expense |
|
199
|
|
834
|
Total operating expenses |
5,601
|
4,970
|
15,972
|
16,277
|
Operating income (loss) from continuing operations |
1,905
|
(16)
|
5,036
|
1,491
|
Interest accretion expense |
(4)
|
(26)
|
(34)
|
(92)
|
Note payable interest |
(141)
|
(230)
|
(514)
|
(682)
|
Other expense, net |
(394)
|
(252)
|
(406)
|
(408)
|
Income (loss) from continuing operations before tax |
1,366
|
(524)
|
4,082
|
309
|
Provision for income taxes |
4
|
4
|
12
|
12
|
Income (loss) from continuing operations |
1,362
|
(528)
|
4,070
|
297
|
Loss from discontinued operations, net of tax |
(82)
|
(86)
|
(260)
|
(385)
|
Net income (loss) |
$ 1,280
|
$ (614)
|
$ 3,810
|
$ (88)
|
Basic income (loss) per share of common stock: |
|
|
|
|
From continuing operations |
$ 0.31
|
$ (0.12)
|
$ 0.93
|
$ 0.07
|
From discontinued operations |
(0.02)
|
(0.02)
|
(0.06)
|
(0.09)
|
Net income (loss) per basic share of common stock |
0.29
|
(0.14)
|
0.87
|
(0.02)
|
Diluted income (loss) per share of common stock: |
|
|
|
|
From continuing operations |
0.31
|
(0.12)
|
0.92
|
0.07
|
From discontinued operations |
(0.02)
|
(0.02)
|
(0.05)
|
(0.09)
|
Net income (loss) per diluted share of common stock |
$ 0.29
|
$ (0.14)
|
$ 0.87
|
$ (0.02)
|
Weighted average number of common shares and common share equivalents outstanding: |
|
|
|
|
Basic |
4,393
|
4,319
|
4,380
|
4,313
|
Diluted |
4,423
|
4,319
|
4,404
|
4,355
|
X |
- DefinitionAmount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1
+ Details
Name: |
us-gaap_AccretionExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_AdjustmentForAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
+ Details
Name: |
us-gaap_CostOfRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPer basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.
+ References
+ Details
Name: |
us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.
+ References
+ Details
Name: |
us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareDilutedAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsPerBasicShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate amount of interest paid or due on all long-term debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph a -Publisher SEC
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1402 -Paragraph b -Subparagraph (1) -Publisher SEC
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_InterestExpenseLongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherNonoperatingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
+ Details
Name: |
us-gaap_SellingAndMarketingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands |
Common Stock [Member] |
Treasury Stock, Common [Member] |
Additional Paid-in Capital [Member] |
Retained Earnings [Member] |
Total |
Balance at Dec. 31, 2022 |
$ 405
|
$ (1,976)
|
$ 187,516
|
$ (249,017)
|
$ (63,072)
|
Balance, shares at Dec. 31, 2022 |
4,367,830
|
71,120
|
|
|
|
Issuance of common stock |
|
|
|
|
|
Issuance of common stock, shares |
22,996
|
|
|
|
|
Treasury stock purchased |
|
$ (9)
|
|
|
(9)
|
Treasury stock purchased, shares |
|
8,292
|
|
|
|
Stock-based compensation expense |
|
|
192
|
|
192
|
Net income (loss) |
|
|
|
351
|
351
|
Balance at Mar. 31, 2023 |
$ 405
|
$ (1,985)
|
187,708
|
(248,666)
|
(62,538)
|
Balance, shares at Mar. 31, 2023 |
4,390,826
|
79,412
|
|
|
|
Balance at Dec. 31, 2022 |
$ 405
|
$ (1,976)
|
187,516
|
(249,017)
|
(63,072)
|
Balance, shares at Dec. 31, 2022 |
4,367,830
|
71,120
|
|
|
|
Net income (loss) |
|
|
|
|
(88)
|
Balance at Sep. 30, 2023 |
$ 405
|
$ (1,997)
|
188,017
|
(249,105)
|
(62,680)
|
Balance, shares at Sep. 30, 2023 |
4,407,492
|
85,720
|
|
|
|
Balance at Mar. 31, 2023 |
$ 405
|
$ (1,985)
|
187,708
|
(248,666)
|
(62,538)
|
Balance, shares at Mar. 31, 2023 |
4,390,826
|
79,412
|
|
|
|
Stock-based compensation expense |
|
|
157
|
|
157
|
Net income (loss) |
|
|
|
175
|
175
|
Balance at Jun. 30, 2023 |
$ 405
|
$ (1,985)
|
187,865
|
(248,491)
|
(62,206)
|
Balance, shares at Jun. 30, 2023 |
4,390,826
|
79,412
|
|
|
|
Issuance of common stock |
|
|
|
|
|
Issuance of common stock, shares |
16,666
|
|
|
|
|
Treasury stock purchased |
|
$ (12)
|
|
|
(12)
|
Treasury stock purchased, shares |
|
6,308
|
|
|
|
Stock-based compensation expense |
|
|
152
|
|
152
|
Net income (loss) |
|
|
|
(614)
|
(614)
|
Balance at Sep. 30, 2023 |
$ 405
|
$ (1,997)
|
188,017
|
(249,105)
|
(62,680)
|
Balance, shares at Sep. 30, 2023 |
4,407,492
|
85,720
|
|
|
|
Balance at Dec. 31, 2023 |
$ 405
|
$ (2,008)
|
188,146
|
(248,215)
|
(61,672)
|
Balance, shares at Dec. 31, 2023 |
4,447,489
|
96,044
|
|
|
|
Issuance of common stock |
$ 1
|
|
(1)
|
|
|
Issuance of common stock, shares |
39,668
|
|
|
|
|
Treasury stock purchased |
|
$ (16)
|
|
|
(16)
|
Treasury stock purchased, shares |
|
14,715
|
|
|
|
Stock-based compensation expense |
|
|
79
|
|
79
|
Net income (loss) |
|
|
|
468
|
468
|
Balance at Mar. 31, 2024 |
$ 406
|
$ (2,024)
|
188,224
|
(247,747)
|
(61,141)
|
Balance, shares at Mar. 31, 2024 |
4,487,157
|
110,759
|
|
|
|
Balance at Dec. 31, 2023 |
$ 405
|
$ (2,008)
|
188,146
|
(248,215)
|
(61,672)
|
Balance, shares at Dec. 31, 2023 |
4,447,489
|
96,044
|
|
|
|
Net income (loss) |
|
|
|
|
3,810
|
Balance at Sep. 30, 2024 |
$ 406
|
$ (2,046)
|
188,363
|
(244,405)
|
(57,682)
|
Balance, shares at Sep. 30, 2024 |
4,532,991
|
128,196
|
|
|
|
Balance at Mar. 31, 2024 |
$ 406
|
$ (2,024)
|
188,224
|
(247,747)
|
(61,141)
|
Balance, shares at Mar. 31, 2024 |
4,487,157
|
110,759
|
|
|
|
Stock-based compensation expense |
|
|
53
|
|
53
|
Net income (loss) |
|
|
|
2,062
|
2,062
|
Balance at Jun. 30, 2024 |
$ 406
|
$ (2,024)
|
188,277
|
(245,685)
|
(59,026)
|
Balance, shares at Jun. 30, 2024 |
4,487,157
|
110,759
|
|
|
|
Issuance of common stock |
|
|
|
|
|
Issuance of common stock, shares |
45,834
|
|
|
|
|
Treasury stock purchased |
|
$ (22)
|
|
|
(22)
|
Treasury stock purchased, shares |
|
17,437
|
|
|
|
Stock-based compensation expense |
|
|
86
|
|
86
|
Net income (loss) |
|
|
|
1,280
|
1,280
|
Balance at Sep. 30, 2024 |
$ 406
|
$ (2,046)
|
$ 188,363
|
$ (244,405)
|
$ (57,682)
|
Balance, shares at Sep. 30, 2024 |
4,532,991
|
128,196
|
|
|
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares that have been repurchased during the period and are being held in treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_TreasuryStockSharesAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1
+ Details
Name: |
us-gaap_TreasuryStockValueAcquiredCostMethod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands |
9 Months Ended |
Sep. 30, 2024 |
Sep. 30, 2023 |
Cash Flows From Operating Activities |
|
|
Net income (loss) |
$ 3,810
|
$ (88)
|
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
Depreciation and amortization |
205
|
954
|
Interest accretion expense |
34
|
92
|
Amortization of deferred financing fees |
|
42
|
Stock-based compensation |
218
|
501
|
Bad debt expense reversal |
(100)
|
|
Credit loss expense |
26
|
|
Change in fair value of note payable |
445
|
400
|
Amortization on operating lease right of use asset |
332
|
461
|
Other changes in operating assets and liabilities: |
|
|
Accounts receivable |
(2,336)
|
202
|
Other current assets |
237
|
176
|
Accounts payable |
137
|
228
|
Accrued salaries and bonus |
(320)
|
(157)
|
Other accrued expenses |
870
|
(118)
|
Operating lease liabilities |
(355)
|
(292)
|
Other long-term liabilities |
259
|
248
|
Net cash provided by operating activities |
3,462
|
2,649
|
Cash Flows From Investing Activity |
|
|
Working capital adjustment on sale of Interpace Pharma Solutions |
|
(117)
|
Proceeds from sale of Interpce Pharma Solutions, net |
|
500
|
Purchase of property and equipment |
(747)
|
(328)
|
Net cash (used in) provided by investing activities |
(747)
|
55
|
Cash Flows From Financing Activities |
|
|
Payments made on note payable |
(4,100)
|
|
Payments on line of credit |
|
(2,500)
|
Net cash used in financing activities |
(4,100)
|
(2,500)
|
Net (decrease) increase in cash and cash equivalents |
(1,385)
|
204
|
Cash and cash equivalents from continuing operations– beginning |
3,498
|
4,828
|
Cash and cash equivalents from discontinued operations– beginning |
|
|
Cash and cash equivalents – beginning |
3,498
|
4,828
|
Cash and cash equivalents from continuing operations– ending |
2,113
|
5,032
|
Cash and cash equivalents from discontinued operations– ending |
|
|
Cash and cash equivalents – ending |
$ 2,113
|
$ 5,032
|
X |
- DefinitionBad debt expense reversal.
+ References
+ Details
Name: |
IDXG_BadDebtExpenseReversal |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCash and cash equivalents from continuing operations.
+ References
+ Details
Name: |
IDXG_CashAndCashEquivalentsFromContinuingOperations |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionChange in fair value of note payable.
+ References
+ Details
Name: |
IDXG_ChangeInFairValueOfNotePayable |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionIncrease decrease in accrued salaries and bonus.
+ References
+ Details
Name: |
IDXG_IncreaseDecreaseInAccruedSalariesAndBonus |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionProceeds from sales of equity method investments.
+ References
+ Details
Name: |
IDXG_ProceedsFromSalesOfEquityMethodInvestments |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481639/420-10-35-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1
+ Details
Name: |
us-gaap_AccretionExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of amortization expense attributable to debt issuance costs.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3
+ Details
Name: |
us-gaap_AmortizationOfFinancingCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_DepreciationAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other expenses incurred but not yet paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherCurrentAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in noncurrent operating liabilities classified as other.
+ References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4
Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B
Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).
+ References
+ Details
Name: |
us-gaap_ProceedsFromRepaymentsOfLinesOfCredit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_ProceedsFromSaleOfEquityMethodInvestments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow for a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15
+ Details
Name: |
us-gaap_RepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.24.3
OVERVIEW
|
9 Months Ended |
Sep. 30, 2024 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
OVERVIEW |
1.
OVERVIEW
Nature
of Business
Interpace
Biosciences, Inc. (“Interpace” or the “Company”) is a company that provides molecular diagnostics, bioinformatics
and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient
diagnosis and management. The Company develops and commercializes genomic tests and related first line assays principally focused on
early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
BASIS OF PRESENTATION
|
9 Months Ended |
Sep. 30, 2024 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
BASIS OF PRESENTATION |
2.
BASIS OF PRESENTATION
The
accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”)
should be read in conjunction with the consolidated financial statements of the Company and its wholly-owned subsidiaries (Interpace
Diagnostics Lab Inc., Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC), and related notes as included in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities & Exchange Commission (“SEC”)
on April 1, 2024 and as amended on April 26, 2024.
The
Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United
States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
they do not include all of the information and footnotes required by GAAP for complete financial statements. The Interim Financial Statements
include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial
statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, InServe Support Solutions;
and TVG, Inc., its Commercial Services business unit, which was sold on December 22, 2015 and its Interpace Pharma Solutions business
(“Pharma Solutions”) which was sold on August 31, 2022. All significant intercompany balances and transactions have been
eliminated in consolidation. Operating results for the three-month period ended September 30, 2024 are not necessarily indicative of
the results that may be expected for the fiscal year ending December 31, 2024.
|
X |
- DefinitionThe entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent
+ Details
Name: |
us-gaap_BasisOfAccounting |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
LIQUIDITY
|
9 Months Ended |
Sep. 30, 2024 |
Liquidity |
|
LIQUIDITY |
3.
LIQUIDITY
In
October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica Bank (“Comerica”) (the “Comerica
Loan Agreement”). In February 2024, the Company terminated the Comerica Loan Agreement. The Company did not owe anything outstanding
on the line of credit at the time of termination and does not owe anything further to Comerica. See Note 16, Revolving Line of Credit.
Also in October 2021, the Company entered into an $8.0 million term loan with BroadOak Fund V, L.P. (“BroadOak”) (the “Term
Loan”), the proceeds of which were used to repay in full at their maturity the existing secured promissory note with Ampersand
Capital Partners (“Ampersand”) and 1315 Capital II, L.P (“1315 Capital”). In May 2022, the Company entered into
a Subordinated Convertible Promissory Note agreement with BroadOak for an additional $2.0 million (the “Convertible Note”),
which was converted into a subordinated term loan and was added to the outstanding Term Loan balance. The Term Loan has been subsequently
amended. See Note 13, Notes Payable, for more details.
Along
with many laboratories, the Company may be affected by the Proposed Local Coverage Determination (“LCD”) DL39365, which is
currently under consideration by Novitas, the Company’s medical administrator contractor. If finalized, this Proposed LCD, which
governs “Genetic Testing for Oncology,” could impact the existing Medicare coverage for one of our molecular tests, PancraGEN®.
On June 5, 2023, the Company announced that Novitas issued the final LCD of Genetic Testing for Oncology (L39365) which if finalized,
would have established non-coverage for the Company’s widely used PancraGEN® test effective July 17, 2023. On July
6, 2023, Novitas announced that it would not be implementing the final Genetic Testing for Oncology LCD (L39365) as scheduled on July
17, 2023. Novitas then issued a new virtually identical proposed LCD affecting the same companies and tests and reaching the same conclusions
as noted in the previously rescinded LCD on July 27, 2023. In response, the Company participated in a public meeting presentation and
submitted detailed written comments supporting the use of PancraGEN®. The timing and content of any final implemented
LCD is uncertain at this time; the process could potentially take a year or longer from issuance of the updated proposed LCD to reach
a conclusion. On July 29, 2024 the Company announced that CMS granted Novitas an undefined extension to the final decision for the LCD.
As a result, the Company is able to continue offering PancraGEN® and the related Point2® fluid chemistry
tests for amylase, CEA, and glucose. In the event Novitas ultimately restricts coverage for the PancraGEN® test, the Company’s
liquidity could be negatively impacted.
For
the nine months ended September 30, 2024, the Company had operating income from continuing operations of $5.0 million. As of September
30, 2024, the Company had cash and cash equivalents of $2.1 million, total current assets of $11.1 million and current liabilities of
$18.8 million. As of November 1, 2024, the Company had approximately $1.8 million of cash and cash equivalents.
The
Company intends to meet its ongoing capital needs by using its available cash, as well as through targeted margin improvement; collection
of accounts receivable; containment of costs; and the potential use of other financing options and other strategic alternatives.
The
Company continues to explore various strategic alternatives, dilutive and non-dilutive sources of funding, including equity and debt
financings, strategic alliances, business development and other sources in order to provide additional liquidity. With the delisting
of its common stock from Nasdaq in February 2021, the Company’s ability to raise additional capital on terms acceptable to it has
been adversely impacted. There can be no assurance that the Company will be successful in obtaining such funding on terms acceptable
to it.
On
October 10, 2024, Ampersand and 1315 Capital exchanged (the “Exchange”) 47,000 shares of the Company’s Series B convertible
preferred stock of the Company, par value $0.01 per share (the “Series B Preferred Stock”) for 47,000 shares of the Company’s
Series C Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”). See Note 18, Subsequent Events.
The Company believes that the 47,000 shares of Series C Preferred Stock will constitute stockholders’ equity under generally accepted
accounting principles. The Exchange is the first significant step for the Company to seek an uplisting of its common stock to Nasdaq.
Other steps may need to be taken in order to satisfy Nasdaq listing requirements, including meeting Nasdaq’s stockholder equity
and minimum bid price requirements. The Company believes that a Nasdaq listing would assist it in raising additional capital, increasing
investor interest and trading volume in its common stock, and pursuing acquisitions. No assurance can be given that a Nasdaq listing
will be achieved.
With
the improvement in operating cash flows associated with the disposition of the Pharma Solutions business, and the Company’s improved
operating performance, as of the date of this filing, the Company anticipates that current cash and cash equivalents and forecasted cash
receipts will be sufficient to meet its anticipated cash requirements through the next twelve months from the date of the filing of this
report.
|
X |
- References
+ Details
Name: |
IDXG_DisclosureLiquidityAbstract |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
IDXG_LiquidityTextBlock |
Namespace Prefix: |
IDXG_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
DISCONTINUED OPERATIONS
|
9 Months Ended |
Sep. 30, 2024 |
Discontinued Operations and Disposal Groups [Abstract] |
|
DISCONTINUED OPERATIONS |
4.
DISCONTINUED OPERATIONS
Liabilities
classified as discontinued operations as of both September 30, 2024 and December 31, 2023 consists of accrued expenses which are liabilities
related to the former Commercial Services business unit.
The
table below presents the significant components of its former Pharma Solutions business unit’s results included within loss from
discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and nine months ended September
30, 2024 and 2023.
SCHEDULE
OF COMPONENTS OF ASSETS AND LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED
| |
| | |
| | |
| | |
| |
| |
For The Three Months Ended | | |
For The Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Revenue, net | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
| - | | |
| - | | |
| - | | |
| (137 | ) |
Income tax expense | |
| 82 | | |
| 86 | | |
| 260 | | |
| 248 | |
Loss from discontinued operations, net of tax | |
$ | (82 | ) | |
$ | (86 | ) | |
$ | (260 | ) | |
$ | (385 | ) |
Cash
used from discontinued operations, operating activities, was $20,000, and provided by investing activities was $0.4 million for the nine
months ended September 30, 2023. There was no cash used from discontinued operations for the nine months ended September 30, 2024. There
was no depreciation and amortization expense for the three or nine months ended September 30, 2024 and September 30, 2023, respectively,
in discontinued operations.
|
X |
- References
+ Details
Name: |
us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent
+ Details
Name: |
us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
|
9 Months Ended |
Sep. 30, 2024 |
Accounting Policies [Abstract] |
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
5.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Accounting
Estimates
The
preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical
experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the
circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration,
allowances for credit losses, revenue recognition, unrecognized tax benefits, and asset impairments involving intangible assets. The
Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially
differ from those estimates.
Revenue
Recognition
We
derive our revenues from the performance of proprietary assays or tests. The Company’s performance obligation is fulfilled upon
the completion, review and release of test results to the customer. We subsequently bill third-party payers or direct-bill payers for
the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net
realizable value, which is determined based on historical collection rates by each payer category for each proprietary test offered by
the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary
tests, we estimate the amount of variable consideration that should be included in the transaction price using the expected value method
based on historical experience.
We
regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates
and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly
from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become
known.
Financing
and Payment
For
non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically
thirty days and in our now discontinued pharma services, were up to sixty days. Commercial third-party-payers are required to respond
to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment
for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where
multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly
for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full.
Costs
to Obtain or Fulfill a Customer Contract
Sales
commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the
condensed consolidated statements of operations.
Accounts
Receivable
The
Company’s accounts receivable represent unconditional rights to consideration and are generated using its clinical services. The
Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with
fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference
between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed
to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months.
The allowance for credit losses balance was $26,000 and $0 at September 30, 2024 and December 31, 2023, respectively.
Leases
The
Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”)
assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation
to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset
and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides
all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information
available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease
when readily determinable.
Our
lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably
certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line
basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases.
Other
Current Assets
Other
current assets consisted of the following as of September 30, 2024 and December 31, 2023:
SCHEDULE
OF OTHER CURRENT ASSETS
| |
September 30, 2024 | | |
December 31, 2023 | |
Lab supplies | |
$ | 1,220 | | |
$ | 1,227 | |
Prepaid expenses | |
| 441 | | |
| 590 | |
Other | |
| 43 | | |
| 24 | |
Total other current assets | |
$ | 1,704 | | |
$ | 1,841 | |
Long-Lived
Assets, including Finite-Lived Intangible Assets
Finite-lived
intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized
on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related
amortization expense in the condensed consolidated statements of operations.
The
Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances
indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is
less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair
value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and,
where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining
whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.
Basic
and Diluted Net Income (Loss) per Share
A
reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted income
(loss) per share for the three- and nine-month periods ended September 30, 2024 and 2023 is as follows:
SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Basic weighted average number of common shares | |
| 4,393 | | |
| 4,319 | | |
| 4,380 | | |
| 4,313 | |
Potential dilutive effect of stock-based awards | |
| 30 | | |
| - | | |
| 24 | | |
| 42 | |
Diluted weighted average number | |
| | | |
| | | |
| | | |
| | |
of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
Diluted weighted average number of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
The
Company’s Series B Redeemable Preferred Stock, on an as converted basis into common stock of 7,833,334 shares for the three- and
nine-months ended September 30, 2024, and the following outstanding stock-based awards, were excluded from the computation of the effect
of dilutive securities on income (loss) per share for the following periods as they would have been anti-dilutive (rounded to thousands):
SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Options | |
| 288 | | |
| 469 | | |
| 288 | | |
| 394 | |
Restricted stock units (RSUs) | |
| 145 | | |
| 277 | | |
| 145 | | |
| 277 | |
Anti-dilutive
securities | |
| 433 | | |
| 746 | | |
| 433 | | |
| 671 | |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent
+ Details
Name: |
us-gaap_SignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
FAIR VALUE MEASUREMENTS
|
9 Months Ended |
Sep. 30, 2024 |
Fair Value Disclosures [Abstract] |
|
FAIR VALUE MEASUREMENTS |
6.
FAIR VALUE MEASUREMENTS
Cash
and cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short-term nature. The Company’s
financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration, warrant
liability and note payable. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including
market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants
would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation
technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation
techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used
in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy
ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:
|
Level
1: |
Valuations
for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical
assets or liabilities. |
|
|
|
|
Level
2: |
Valuations
for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services
for identical or similar assets or liabilities. |
|
|
|
|
Level
3: |
Valuations
incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities. |
In
instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy,
the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is
significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to
the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation
methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification
of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:
SCHEDULE
OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS
| |
As of September 30, 2024 | | |
Fair Value Measurements | |
| |
| | |
Fair | | |
As of September 30, 2024 | |
| |
Amount | | |
Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| |
| | |
| | |
| | |
| | |
| |
Liabilities: | |
| | | |
| | | |
| | | |
| | | |
| | |
Contingent consideration: | |
| | | |
| | | |
| | | |
| | | |
| | |
Asuragen (1) | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Note payable: | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loan | |
| 5,900 | | |
| 5,688 | | |
| - | | |
| - | | |
| 5,688 | |
| |
$ | 5,900 | | |
$ | 5,688 | | |
$ | - | | |
$ | - | | |
$ | 5,688 | |
(1) |
See
Note 9, Other Accrued Expenses |
| |
As of December 31, 2023 | | |
Fair Value Measurements | |
| |
Carrying | | |
Fair | | |
As of December 31, 2023 | |
| |
Amount | | |
Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
Liabilities: | |
| | |
| | |
| | |
| | |
| |
Contingent consideration: | |
| | | |
| | | |
| | | |
| | | |
| | |
Asuragen (1) | |
$ | 453 | | |
$ | 453 | | |
$ | - | | |
$ | - | | |
$ | 453 | |
Note payable: | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loan | |
| 10,000 | | |
| 9,343 | | |
| - | | |
| - | | |
| 9,343 | |
| |
$ | 10,453 | | |
$ | 9,796 | | |
$ | - | | |
$ | - | | |
$ | 9,796 | |
(1) |
See
Note 9, Other Accrued Expenses |
In
connection with the acquisition of certain assets from Asuragen, Inc., the Company recorded contingent consideration related to contingent
payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted
income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market
and thus represents a Level 3 measurement.
In
connection with the Term Loan, the Company records the loan at fair value. The fair value of the loan is determined by a probability-weighted
approach regarding the loan’s change in control feature. See Note 13, Notes Payable, for more details. The fair value measurement
is based on the estimated probability of a change in control and thus represents a Level 3 measurement.
A
roll forward of the carrying value of the Contingent Consideration Liability and BroadOak Loan to September 30, 2024 is as follows:
SCHEDULE
OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION
| |
| | |
| | |
| | |
| | |
Adjustment | | |
| |
| |
| | |
| | |
| | |
| | |
to Fair | | |
| |
| |
December 31, 2023 | | |
Payments | | |
Transferred to Accrued Expenses | | |
Accretion/Interest Accrued | | |
Value/
Mark to Market | | |
September 30, 2024 | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Asuragen | |
$ | 453 | | |
$ | - | | |
$ | (487 | ) | |
$ | 34 | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loans | |
| 9,343 | | |
| (4,100 | ) | |
| - | | |
| - | | |
| 445 | | |
| 5,688 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
$ | 9,796 | | |
$ | (4,100 | ) | |
$ | (487 | ) | |
$ | 34 | | |
$ | 445 | | |
$ | 5,688 | |
Certain
of the Company’s non-financial assets, such as intangible assets are measured at fair value on a nonrecurring basis when there
is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1
+ Details
Name: |
us-gaap_FairValueDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
LEASES
|
9 Months Ended |
Sep. 30, 2024 |
Leases [Abstract] |
|
LEASES |
7.
LEASES
The
table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:
SCHEDULE
OF LEASE RELATED ASSETS AND LIABILITIES
| |
Classification on the Balance Sheet | |
September 30, 2024 | | |
December 31, 2023 | |
| |
| |
| | |
| |
Assets | |
| |
| | | |
| | |
Operating lease assets | |
Operating lease right of use assets | |
| 1,532 | | |
| 1,864 | |
Total lease assets | |
| |
$ | 1,532 | | |
$ | 1,864 | |
| |
| |
| | | |
| | |
Liabilities | |
| |
| | | |
| | |
Current | |
| |
| | | |
| | |
Operating lease liabilities | |
Other accrued expenses | |
| 305 | | |
| 377 | |
Total current lease liabilities | |
| |
$ | 305 | | |
$ | 377 | |
Noncurrent | |
| |
| | | |
| | |
Operating lease liabilities | |
Operating lease liabilities, net of current portion | |
| 1,189 | | |
| 1,472 | |
Total long-term lease liabilities | |
| |
| 1,189 | | |
| 1,472 | |
Total lease liabilities | |
| |
$ | 1,494 | | |
$ | 1,849 | |
The
weighted average remaining lease term for the Company’s operating leases was 3.7 years as of September 30, 2024 and the weighted
average discount rate for those leases was 12.0%. Total operating lease expense from continuing operations under these agreements for
both the three months ended September 30, 2024 and 2023 was approximately $0.2 million and for the nine months ended September 30, 2024
and 2023 was approximately $0.5 million and $0.6 million, respectively. Total cash paid under these agreements for both the nine months
ended September 30, 2024 and 2023 was approximately $0.5 million and $0.6 million respectively. The Company’s operating lease expenses
are recorded within “Cost of revenue” and “General and administrative expenses.”
The
table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as
of September 30, 2024:
SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES
| |
Operating Leases | |
2024 - remaining three months | |
$ | 155 | |
2025 | |
| 450 | |
2026 | |
| 450 | |
2027 | |
| 550 | |
2028 | |
| 275 | |
Total minimum lease payments | |
| 1,880 | |
Less: amount of lease payments representing effects of discounting | |
| 386 | |
Present value of future minimum lease payments | |
| 1,494 | |
Less: current obligations under leases | |
| 305 | |
Long-term lease obligations | |
$ | 1,189 | |
| |
| | |
|
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent
+ Details
Name: |
us-gaap_LesseeOperatingLeasesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
COMMITMENTS AND CONTINGENCIES
|
9 Months Ended |
Sep. 30, 2024 |
Commitments and Contingencies Disclosure [Abstract] |
|
COMMITMENTS AND CONTINGENCIES |
8.
COMMITMENTS AND CONTINGENCIES
Litigation
From
time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.
When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a
loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition
to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim.
Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may
harm the Company’s business. There is no pending litigation involving the Company at this time.
Due
to the nature of the businesses in which the Company is engaged, it is subject to certain risks. Such risks include, among others, risk
of liability for personal injury or death to persons using products or services that the Company promotes or commercializes. There can
be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business
activities. There is also the risk of employment related litigation and other litigation in the ordinary course of business.
The
Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside
the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages
or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although
applicable, is not performed in accordance with its terms, or if the Company’s liability exceeds the amount of applicable insurance
or indemnity.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
OTHER ACCRUED EXPENSES
|
9 Months Ended |
Sep. 30, 2024 |
Payables and Accruals [Abstract] |
|
OTHER ACCRUED EXPENSES |
9. OTHER ACCRUED EXPENSES
Other accrued expenses consisted of the
following as of September 30, 2024 and December 31, 2023:
SCHEDULE OF OTHER ACCRUED EXPENSES
| |
September 30, 2024 | | |
December 31, 2023 | |
Accrued royalties | |
$ | 7,235 | | |
$ | 6,268 | |
Contingent consideration | |
| - | | |
| 453 | |
Operating lease liability | |
| 305 | | |
| 377 | |
Accrued sales and marketing | |
| 55 | | |
| 43 | |
Accrued lab costs | |
| 233 | | |
| 68 | |
Accrued professional fees | |
| 369 | | |
| 241 | |
Taxes payable | |
| 259 | | |
| 261 | |
All others | |
| 577 | | |
| 490 | |
Total other accrued expenses | |
$ | 9,033 | | |
$ | 8,201 | |
|
X |
- DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1
+ Details
Name: |
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
STOCK-BASED COMPENSATION
|
9 Months Ended |
Sep. 30, 2024 |
Share-Based Payment Arrangement [Abstract] |
|
STOCK-BASED COMPENSATION |
10. STOCK-BASED COMPENSATION
Historically, stock options have been granted
with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they
are granted, and generally vest over a one to three-year period for employees and members of the Board. Upon exercise, new shares will
be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to Board members and employees
generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.
There were no stock option awards issued
during the nine months ended September 30, 2024 and September 30, 2023.
The Company recognized approximately $0.1
million and $0.2 million of stock-based compensation expense within continuing operations during the three-month periods ended September
30, 2024 and 2023, respectively, and approximately $0.2 million and $0.5 million for the nine-month periods ended September 30, 2024 and
2023, respectively. The following table has a breakout of stock-based compensation expense from continuing operations by line item.
SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD
| |
| | | |
| | | |
| | | |
| | |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| |
Cost of revenue | |
$ | - | | |
$ | 13 | | |
$ | 4 | | |
$ | 39 | |
Sales and marketing | |
| 28 | | |
| 31 | | |
| 81 | | |
| 92 | |
General and administrative | |
| 58 | | |
| 108 | | |
| 133 | | |
| 370 | |
Total stock compensation expense | |
$ | 86 | | |
$ | 152 | | |
$ | 218 | | |
$ | 501 | |
|
X |
- DefinitionThe entire disclosure for share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
INCOME TAXES
|
9 Months Ended |
Sep. 30, 2024 |
Income Tax Disclosure [Abstract] |
|
INCOME TAXES |
11. INCOME TAXES
Generally, accounting standards require
companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative
guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due
to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate
estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.
As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following
table summarizes income tax expense on income from continuing operations and the effective tax rate for the three- and nine-month periods
ended September 30, 2024 and 2023:
SCHEDULE OF EFFECTIVE INCOME TAX RATE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Provision for income tax | |
$ | 4 | | |
$ | 4 | | |
$ | 12 | | |
$ | 12 | |
Effective income tax rate | |
| 0.3 | % | |
| (0.8 | %) | |
| 0.3 | % | |
| 3.9 | % |
Income tax expense for both periods was
primarily due to state franchise taxes.
Other long-term liabilities consisted of
uncertain tax positions as of September 30, 2024 and December 31, 2023.
|
X |
- DefinitionThe entire disclosure for income tax.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2
+ Details
Name: |
us-gaap_IncomeTaxDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
X |
- References
+ Details
Name: |
us-gaap_SegmentReportingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54
Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47
Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54
Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_SegmentReportingDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
NOTES PAYABLE
|
9 Months Ended |
Sep. 30, 2024 |
Debt Disclosure [Abstract] |
|
NOTES PAYABLE |
13. NOTES PAYABLE
BroadOak Loan
On October 29, 2021, the Company and its
subsidiaries entered into the Term Loan with BroadOak, providing for a term loan in the aggregate principal amount of $8,000,000. Funding
of the Term Loan took place on November 1, 2021. The Term Loan was scheduled to mature upon the earlier of (i) October 31, 2024 or (ii)
the occurrence of a change in control, and bears interest at the rate of 9% per annum. The Term Loan is secured by a security interest
in substantially all of the Company’s and its subsidiaries’ assets and was subordinate to the Company’s $7,500,000 revolving
credit facility with Comerica Bank. See Note 16, Revolving Line of Credit. The Term Loan had an origination fee of 3% of the Term
Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs
on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the
change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii)
30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the
Term Loan, or if the Term Loan is repaid on its maturity date.
The Term Loan contains affirmative and negative
restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants, which include
restrictions on certain mergers, acquisitions, investments, encumbrances, etc., could adversely affect our ability to conduct our business.
The Term Loan also contains customary events of default.
The Company concluded that the Term Loan
met the definition of a “recognized financial liability” which is an acceptable financial instrument eligible for the fair
value option under ASC 825-10-15-4, and did not meet the definition of any of the financial instruments listed within ASC 825-10-15-5
that are not eligible for the fair value option. The Note is not convertible and does not have any component recorded to stockholders’
deficit. Accordingly, the Company elected the fair value option for the Note.
In May 2022, the Company issued a convertible
note to BroadOak, pursuant to which BroadOak funded a term loan in the aggregate principal amount of $2.0 million, which was converted
into a subordinated term loan and was added to the outstanding balance of the Term Loan.
On October 24, 2023, the Company entered
into a Second Amendment to Loan and Security Agreement (the “Second Amendment”) with BroadOak. The primary changes to the
original Term Loan were as follows:
|
● |
The Company made a one-time payment in an aggregate amount equal to $2,500,000, on October 30, 2023 and applied the payment in full satisfaction of the $3,000,000 Terminal Payment (as defined in the Term Loan). See above regarding the Terminal Payment. |
|
● |
Effective November 1, 2023, the interest rate under the Term Loan was reduced from 9% to 8% through the maturity date of October 31, 2024 or earlier, upon the occurrence of a change in control (“Loan Maturity Date”). |
|
|
|
|
● |
The Company had the option to request an extension of the Loan Maturity Date in writing no less than sixty days prior to the Loan Maturity Date. If BroadOak agreed to the extension, the Loan Maturity Date would automatically be extended. |
On March 29, 2024, the Company entered into
a Third Amendment to Loan and Security Agreement with BroadOak (the “Third Amendment”). The primary changes to the Second
Amendment were as follows:
|
● |
The maturity date was extended to June 30, 2025. |
|
● |
Beginning April 1, 2024, the Company will make $500,000 monthly payments with the remaining loan balance due on the new maturity date. |
The Third Amendment was treated as a debt
modification which is accounted for prospectively. Since the Term Loan is carried at fair value under the fair value option, the Second
Amendment did not result in any extinguishment gain or loss upon amendment, and the impact of the revised terms was incorporated into
the Company’s first quarter 2024 fair value calculation.
The balance of the loan outstanding at September
30, 2024 was $5.9 million.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
SUPPLEMENTAL CASH FLOW INFORMATION
|
9 Months Ended |
Sep. 30, 2024 |
Supplemental Cash Flow Elements [Abstract] |
|
SUPPLEMENTAL CASH FLOW INFORMATION |
14. SUPPLEMENTAL CASH FLOW INFORMATION
Supplemental Disclosures of Non-Cash Activities
(in thousands)
SUPPLEMENTAL CASH FLOW INFORMATION
| |
| | |
| |
| |
Nine Months Ended | |
| |
September 30, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
Taxes accrued for repurchase of restricted shares | |
$ | 38 | | |
$ | 21 | |
Purchase of property and equipment included in accounts payable | |
| 20 | | |
| 74 | |
|
X |
- DefinitionThe entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/230/tableOfContent
+ Details
Name: |
us-gaap_CashFlowSupplementalDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_SupplementalCashFlowElementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
MEZZANINE EQUITY
|
9 Months Ended |
Sep. 30, 2024 |
Equity [Abstract] |
|
MEZZANINE EQUITY |
15. MEZZANINE EQUITY
Redeemable Preferred Stock
On January 10, 2020, the Company entered
into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and
Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $20.0
million in Series B Preferred Stock of the Company, at an issuance price per share of $1,000 (“New Investment Shares”). Pursuant
to the Securities Purchase and Exchange Agreement, 1315 Capital agreed to purchase 19,000 shares of Series B Preferred Stock at an aggregate
purchase price of $19.0 million and Ampersand agreed to purchase 1,000 shares of Series B Preferred Stock at an aggregate purchase price
of $1.0 million.
In addition, the Company agreed to exchange
$27.0 million of the Company’s existing Series A convertible preferred stock, par value $0.01 per share, held by Ampersand (the
“Series A Preferred Stock”), represented by 270 shares of Series A Preferred Stock with a stated value of $100,000 per share,
which represents all of the Company’s issued and outstanding Series A Preferred Stock, for 27,000 newly issued shares of Series
B Preferred Stock (such shares of Series B Preferred Stock, the “Exchange Shares” and such transaction, the “Exchange”).
Following the Exchange, no shares of Series A Preferred Stock remained designated, authorized, issued or outstanding. The Series B Preferred
Stock has a conversion price of $6.00. On October 10, 2024, the Investors (as defined below) exchanged their shares of Series B Preferred
Stock for shares of Series C Preferred Stock with a conversion price of $2.02. See Note 18, Subsequent Events.
Voting
On any matter presented to the stockholders
of the Company for their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders
in lieu of meeting), each holder of outstanding shares of Series B Preferred Stock will be entitled to cast the number of votes equal
to the number of whole shares of the Company’s common stock into which the shares of Series B Preferred Stock held by such holder
are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the
Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the “Series B Certificate
of Designation”), holders of Series B Preferred Stock will vote together with the holders of common stock as a single class and
on an as-converted to common stock basis.
Director Designation Rights
The Series B Certificate of Designation
also provides each Investor with the following director designation rights: for so long such Investor holds at least sixty percent (60%)
of the Series B Preferred Stock issued to it on the Issuance Date (as defined therein), such Investor will be entitled to elect two directors
to the Company’s Board of Directors (the “Board”), provided that one of the directors qualifies as an “independent
director” under Rule 5605(a)(2) of the listing rules of the Nasdaq Stock Market (or any successor rule or similar rule promulgated
by another exchange on which the Company’s securities are then listed or designated) (“Independent Director”). However,
if at any time such Investor holds less than sixty percent (60%), but at least forty percent (40%), of the Series B Preferred Stock issued
to them on the Issuance Date, such Investor would only be entitled to elect one director to the Board. Any director elected pursuant to
the terms of the Series B Certificate of Designation may be removed without cause by, and only by, the affirmative vote of the holders
of Series B Preferred Stock. A vacancy in any directorship filled by the holders of Series B Preferred Stock may be filled only by vote
or written consent in lieu of a meeting of such holders of Series B Preferred Stock or by any remaining director or directors elected
by such holders of Series B Preferred Stock.
On November 15, 2023, Edward Chan, a director
designated by 1315 Capital to the Board, provided notice to the Company of his resignation from the Board, effective immediately. Further,
on December 7, 2023, Robert Gorman, a director designated by Ampersand to the Board, provided notice to the Company of his resignation
as a director and as Chairman of the Board, effective immediately.
As of the date of this report, each of 1315
Capital and Ampersand has appointed one director to the Board, and each has not appointed a second director to the Board.
Conversion
The Series B Certificate of Designation
provides that from and after the Issuance Date and subject to the terms of the Series B Certificate of Designation, each share of Series
B Preferred Stock is convertible, at any time and from time to time, at the option of the holder into a number of shares of common stock
equal to dividing the amount equal to the greater of the Stated Value of such Series B Preferred Stock, plus any dividends declared but
unpaid thereon, or such amount per share as would have been payable had each such share been converted into common stock immediately prior
to a liquidation, by six dollars ($6.00) (subject to adjustment in the event of any stock dividend, stock split, combination, or other
similar recapitalization affecting such shares). The aggregate number of shares of common stock that may be issued through conversion
of all of the New Investment Shares and Exchange Shares is 7,833,334 shares (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization affecting such shares).
Mandatory Conversion
If the Company consummates the sale of shares
of common stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under
the Securities Act pursuant to which the price of the common stock in such offering is at least equal to twelve dollars ($12.00) (subject
to adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization affecting such shares) and
such offering does not include warrants (or any other convertible security) and results in at least $25,000,000 in proceeds, net of the
underwriting discount and commissions, to the Company, and the common stock continues to be listed for trading on the Nasdaq Capital Market
or another exchange, all outstanding shares of Series B Preferred Stock will automatically be converted into shares of common stock, at
the then effective Series B Conversion Ratio (as defined in the Series B Certificate of Designation).
Liquidation
Upon any voluntary or involuntary liquidation,
dissolution or winding up of the Company or Deemed Liquidation (as defined in the Series B Certificate of Designation) (a “Liquidation”),
the holders of shares of Series B Preferred Stock then outstanding will be entitled to be paid out of the assets of the Company available
for distribution to its stockholders (on a pari passu basis with the holders of any class or series of preferred stock ranking on liquidation
on a parity with the Series B Preferred Stock), and before any payment will be made to the holders of common stock or any other class
or series of preferred stock ranking on liquidation junior to the Series B Preferred Stock by reason of their ownership thereof, an amount
per share of Series B Preferred Stock equal to the greater of (i) the Stated Value of such share of Series B Preferred Stock, plus any
dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had each such share been converted into
common stock immediately prior to such Liquidation.
As of September 30, 2024 and December 31,
2023, there were 47,000 issued and outstanding shares of Series B Preferred Stock, respectively. See Note 18, Subsequent Events,
for updates regarding the status of the Series B Preferred Stock.
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
REVOLVING LINE OF CREDIT
|
9 Months Ended |
Sep. 30, 2024 |
Debt Disclosure [Abstract] |
|
REVOLVING LINE OF CREDIT |
16. REVOLVING LINE OF CREDIT
On October 13, 2021, the Company and its
subsidiaries entered into the Comerica Loan Agreement with Comerica, providing for a revolving credit facility of up to $7,500,000 (the
“Credit Facility”). The Company could use the proceeds of the Credit Facility for working capital and other general corporate
purposes.
On October 6, 2023, effective September
30, 2023, the Company entered into a Fifth Amendment to its Loan and Security Agreement (the “Fifth Amendment to the Comerica Loan
Agreement”) with Comerica providing for a revolving credit facility of up to $5,000,000.
In February 2024, the Company terminated
the Comerica Loan Agreement. The Company did not owe anything outstanding on the line of credit at the time of termination and does not
owe anything further to Comerica.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for short-term debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent
+ Details
Name: |
us-gaap_ShortTermDebtTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
RECENT ACCOUNTING STANDARDS
|
9 Months Ended |
Sep. 30, 2024 |
Accounting Changes and Error Corrections [Abstract] |
|
RECENT ACCOUNTING STANDARDS |
17. RECENT ACCOUNTING STANDARDS
Accounting Pronouncements
Adopted
In August 2020, the FASB issued ASU 2020-06,
Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s
Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments
with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU
2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. This
was adopted on January 1, 2024 and there was no impact upon adoption.
Accounting Pronouncements
Pending
In November 2023, the FASB
modified authoritative guidance within the codification’s Segment Reporting topic (ASC 280), which enhanced the disclosure requirements
for significant segment expenses and other segment items. The authoritative guidance will become effective for fiscal years beginning
after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The Company will adopt the standard
as of the effective date.
In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires public entities, on an annual basis, to provide disclosure
of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09
is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the
impact the adoption of this standard on its financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingChangesAndErrorCorrectionsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 250 -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1
+ Details
Name: |
us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
SUBSEQUENT EVENTS
|
9 Months Ended |
Sep. 30, 2024 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
18. SUBSEQUENT EVENTS
On
October 10, 2024, the Company and the Investors entered into an Exchange Agreement (the “Exchange Agreement”) pursuant to
which the Investors exchanged (the “Exchange”) an aggregate of 47,000 shares of the Company’s Series B Preferred Stock,
comprised of 28,000 shares of Series B Preferred Stock held by Ampersand and 19,000 shares of Series B Preferred Stock held by 1315 Capital,
which represented all of the Company’s issued and outstanding Series B Preferred Stock, for 47,000 newly created shares of Series
C Preferred Stock, at an issuance price per share of $1,000. In the Exchange, Ampersand received 28,000 shares of Series C Preferred Stock
and 1315 received 19,000 shares of Series C Preferred Stock.
The
Series C Preferred Stock is convertible into the Company’s common stock at a conversion price of $2.02 per share of common stock
(subject to further adjustment in the event of any stock dividend, stock split, combination, or other similar recapitalization affecting
such shares) which was the closing price of the common stock on the date of the Exchange Agreement. The Series C Preferred Stock does
not have a liquidation preference over the common stock in the event of a sale or dissolution of the Company, does not have director designation
rights and includes limited customary protective provisions. The Series B Preferred Stock had a conversion price of $6.00 per share of
common stock and included additional protective provisions not applicable to the Series C Preferred Stock, including (i) limitations on
the Board to declare dividends, (ii) director designation rights for each of the Investors, (iii) liquidation rights of holders upon “deemed
liquidation” events, including a liquidation preference over the common stock, (iv) limitations on the ability to authorize, issue
or create debt securities, (v) limitations on the ability to enter into mergers or acquisitions and (vi) limitations on the ability to
conduct public offerings of the Company’s common stock. See Note 15, Mezzanine Equity. The Series C Preferred Stock is convertible
into 23,267,326 shares of common stock.
In
connection with the Exchange, on October 11, 2024 the Company filed a Certificate of Designation of Preferences, Rights and Limitations
of Series C Convertible Preferred Stock (the “Series C Certificate of Designation”), with the Secretary of State of the State
of Delaware. The Series C Certificate of Designation set forth the rights and obligations of the Series C Preferred Stock, including with
respect to voting rights, conversion rights, certain protective provisions and liquidation rights. Please refer to the Company’s
current report on Form 8-K, filed with the SEC on October 15, 2024, for more information.
The
closing of the transactions contemplated by the Exchange Agreement occurred on October 11, 2024, following the satisfaction of customary
conditions set forth in the Exchange Agreement and did not result in the receipt of any cash proceeds by the Company.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
|
9 Months Ended |
Sep. 30, 2024 |
Accounting Policies [Abstract] |
|
Accounting Estimates |
Accounting
Estimates
The
preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical
experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the
circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration,
allowances for credit losses, revenue recognition, unrecognized tax benefits, and asset impairments involving intangible assets. The
Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially
differ from those estimates.
|
Revenue Recognition |
Revenue
Recognition
We
derive our revenues from the performance of proprietary assays or tests. The Company’s performance obligation is fulfilled upon
the completion, review and release of test results to the customer. We subsequently bill third-party payers or direct-bill payers for
the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net
realizable value, which is determined based on historical collection rates by each payer category for each proprietary test offered by
the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary
tests, we estimate the amount of variable consideration that should be included in the transaction price using the expected value method
based on historical experience.
We
regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates
and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly
from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become
known.
|
Financing and Payment |
Financing
and Payment
For
non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically
thirty days and in our now discontinued pharma services, were up to sixty days. Commercial third-party-payers are required to respond
to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment
for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where
multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly
for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full.
|
Costs to Obtain or Fulfill a Customer Contract |
Costs
to Obtain or Fulfill a Customer Contract
Sales
commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the
condensed consolidated statements of operations.
|
Accounts Receivable |
Accounts
Receivable
The
Company’s accounts receivable represent unconditional rights to consideration and are generated using its clinical services. The
Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with
fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference
between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed
to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months.
The allowance for credit losses balance was $26,000 and $0 at September 30, 2024 and December 31, 2023, respectively.
|
Leases |
Leases
The
Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”)
assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation
to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset
and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides
all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information
available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease
when readily determinable.
Our
lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably
certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line
basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases.
|
Other Current Assets |
Other
Current Assets
Other
current assets consisted of the following as of September 30, 2024 and December 31, 2023:
SCHEDULE
OF OTHER CURRENT ASSETS
| |
September 30, 2024 | | |
December 31, 2023 | |
Lab supplies | |
$ | 1,220 | | |
$ | 1,227 | |
Prepaid expenses | |
| 441 | | |
| 590 | |
Other | |
| 43 | | |
| 24 | |
Total other current assets | |
$ | 1,704 | | |
$ | 1,841 | |
|
Long-Lived Assets, including Finite-Lived Intangible Assets |
Long-Lived
Assets, including Finite-Lived Intangible Assets
Finite-lived
intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized
on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related
amortization expense in the condensed consolidated statements of operations.
The
Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances
indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is
less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair
value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and,
where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining
whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.
|
Basic and Diluted Net Income (Loss) per Share |
Basic
and Diluted Net Income (Loss) per Share
A
reconciliation of the number of shares of common stock, par value $0.01 per share, used in the calculation of basic and diluted income
(loss) per share for the three- and nine-month periods ended September 30, 2024 and 2023 is as follows:
SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Basic weighted average number of common shares | |
| 4,393 | | |
| 4,319 | | |
| 4,380 | | |
| 4,313 | |
Potential dilutive effect of stock-based awards | |
| 30 | | |
| - | | |
| 24 | | |
| 42 | |
Diluted weighted average number | |
| | | |
| | | |
| | | |
| | |
of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
Diluted weighted average number of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
The
Company’s Series B Redeemable Preferred Stock, on an as converted basis into common stock of 7,833,334 shares for the three- and
nine-months ended September 30, 2024, and the following outstanding stock-based awards, were excluded from the computation of the effect
of dilutive securities on income (loss) per share for the following periods as they would have been anti-dilutive (rounded to thousands):
SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Options | |
| 288 | | |
| 469 | | |
| 288 | | |
| 394 | |
Restricted stock units (RSUs) | |
| 145 | | |
| 277 | | |
| 145 | | |
| 277 | |
Anti-dilutive
securities | |
| 433 | | |
| 746 | | |
| 433 | | |
| 671 | |
|
X |
- DefinitionCosts To Obtain Or Fulfill Customer Contract [Policy Text Block]
+ References
+ Details
Name: |
IDXG_CostsToObtainOrFulfillCustomerContractPolicyTextBlock |
Namespace Prefix: |
IDXG_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFinancing And Payment [Policy Text Block]
+ References
+ Details
Name: |
IDXG_FinancingAndPaymentPolicyTextBlock |
Namespace Prefix: |
IDXG_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionOther Current Assets [Policy Text Block]
+ References
+ Details
Name: |
IDXG_OtherCurrentAssetsPolicyTextBlock |
Namespace Prefix: |
IDXG_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2
+ Details
Name: |
us-gaap_EarningsPerSharePolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.
+ References
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1
+ Details
Name: |
us-gaap_LesseeLeasesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue from contract with customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20
Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for accounts receivable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B
+ Details
Name: |
us-gaap_TradeAndOtherAccountsReceivablePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
DISCONTINUED OPERATIONS (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
Discontinued Operations and Disposal Groups [Abstract] |
|
SCHEDULE OF COMPONENTS OF ASSETS AND LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED |
The
table below presents the significant components of its former Pharma Solutions business unit’s results included within loss from
discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and nine months ended September
30, 2024 and 2023.
SCHEDULE
OF COMPONENTS OF ASSETS AND LIABILITIES AND REVENUE CLASSIFIED AS DISCONTINUED
| |
| | |
| | |
| | |
| |
| |
For The Three Months Ended | | |
For The Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Revenue, net | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Loss from discontinued operations | |
| - | | |
| - | | |
| - | | |
| (137 | ) |
Income tax expense | |
| 82 | | |
| 86 | | |
| 260 | | |
| 248 | |
Loss from discontinued operations, net of tax | |
$ | (82 | ) | |
$ | (86 | ) | |
$ | (260 | ) | |
$ | (385 | ) |
|
X |
- References
+ Details
Name: |
us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3
+ Details
Name: |
us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
Accounting Policies [Abstract] |
|
SCHEDULE OF OTHER CURRENT ASSETS |
Other
current assets consisted of the following as of September 30, 2024 and December 31, 2023:
SCHEDULE
OF OTHER CURRENT ASSETS
| |
September 30, 2024 | | |
December 31, 2023 | |
Lab supplies | |
$ | 1,220 | | |
$ | 1,227 | |
Prepaid expenses | |
| 441 | | |
| 590 | |
Other | |
| 43 | | |
| 24 | |
Total other current assets | |
$ | 1,704 | | |
$ | 1,841 | |
|
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE |
SCHEDULE
OF BASIC AND DILUTED NET LOSS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Basic weighted average number of common shares | |
| 4,393 | | |
| 4,319 | | |
| 4,380 | | |
| 4,313 | |
Potential dilutive effect of stock-based awards | |
| 30 | | |
| - | | |
| 24 | | |
| 42 | |
Diluted weighted average number | |
| | | |
| | | |
| | | |
| | |
of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
Diluted weighted average number of common shares | |
| 4,423 | | |
| 4,319 | | |
| 4,404 | | |
| 4,355 | |
|
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE |
SCHEDULE
OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| |
| | |
| | |
| | |
| |
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Options | |
| 288 | | |
| 469 | | |
| 288 | | |
| 394 | |
Restricted stock units (RSUs) | |
| 145 | | |
| 277 | | |
| 145 | | |
| 277 | |
Anti-dilutive
securities | |
| 433 | | |
| 746 | | |
| 433 | | |
| 671 | |
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amounts of other current assets.
+ References
+ Details
Name: |
us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
FAIR VALUE MEASUREMENTS (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
Fair Value Disclosures [Abstract] |
|
SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS |
SCHEDULE
OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS
| |
As of September 30, 2024 | | |
Fair Value Measurements | |
| |
| | |
Fair | | |
As of September 30, 2024 | |
| |
Amount | | |
Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
| |
| | |
| | |
| | |
| | |
| |
Liabilities: | |
| | | |
| | | |
| | | |
| | | |
| | |
Contingent consideration: | |
| | | |
| | | |
| | | |
| | | |
| | |
Asuragen (1) | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
Note payable: | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loan | |
| 5,900 | | |
| 5,688 | | |
| - | | |
| - | | |
| 5,688 | |
| |
$ | 5,900 | | |
$ | 5,688 | | |
$ | - | | |
$ | - | | |
$ | 5,688 | |
(1) |
See
Note 9, Other Accrued Expenses |
| |
As of December 31, 2023 | | |
Fair Value Measurements | |
| |
Carrying | | |
Fair | | |
As of December 31, 2023 | |
| |
Amount | | |
Value | | |
Level 1 | | |
Level 2 | | |
Level 3 | |
Liabilities: | |
| | |
| | |
| | |
| | |
| |
Contingent consideration: | |
| | | |
| | | |
| | | |
| | | |
| | |
Asuragen (1) | |
$ | 453 | | |
$ | 453 | | |
$ | - | | |
$ | - | | |
$ | 453 | |
Note payable: | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loan | |
| 10,000 | | |
| 9,343 | | |
| - | | |
| - | | |
| 9,343 | |
| |
$ | 10,453 | | |
$ | 9,796 | | |
$ | - | | |
$ | - | | |
$ | 9,796 | |
(1) |
See
Note 9, Other Accrued Expenses |
|
SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION |
A
roll forward of the carrying value of the Contingent Consideration Liability and BroadOak Loan to September 30, 2024 is as follows:
SCHEDULE
OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION
| |
| | |
| | |
| | |
| | |
Adjustment | | |
| |
| |
| | |
| | |
| | |
| | |
to Fair | | |
| |
| |
December 31, 2023 | | |
Payments | | |
Transferred to Accrued Expenses | | |
Accretion/Interest Accrued | | |
Value/
Mark to Market | | |
September 30, 2024 | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Asuragen | |
$ | 453 | | |
$ | - | | |
$ | (487 | ) | |
$ | 34 | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
BroadOak loans | |
| 9,343 | | |
| (4,100 | ) | |
| - | | |
| - | | |
| 445 | | |
| 5,688 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
$ | 9,796 | | |
$ | (4,100 | ) | |
$ | (487 | ) | |
$ | 34 | | |
$ | 445 | | |
$ | 5,688 | |
|
X |
- DefinitionTabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
LEASES (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
Leases [Abstract] |
|
SCHEDULE OF LEASE RELATED ASSETS AND LIABILITIES |
The
table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet:
SCHEDULE
OF LEASE RELATED ASSETS AND LIABILITIES
| |
Classification on the Balance Sheet | |
September 30, 2024 | | |
December 31, 2023 | |
| |
| |
| | |
| |
Assets | |
| |
| | | |
| | |
Operating lease assets | |
Operating lease right of use assets | |
| 1,532 | | |
| 1,864 | |
Total lease assets | |
| |
$ | 1,532 | | |
$ | 1,864 | |
| |
| |
| | | |
| | |
Liabilities | |
| |
| | | |
| | |
Current | |
| |
| | | |
| | |
Operating lease liabilities | |
Other accrued expenses | |
| 305 | | |
| 377 | |
Total current lease liabilities | |
| |
$ | 305 | | |
$ | 377 | |
Noncurrent | |
| |
| | | |
| | |
Operating lease liabilities | |
Operating lease liabilities, net of current portion | |
| 1,189 | | |
| 1,472 | |
Total long-term lease liabilities | |
| |
| 1,189 | | |
| 1,472 | |
Total lease liabilities | |
| |
$ | 1,494 | | |
$ | 1,849 | |
|
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES |
The
table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as
of September 30, 2024:
SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES
| |
Operating Leases | |
2024 - remaining three months | |
$ | 155 | |
2025 | |
| 450 | |
2026 | |
| 450 | |
2027 | |
| 550 | |
2028 | |
| 275 | |
Total minimum lease payments | |
| 1,880 | |
Less: amount of lease payments representing effects of discounting | |
| 386 | |
Present value of future minimum lease payments | |
| 1,494 | |
Less: current obligations under leases | |
| 305 | |
Long-term lease obligations | |
$ | 1,189 | |
| |
| | |
|
X |
- DefinitionSchedule Of Operating Leases Assets And Liabilities [Table Text Block]
+ References
+ Details
Name: |
IDXG_ScheduleOfOperatingLeasesAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
IDXG_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
OTHER ACCRUED EXPENSES (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
Payables and Accruals [Abstract] |
|
SCHEDULE OF OTHER ACCRUED EXPENSES |
Other accrued expenses consisted of the
following as of September 30, 2024 and December 31, 2023:
SCHEDULE OF OTHER ACCRUED EXPENSES
| |
September 30, 2024 | | |
December 31, 2023 | |
Accrued royalties | |
$ | 7,235 | | |
$ | 6,268 | |
Contingent consideration | |
| - | | |
| 453 | |
Operating lease liability | |
| 305 | | |
| 377 | |
Accrued sales and marketing | |
| 55 | | |
| 43 | |
Accrued lab costs | |
| 233 | | |
| 68 | |
Accrued professional fees | |
| 369 | | |
| 241 | |
Taxes payable | |
| 259 | | |
| 261 | |
All others | |
| 577 | | |
| 490 | |
Total other accrued expenses | |
$ | 9,033 | | |
$ | 8,201 | |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the components of accrued liabilities.
+ References
+ Details
Name: |
us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
X |
- DefinitionTabular disclosure of share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
X |
- DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12
+ Details
Name: |
us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
SUPPLEMENTAL CASH FLOW INFORMATION (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
Supplemental Cash Flow Elements [Abstract] |
|
SUPPLEMENTAL CASH FLOW INFORMATION |
Supplemental Disclosures of Non-Cash Activities
(in thousands)
SUPPLEMENTAL CASH FLOW INFORMATION
| |
| | |
| |
| |
Nine Months Ended | |
| |
September 30, | |
| |
2024 | | |
2023 | |
| |
| | |
| |
Taxes accrued for repurchase of restricted shares | |
$ | 38 | | |
$ | 21 | |
Purchase of property and equipment included in accounts payable | |
| 20 | | |
| 74 | |
|
X |
- DefinitionTabular disclosure of supplemental cash flow information for the periods presented.
+ References
+ Details
Name: |
us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_SupplementalCashFlowElementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
LIQUIDITY (Details Narrative) - USD ($)
|
|
3 Months Ended |
9 Months Ended |
|
|
|
|
|
|
Oct. 10, 2024 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Nov. 01, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
May 31, 2022 |
Oct. 31, 2021 |
Oct. 29, 2021 |
Operating income from continuing operation |
|
$ 1,905,000
|
$ (16,000)
|
$ 5,036,000
|
$ 1,491,000
|
|
|
|
|
|
|
Cash and cash equivalents |
|
2,113,000
|
$ 5,032,000
|
2,113,000
|
$ 5,032,000
|
|
$ 3,498,000
|
$ 4,828,000
|
|
|
|
Current assets |
|
11,110,000
|
|
11,110,000
|
|
|
10,322,000
|
|
|
|
|
Current liabilities |
|
$ 18,769,000
|
|
$ 18,769,000
|
|
|
$ 17,474,000
|
|
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Number of shares exchanged |
|
7,833,334
|
|
7,833,334
|
|
|
|
|
|
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
|
|
$ 1,800,000
|
|
|
|
|
|
Subsequent Event [Member] | Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Number of shares exchanged |
47,000
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, par value |
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Series C Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Number of shares exchanged |
47,000
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, par value |
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
Term Loan [Member] | Broad Oak [Member] |
|
|
|
|
|
|
|
|
|
|
|
Term loan |
|
|
|
|
|
|
|
|
$ 2,000,000.0
|
$ 8,000,000.0
|
$ 8,000,000
|
Term Loan [Member] | Broad Oak [Member] | Convertible Debt [Member] |
|
|
|
|
|
|
|
|
|
|
|
Term loan |
|
|
|
|
|
|
|
|
$ 2,000,000.0
|
|
|
Comerica Bank [Member] |
|
|
|
|
|
|
|
|
|
|
|
Long-term line of credit |
|
|
|
|
|
|
|
|
|
$ 7,500,000
|
|
X |
- DefinitionAmount of asset recognized for present right to economic benefit, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_LineOfCredit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=IDXG_TermLoanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_BroadOakMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LineOfCreditFacilityAxis=IDXG_ComericaBankMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
X |
- DefinitionAmount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1
+ Details
Name: |
us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of revenue attributable to disposal group, including, but not limited to, discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3
+ Details
Name: |
us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.24.3
X |
- DefinitionAmount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B
+ Details
Name: |
us-gaap_DepreciationAndAmortizationDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of other miscellaneous assets.
+ References
+ Details
Name: |
us-gaap_OtherAssetsMiscellaneous |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_OtherPrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.24.3
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares shares in Thousands |
3 Months Ended |
9 Months Ended |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Accounting Policies [Abstract] |
|
|
|
|
Basic weighted average number of common shares |
4,393
|
4,319
|
4,380
|
4,313
|
Potential dilutive effect of stock-based awards |
30
|
|
24
|
42
|
Diluted weighted average number of common shares |
4,423
|
4,319
|
4,404
|
4,355
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
|
Sep. 30, 2024 |
Sep. 30, 2024 |
Dec. 31, 2023 |
Sep. 30, 2023 |
Property, Plant and Equipment [Line Items] |
|
|
|
|
Allowance for credit losses |
$ 26,000
|
$ 26,000
|
$ 0
|
|
Common stock, par value |
$ 0.01
|
$ 0.01
|
$ 0.01
|
$ 0.01
|
Series B Preferred Stock [Member] |
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
Number of preferred stocks on converted basis |
7,833,334
|
7,833,334
|
|
|
Minimum [Member] |
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
Finite lived intangible asset, useful life |
2 years
|
2 years
|
|
|
Maximum [Member] |
|
|
|
|
Property, Plant and Equipment [Line Items] |
|
|
|
|
Finite lived intangible asset, useful life |
10 years
|
10 years
|
|
|
X |
- DefinitionAmount of allowance for credit loss on accounts receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS (Details) - USD ($) $ in Thousands |
Sep. 30, 2024 |
Dec. 31, 2023 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Notes payable |
|
|
$ 4,243
|
|
Fair value of liabilities |
5,900
|
|
10,453
|
|
Fair Value Measured at Net Asset Value Per Share [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Fair value of liabilities |
5,688
|
|
9,796
|
|
Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Fair value of liabilities |
|
|
|
|
Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Fair value of liabilities |
|
|
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Fair value of liabilities |
5,688
|
|
9,796
|
|
Asuragen [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Contingent consideration |
|
[1] |
453
|
[2] |
Asuragen [Member] | Fair Value Measured at Net Asset Value Per Share [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Contingent consideration |
|
[1] |
453
|
[2] |
Asuragen [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Contingent consideration |
|
[1] |
|
[2] |
Asuragen [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Contingent consideration |
|
[1] |
|
[2] |
Asuragen [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Contingent consideration |
|
[1] |
453
|
[2] |
BroadOak Loan [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Notes payable |
5,900
|
|
10,000
|
|
BroadOak Loan [Member] | Fair Value Measured at Net Asset Value Per Share [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Notes payable |
5,688
|
|
9,343
|
|
BroadOak Loan [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Notes payable |
|
|
|
|
BroadOak Loan [Member] | Fair Value, Inputs, Level 2 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Notes payable |
|
|
|
|
BroadOak Loan [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |
|
|
|
|
Notes payable |
$ 5,688
|
|
$ 9,343
|
|
|
|
X |
- DefinitionAmount of liability recognized arising from contingent consideration in a business combination.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6
+ Details
Name: |
us-gaap_BusinessCombinationContingentConsiderationLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair value of financial and nonfinancial obligations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_LiabilitiesFairValueDisclosure |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_AsuragenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_BroadOakLoanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_AsuragenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_BroadOakLoanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
SCHEDULE OF LEASE RELATED ASSETS AND LIABILITIES (Details) - USD ($) $ in Thousands |
Sep. 30, 2024 |
Dec. 31, 2023 |
Leases [Abstract] |
|
|
Operating lease assets |
$ 1,532
|
$ 1,864
|
Total lease assets |
1,532
|
1,864
|
Operating lease, liability, current |
305
|
377
|
Total current lease liabilities |
305
|
377
|
Operating lease, liability, noncurrent |
1,189
|
1,472
|
Total long-term lease liabilities |
1,189
|
1,472
|
Total lease liabilities |
$ 1,494
|
$ 1,849
|
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.24.3
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.3
X |
- References
+ Details
Name: |
us-gaap_LeasesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating lease expense. Excludes sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4
+ Details
Name: |
us-gaap_OperatingLeaseExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePayments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
v3.24.3
X |
- DefinitionOthers accrued expenses current.
+ References
+ Details
Name: |
IDXG_OthersAccruedExpensesCurrent |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
+ Details
Name: |
us-gaap_AccruedMarketingCostsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedProfessionalFeesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8
+ Details
Name: |
us-gaap_AccruedRoyaltiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6
+ Details
Name: |
us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TaxesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.24.3
SCHEDULE OF SHARE-BASED COMPENSATION ARRANGEMENTS BY SHARE-BASED PAYMENT AWARD (Details) - USD ($) $ in Thousands |
3 Months Ended |
9 Months Ended |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
Total stock compensation expense |
$ 86
|
$ 152
|
$ 218
|
$ 501
|
Cost of Sales [Member] |
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
Total stock compensation expense |
|
13
|
4
|
39
|
Selling and Marketing Expense [Member] |
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
Total stock compensation expense |
28
|
31
|
81
|
92
|
General and Administrative Expense [Member] |
|
|
|
|
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] |
|
|
|
|
Total stock compensation expense |
$ 58
|
$ 108
|
$ 133
|
$ 370
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
X |
- DefinitionAmount of expense for employee benefit and equity-based compensation.
+ References
+ Details
Name: |
us-gaap_EmployeeBenefitsAndShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDescription of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=IDXG_StockIncentivePlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
v3.24.3
X |
- DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18
+ Details
Name: |
us-gaap_NumberOfOperatingSegments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_SegmentReportingAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
NOTES PAYABLE (Details Narrative) - USD ($)
|
Apr. 01, 2024 |
Mar. 29, 2024 |
Nov. 01, 2023 |
Oct. 30, 2023 |
Oct. 24, 2023 |
Oct. 29, 2021 |
Sep. 30, 2024 |
Oct. 31, 2023 |
May 31, 2022 |
Oct. 31, 2021 |
Line of Credit Facility [Line Items] |
|
|
|
|
|
|
|
|
|
|
Loan outstanding |
|
|
|
|
|
|
$ 5,900,000
|
|
|
|
BroadOak Loan Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
Line of Credit Facility [Line Items] |
|
|
|
|
|
|
|
|
|
|
Loan maturity date |
|
|
Oct. 31, 2024
|
|
|
|
|
|
|
|
Debt interest percentage |
|
|
8.00%
|
|
|
|
|
9.00%
|
|
|
Monthly payments |
|
|
|
$ 2,500,000
|
|
|
|
|
|
|
Terminal payment |
|
|
|
|
$ 3,000,000
|
|
|
|
|
|
Loan and Security Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
Line of Credit Facility [Line Items] |
|
|
|
|
|
|
|
|
|
|
Monthly payments |
$ 500,000,000
|
|
|
|
|
|
|
|
|
|
Maturity date extended |
|
The maturity date was extended to June 30, 2025.
|
|
|
|
|
|
|
|
|
Comerica Bank [Member] |
|
|
|
|
|
|
|
|
|
|
Line of Credit Facility [Line Items] |
|
|
|
|
|
|
|
|
|
|
Revolving credit facility |
|
|
|
|
|
|
|
|
|
$ 7,500,000
|
Comerica Bank [Member] | Revolving Credit Facility [Member] |
|
|
|
|
|
|
|
|
|
|
Line of Credit Facility [Line Items] |
|
|
|
|
|
|
|
|
|
|
Revolving credit facility |
|
|
|
|
|
$ 7,500,000
|
|
|
|
|
Debt instrument interest, description |
|
|
|
|
|
The Term Loan had an origination fee of 3% of the Term
Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs
on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the
change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii)
30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the
Term Loan, or if the Term Loan is repaid on its maturity date.
|
|
|
|
|
Term Loan [Member] | Broad Oak [Member] |
|
|
|
|
|
|
|
|
|
|
Line of Credit Facility [Line Items] |
|
|
|
|
|
|
|
|
|
|
Debt instrument, face amount |
|
|
|
|
|
$ 8,000,000
|
|
|
$ 2,000,000.0
|
$ 8,000,000.0
|
Term Loan [Member] | Ampersand 2018 [Member] |
|
|
|
|
|
|
|
|
|
|
Line of Credit Facility [Line Items] |
|
|
|
|
|
|
|
|
|
|
Loan maturity date |
|
|
|
|
|
Oct. 31, 2024
|
|
|
|
|
Debt interest percentage |
|
|
|
|
|
9.00%
|
|
|
|
|
Percentage of debt origination fee |
|
|
|
|
|
3.00%
|
|
|
|
|
X |
- DefinitionPercentage of debt origination fee.
+ References
+ Details
Name: |
IDXG_DebtInstrumentOriginationFeePercentage |
Namespace Prefix: |
IDXG_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateTerms |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the required periodic payments including both interest and principal payments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3
+ Details
Name: |
us-gaap_DebtInstrumentPeriodicPayment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_LineOfCredit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_LineOfCreditFacilityLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_LoansPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IDXG_BroadOakLoanAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IDXG_LoanAndSecurityAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_LineOfCreditFacilityAxis=IDXG_ComericaBankMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=IDXG_TermLoanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_BroadOakMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_AmpersandTwoThousandEighteenMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
X |
- DefinitionAccrued capital expenditures.
+ References
+ Details
Name: |
IDXG_AccruedCapitalExpenditures |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionTaxes accrued for repurchase of restricted shares.
+ References
+ Details
Name: |
IDXG_TaxesAccruedForRepurchaseOfRestrictedShares |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_SupplementalCashFlowElementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.24.3
MEZZANINE EQUITY (Details Narrative) - USD ($)
|
|
3 Months Ended |
9 Months Ended |
|
|
Jan. 10, 2020 |
Sep. 30, 2024 |
Mar. 31, 2024 |
Sep. 30, 2023 |
Mar. 31, 2023 |
Sep. 30, 2024 |
Oct. 10, 2024 |
Dec. 31, 2023 |
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Preferred stock aggregate purchase price |
|
|
|
|
|
|
|
|
Preferred stock liquidation preference |
|
$ 6.00
|
|
|
|
$ 6.00
|
|
|
Proceeds from underwriting discount and commission |
|
|
|
|
|
$ 25,000,000
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Preferred stock aggregate purchase price |
|
|
$ 1,000
|
|
|
|
|
|
Aggregate of shares issued |
|
45,834
|
39,668
|
16,666
|
22,996
|
|
|
|
Reserve stock split |
|
|
|
|
|
7,833,334
|
|
|
Sale of stock price per share |
|
$ 12.00
|
|
|
|
$ 12.00
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Aggregate of shares issued |
27,000
|
|
|
|
|
|
|
|
Preferred stock conversion price per share |
$ 6.00
|
|
|
|
|
|
|
|
Maximum preferred stock holders rights percentage |
|
|
|
|
|
The Series B Certificate of Designation
also provides each Investor with the following director designation rights: for so long such Investor holds at least sixty percent (60%)
of the Series B Preferred Stock issued to it on the Issuance Date (as defined therein), such Investor will be entitled to elect two directors
to the Company’s Board of Directors (the “Board”), provided that one of the directors qualifies as an “independent
director” under Rule 5605(a)(2) of the listing rules of the Nasdaq Stock Market (or any successor rule or similar rule promulgated
by another exchange on which the Company’s securities are then listed or designated) (“Independent Director”). However,
if at any time such Investor holds less than sixty percent (60%), but at least forty percent (40%), of the Series B Preferred Stock issued
to them on the Issuance Date, such Investor would only be entitled to elect one director to the Board. Any director elected pursuant to
the terms of the Series B Certificate of Designation may be removed without cause by, and only by, the affirmative vote of the holders
of Series B Preferred Stock. A vacancy in any directorship filled by the holders of Series B Preferred Stock may be filled only by vote
or written consent in lieu of a meeting of such holders of Series B Preferred Stock or by any remaining director or directors elected
by such holders of Series B Preferred Stock.
|
|
|
Temporary equity shares issued |
|
47,000
|
|
|
|
47,000
|
|
47,000
|
Temporary equity shares outstanding |
|
47,000
|
|
|
|
47,000
|
|
47,000
|
Series B Preferred Stock [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Preferred stock par value per share |
|
|
|
|
|
|
$ 0.01
|
|
Preferred stock conversion price per share |
|
|
|
|
|
|
6.00
|
|
Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Aggregate of shares issued |
270
|
|
|
|
|
|
|
|
Value of preferred stock exchanged |
$ 27,000,000.0
|
|
|
|
|
|
|
|
Preferred stock par value per share |
$ 0.01
|
|
|
|
|
|
|
|
Preferred shares stated value per share |
$ 100,000
|
|
|
|
|
|
|
|
Preferred stock shares authorized |
0
|
|
|
|
|
|
|
|
Preferred stock shares issued |
0
|
|
|
|
|
|
|
|
Preferred stock shares outstanding |
0
|
|
|
|
|
|
|
|
Series C Preferred Stock [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Preferred stock par value per share |
|
|
|
|
|
|
0.01
|
|
Preferred stock conversion price per share |
|
|
|
|
|
|
$ 2.02
|
|
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Preferred stock aggregate purchase price |
$ 20,000,000.0
|
|
|
|
|
|
|
|
Issuance price per preferred stock |
$ 1,000
|
|
|
|
|
|
|
|
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | 1315 Capital [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Preferred stock aggregate purchase price |
$ 19,000,000.0
|
|
|
|
|
|
|
|
Aggregate of shares issued |
19,000
|
|
|
|
|
|
|
|
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | Ampersand Limited Partners [Member] |
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
Preferred stock aggregate purchase price |
$ 1,000,000.0
|
|
|
|
|
|
|
|
Aggregate of shares issued |
1,000
|
|
|
|
|
|
|
|
X |
- DefinitionMaximum preferred stock holders rights percentage.
+ References
+ Details
Name: |
IDXG_MaximumPreferredStockHoldersRightsPercentage |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPreferred shares stated value.
+ References
+ Details
Name: |
IDXG_PreferredSharesStatedValue |
Namespace Prefix: |
IDXG_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionProceeds from underwriting discount and commissions.
+ References
+ Details
Name: |
IDXG_ProceedsFromUnderwritingDiscountAndCommissions |
Namespace Prefix: |
IDXG_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockAmountConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPer share conversion price of preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockConvertibleConversionPrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockLiquidationPreference |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionReduction in the number of shares during the period as a result of a reverse stock split.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquitySharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_TemporaryEquitySharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IDXG_SecurityPurchaseAndExchangeAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_OneThreeOneFiveCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_AmpersandLimitedPartnersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
X |
- DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1
+ Details
Name: |
us-gaap_LineOfCredit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1
+ Details
Name: |
us-gaap_LineOfCreditFacilityLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IDXG_ComericaLoanAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.24.3
SUBSEQUENT EVENTS (Details Narrative) - $ / shares
|
|
3 Months Ended |
9 Months Ended |
|
Oct. 10, 2024 |
Sep. 30, 2024 |
Sep. 30, 2024 |
Jan. 10, 2020 |
Series B Preferred Stock [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
|
7,833,334
|
7,833,334
|
|
Preferred stock conversion price per share |
|
|
|
$ 6.00
|
Subsequent Event [Member] | Series B Preferred Stock [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
47,000
|
|
|
|
Preferred stock conversion price per share |
$ 6.00
|
|
|
|
Subsequent Event [Member] | Series B Preferred Stock [Member] | Exchange Agreement [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
47,000
|
|
|
|
Subsequent Event [Member] | Series B Preferred Stock [Member] | Exchange Agreement [Member] | Ampersand Limited Partners [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
28,000
|
|
|
|
Subsequent Event [Member] | Series B Preferred Stock [Member] | Exchange Agreement [Member] | 1315 Capital [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
19,000
|
|
|
|
Subsequent Event [Member] | Series C Preferred Stock [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
47,000
|
|
|
|
Preferred stock conversion price per share |
$ 2.02
|
|
|
|
Number of shares converted |
23,267,326
|
|
|
|
Subsequent Event [Member] | Series C Preferred Stock [Member] | Exchange Agreement [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
47,000
|
|
|
|
Issuance price per share |
$ 1,000
|
|
|
|
Subsequent Event [Member] | Series C Preferred Stock [Member] | Exchange Agreement [Member] | Ampersand Limited Partners [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
28,000
|
|
|
|
Subsequent Event [Member] | Series C Preferred Stock [Member] | Exchange Agreement [Member] | 1315 Capital [Member] |
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
Number of shares exchanged |
19,000
|
|
|
|
X |
- DefinitionThe number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_ConversionOfStockSharesConverted1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPer share conversion price of preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13
+ Details
Name: |
us-gaap_PreferredStockConvertibleConversionPrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionPer share or per unit amount of equity securities issued.
+ References
+ Details
Name: |
us-gaap_SharesIssuedPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=IDXG_ExchangeAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_AmpersandLimitedPartnersMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=IDXG_OneThreeOneFiveCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Interpace Biosciences (QX) (USOTC:IDXG)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Interpace Biosciences (QX) (USOTC:IDXG)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024